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Changes in the age structure of the Dutch population
Elderly form the fastest growing segment of the population. The post-war baby boom, which 
lasted from 1946 until approximately 1970, brought on a demographic shift leading to a 
rapid increase in the population of elderly in the Netherlands (figure 1). On top of that, life 
expectancy is also increasing: the remaining life expectancy for a 70-year old man increased 
from 12 years in 1990 to 16 years in 2015. Similarly, for a 70-year old female, remaining life 
expectancy increased from 16 years in 1990 to 18 years in 20151. Both factors contribute 
to an increase in the proportion of elderly over time. In the year 1990, the proportion of 
persons aged 70 years or older was 9%. This proportion has increased to 12% in 2015 and 
is projected to rise further to a peak of 21% by the year 20401.
Ageing and colon cancer 
Due to the ageing of the population, but also due to the introduction of a screening program 
and unfavourable lifestyle changes, the incidence of colorectal cancer is increasing2,3. 
Colorectal cancer is currently the most common cancer in terms of newly diagnosed 
patients per year in the Netherlands4. Approximately two third of the colorectal cancers 
is located in the colon.
The European age-standardized incidence rate of colon cancer has increased substantially 
over the past 25 years: from 29 per 100,000 persons in 1990 to 44 per 100,000 persons in 2015. 
The absolute number of colon cancer patients in the Netherlands has more than doubled 
Figure 1 Age structure of the Dutch population in 1990, 2015 and as projected for 2040
Source: Statistics Netherlands (CBS)
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Comorbidity and polypharmacy
Due to the high mean age at colon cancer diagnosis, a large proportion of the patients 
also suffer from other chronic medical conditions (comorbidity)5-7. A previous study 
among unselected colorectal cancer patients showed that in 55% of the patients at least 
one comorbid condition was present and that 29% of the patients suffered from two or 
more comorbid conditions. The most common concomitant diseases were hypertension 
(22%), cardiac disease (19%), other malignancies (15%) and diabetes (11%). In general, the 
prevalence of comorbidity increased with age until the age of 80-89 years, with 30% of 
the colorectal cancer patients aged <60 years suffering from comorbidity compared to 
71% of the patients aged ≥80 years. In the oldest patients (i.e. ≥90 years) a slight decrease 
was observed7. It is well established that colorectal cancer patients with comorbidity are 
treated less aggressively and that the presence of comorbidity is associated with worse 
short- and long-term outcomes6,8-11.
As a consequence of multimorbidity, polypharmacy is also prevalent among elderly12. 
Polypharmacy can be problematic when decreased drug compliance, wrong intakes 
and drug interactions lead to adverse drug reactions, toxicity and therapeutic failure13. 
Subsequent cancer treatments with antineoplastic and supportive care agents lead to even 
greater complexity and might have impact on the tolerance and effect of the treatments14.
Figure 2 Incidence of colon cancer in the Netherlands, by year of diagnosis and 5-year age group
Source: Netherlands Cancer Registry
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(figure 2); from 4,600 in 1990 to 10,900 in 20154, and is expected to rise further. Nowadays, 
mean age at time of colon cancer diagnosis is 69 years and approximately one third of 
the patients is aged ≥75 years.
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Adjuvant chemotherapy for stage III colon cancer
To classify the extensiveness of colon cancer, the tumour-node-metastasis (TNM) staging 
system is used15. The TNM system consists of four stages. Approximately a quarter of all 
colon cancer patients presents with stage III disease (T1-4N1-2M0), in which the cancer is not 
confined to the bowel but has spread to at least one regional lymph node, but not to other, 
distant organs or tissues. 
Treatment for stage III colon cancer consists of oncologic resection of the primary tumour 
and regional lymph nodes, followed by adjuvant chemotherapy. Adjuvant chemotherapy 
is used with the intention to eradicate any residual micrometastatic disease16.
The positive effect of adjuvant chemotherapy on disease-free and overall survival for patients 
with stage III colon cancer has been established in clinical trials and is standard treatment 
since the nineties17-20. Treatment with 5-fluorouracil and leucovorin (5-FU/LV) was the only 
effective option until 2005. At that time, the oral fluoropyrimidine capecitabine became 
available. The X-ACT trial demonstrated that capecitabine was at least equivalent to 5-FU/LV 
with regard to five-year disease-free (61% vs. 57%) and overall survival (71% vs. 68%) with 
an improved safety profile except for more hand-foot syndrome21,22. Another development 
was the introduction of the chemotherapeutic oxaliplatin. The MOSAIC and NSABP C-07 
study showed that the addition of oxaliplatin to 5-FU/LV (FOLFOX) provided an additional 
survival gain, but at the cost of higher toxicity rates, especially significant neurotoxicity23-26. 
In the MOSAIC trial, the absolute gain in five-year disease-free survival was 7% (66% vs. 59%) 
and in six-year overall survival 4% (73% vs. 69%), corresponding to relative risk reductions 
of 22% and 20% respectively23. The XELOXA trial showed a comparable survival gain from 
the combination of oxaliplatin with capecitabine (CAPOX) compared to 5-FU/LV with an 
absolute gain in five-year disease-free survival of 6% (67% vs. 61%, relative risk reduction 
20%) and in six-year overall survival of 5% (76% vs. 71%, relative risk reduction 17%)27 and 
provided an alternative treatment option. However, the rates of grade III-IV neurotoxicity 
and grade III hand-foot syndrome were higher28.
Underrepresentation and exclusion of elderly in trials
Despite colon cancer being a disease of the elderly, patients aged 70-75 years were 
underrepresented in the aforementioned trials and patients aged >75 years were even 
excluded21,23,29. Clinical trials often use eligibility criteria that do not take into account the 
patient characteristics as seen in real life. As a consequence, the elderly patients who 
participate in trials, are usually the relatively healthy with minimal comorbidity and good 
performance status to fulfil the eligibility criteria30. They do not represent the typical older 
patient seen in everyday clinical practice. 
Subgroup analyses by age group and pooled data from trials are used to evaluate the effects 
for the elderly patients. It was shown by one subgroup analysis that selected elderly received 
the same benefit from 5-FU-based adjuvant chemotherapy as their younger counterparts 
without a significant increase in toxic effects31. Similarly, oral capecitabine also maintained 
its effectiveness in older patients and the prevalence of grade III-V chemotherapy-related 
toxicity did not differ by age (<65 versus ≥65 years)21,22. However, patients aged 70-75 years 
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were more likely to discontinue treatment prematurely as compared to younger patients 
and dose modifications and reductions were required more often21. Regarding the beneficial 
survival effect of adding oxaliplatin to 5-FU-based regimens, inconsistent results were 
found32,33. One study that used pooled data from trials found that the efficacy of FOLFOX was 
similar for patients aged <70 years and patients aged ≥70 years with regard to disease-free 
and overall survival34. Furthermore, although results were inconclusive, differences in 
toxicity suggested that older patients may be more prone to develop oxaliplatin-related 
toxicity32. In the NSABP C-07 trial, patients aged 70-75 years were more likely to discontinue 
treatment prematurely as compared to younger patients and grade IV-V toxicity was 
experienced at a higher rate32. The XELOXA trial showed an overall higher rate of grade 
III-IV toxicity with CAPOX for patients aged ≥65 years versus younger patients (65% versus 
57% respectively)28.
However, the limitation remains that the results of these studies may not be applicable 
to unselected elderly patients treated in every clinical practice30. Oncological medical 
specialists have to deal with elderly patients who are very heterogeneous with respect to 
their underlying health status. As a result, clinicians have to extrapolate the data to help 
them make a meaningful decision, which can result in both undertreatment and excessive 
toxicity35. Therefore, besides clinical trials other sources of information are needed to 
evaluate the effects of adjuvant chemotherapy in elderly stage III colon cancer patients30.
Population-based studies
Population-based studies are needed to bridge the gap of knowledge between clinical 
trials in selected patients and unselected patients treated in everyday clinical practice30,36. 
Population-based studies can offer additional insight in the use and effectiveness of 
the various adjuvant chemotherapy options among unselected elderly patients. These 
studies can therefore provide new insights that will help oncological medical specialists 
to discuss more adequately the benefits and drawbacks of the various treatment options 
with elderly patients.
In 2012, a research grant from the Netherlands Organisation for Health Research and 
Development (ZonMw) enabled the Netherlands Comprehensive Cancer Organisation 
(IKNL) to perform the research included in this thesis. At that time, observational 
studies had already shown that elderly patients were less often treated with adjuvant 
chemotherapy and less often receive oxaliplatin-containing regimens37-45. Additionally, 
dose reductions and treatment discontinuations were more frequent among elderly37,38. 
However, a distinction between the different single agent chemotherapies (i.e. 5-FU or 
capecitabine) and combination therapies (i.e. FOLFOX or CAPOX) was hardly made. There 
were also hardly any data available on factors playing a role in the decision-making on 
adjuvant chemotherapy in daily practice among elderly patients with stage III colon 
cancer. Furthermore, it was unknown to what degree unselected elderly patients tolerate 
the various adjuvant chemotherapy options and develop toxicity, and what the differences 
are in recurrence-free and overall survival between the various treatment modalities in 
the real world.
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Aim and outline of the thesis
This thesis intends to realise a more evidence-based use of the existing adjuvant treatment 
options for elderly patients with stage III colon cancer. The main objectives of this thesis were:
• To provide insight in the administration of the different adjuvant chemotherapy 
options (part I).
• To investigate the dose intensity and related toxicity of the different adjuvant 
chemotherapy options (part II).
• To evaluate the associations between adjuvant chemotherapy and the risk of recurrence, 
and to evaluate the associations between adjuvant chemotherapy and recurrence-free 
and overall survival (part III).
First, an overview of drugs dispensed to elderly colon cancer patients in the year before 
colon cancer diagnosis is provided and compared to an age- and gender-matched control 
group without cancer (chapter 2). The intent of this chapter is to create awareness among 
(oncology) health care providers as to which drugs are commonly dispensed to their patients. 
The next two chapters cover part I of the thesis. In chapter 3, subjective, doctor-related 
factors influencing the decision-making on adjuvant chemotherapy are identified. More 
specifically, motives for non-referral or non-treatment, the consultation of geriatricians, 
the choice for monotherapy or combination therapy, and the (grade of) toxicity deemed 
acceptable is investigated. For this study, surgeons and medical oncologists were invited 
to complete a short questionnaire. Subsequently, chapter 4 evaluates which patient and 
tumour characteristics influence the administration of oxaliplatin-based chemotherapy 
as compared to non-oxaliplatin-based chemotherapy and presents variation in both types 
of chemotherapy between hospitals.
For part II of this thesis, chapter 5 provides a detailed insight in the completion of all 
planned cycles and received cumulative dosage of the regimens CAPOX and CapMono and 
investigates the association with grade III-V toxicity. Additionally, chapter 6 focuses on 
differences in the course of neuropathic symptoms between patients who are treated with 
either CAPOX or capecitabine and patients who are not treated with adjuvant chemotherapy. 
For this study, patients were invited to complete a questionnaire after resection and 
subsequently six and twelve months later.
The next three chapters comprise part III of the thesis. In chapter 7, the association between 
adjuvant chemotherapy and the risk of distant recurrence is investigated. Additionally, 
we investigate whether the association is comparable for patients aged ≥75 years and 
their younger counterparts. In chapter 8, the associations of the regimens CAPOX and 
CapMono with recurrence-free and overall survival are investigated and it is assessed 
whether oxaliplatin provides additional benefit. This chapter also investigates the effects 
of (non-)completion of both regimens on recurrence-free and overall survival. Chapter 9 
investigates which demographic and clinical variables are associated with the timing of 
adjuvant chemotherapy and how this timing is associated with overall survival.
In chapter 10, the main findings and methodological considerations are discussed. 
Additionally, implications for clinical practice and future research are outlined.
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Abstract
What is known and objective: The concomitant use of multiple drugs is common among 
the general population of elderly. The aim of this study was to provide an overview of which 
drugs are dispensed to elderly in the year before colon cancer diagnosis and to compare 
this with cancer-free controls.
Methods: Data from the Eindhoven Cancer Registry were linked to the PHARMO Database 
Network. Colon cancer patients aged ≥70 years were included and matched with controls 
on gender, birthyear and postal code. Proportions of cases and controls with ≥1 dispensing 
of each WHO-ATC 2nd-level drug during the total year and during each quarter of the year 
were calculated and differences between cases and controls tested. 
Results and discussion: Proportion of cases with ≥1 drug dispensing was highest for drugs 
for constipation (cases vs. controls 58% vs. 10%), antithrombotics (42% vs. 33%), drugs for 
acid related disorders (35% vs. 22%), antibacterials (34% vs. 24%), agents acting on the 
renin-angiotensin system (33% vs. 27%), beta blockers (33% vs. 23%), lipid modifying agents 
(29% vs. 22%), diuretics (29% vs. 21%), psycholeptics (25% vs. 18%) and antianemics (23% vs. 
6%). The proportion of cases with ≥1 drug dispensing increased from the first to the last 
quarter of the year for drugs for constipation (7% to 53%), drugs for acid related disorders 
(16% to 27%), antibacterials (12% to 16%), beta blockers (26% to 28%), psycholeptics (15% to 
19%) and antianemics (6% to 18%). Elevated proportions of cases with ≥1 drug dispensing 
for several drugs is mostly related to comorbidity, although increasing proportions of 
cases with ≥1 drug dispensing for certain drugs during the year can be attributed to the 
incidence of colon cancer.
What is new and conclusion: We have provided insight into which drugs are commonly 
used in the year preceding colon cancer diagnosis. This may trigger general practitioners 
and medical specialists to further evaluate the patient.
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What is known and objective
In the Netherlands, more than 9000 patients were newly diagnosed with colon cancer 
in 2013, and 55% of these patients was aged 70 years or older1. Due to the aging of the 
population and the rising incidence rates of colon cancer with age, the age of patients 
with colon cancer will increase2.
Among elderly colon cancer patients, comorbidities such as cardiovascular diseases, 
diabetes and other malignancies all occur relatively frequent3. Patients often also receive 
drugs for these diseases. Polypharmacy, defined as the use of several drugs for the treatment 
of coexisting diseases, can be problematic. Polypharmacy can lead to decreased drug 
compliance, wrong intakes and drug interactions, thereby increasing the risk of adverse 
drug reactions, toxicity and therapeutic failure4,5. Additionally, among elderly, age dependent 
changes in organ function can alter pharmacokinetics and pharmacodynamics of drugs, 
which also increases the risk of toxicity and therapeutic failure5,6. On the other side, 
polypharmacy can potentially also lead to more frequent medical consultations which 
may lead to earlier recognition of symptoms and diagnosis. Subsequent cancer treatments 
with antineoplastic and supportive care agents will lead to an even greater complexity 
and might have an impact on tolerance to and effect of the treatments7. 
It has already been shown that the concomitant use of multiple drugs is common among 
the general population of elderly8. However, information related to drug use among 
elderly cancer patients is limited9,10. So far, studies usually focused on the prevalence of 
polypharmacy, but lacked a detailed specification of which drugs were commonly used8. 
A mere quantification of the number of drugs used has been proven to be an indicator of 
limited value4. Therefore, knowing which drugs are commonly dispensed is important 
when deciding on prescribing anticancer drugs. 
The aim of the current study is to provide an overview of drugs dispensed to elderly colon 
cancer patients in the year before colon cancer diagnosis and to compare this with an 
age- and gender-matched control group without cancer, with the primary intent to create 
awareness among (oncology) health care providers (i.e. medical oncologists, geriatricians 
and general practitioners) as to which drugs are commonly dispensed to their patients. 
The secondary objective is to obtain more insight into associations between commonly 
dispensed drugs and patient and tumor characteristics.
Methods
Data were obtained from the Eindhoven Cancer Registry (ECR) and linked on a patient-level 
to the PHARMO Database Network, covering an overlapping demographic region in the 
southeastern part of the Netherlands of approximately 1.2 million inhabitants. The construct 
and validity of the ECR-PHARMO cohort are described elsewhere11. 
The ECR, maintained by the Netherlands Comprehensive Cancer Organisation (IKNL), is a 
population-based registry that collects data on all newly diagnosed cancer patients in the 
southern part of the Netherlands. Information on patient and tumor characteristics, diagnosis 
and treatment is routinely extracted from the medical records by trained administrators. 
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Anatomical site of the tumor is registered according to the International Classification of 
Disease – Oncology (ICD-O). The tumor-node-metastasis (TNM) classification is used for 
stage notification of the primary tumor, according to the edition valid at time of diagnosis. 
Comorbidities present at time of cancer diagnosis are registered according to a slightly 
modified version of the Charlson comorbidity index. Socioeconomic status (SES), based 
on individual fiscal data on the economic value of the home and household income, is 
provided at an aggregated level for each postal code. 
The PHARMO Database Network is a large patient-centric data network including multiple 
linked observational databases designed for drug safety and outcomes research. The 
database used for this study includes complete longitudinal data obtained from out-patient 
pharmacies in which drugs are classified according to the WHO Anatomic Therapeutic 
Chemical (ATC) coding. Additionally, the Chronic Disease Score (CDS) was assessed based 
on drug prescriptions in the year prior to cohort entry date. The CDS is defined as a set of 
scoring rules that assigns “chronic disease” weights based on single or combinations of 
used drugs. Higher scores signify more comorbid conditions. Scores were classified into 
four categories (0-5, 6-8, 9-11, ≥12).
In the Netherlands, studies with anonymized patient records do not fall under the scope 
of the Medical Research Involving Human Subjects Act. This study is therefore exempt 
from medical ethics review.
Study population
All stage I-IV colon cancer patients aged 70 years or older diagnosed between 2000 and 
2011 and registered in the ECR-PHARMO cohort were included. Cancer-free controls were 
identified and included by selecting patients living in the overlapping ECR-PHARMO region 
who were included in the PHARMO Database Network but not in the ECR. Cancer patients 
were matched with controls –1 control per case– on gender, year of birth and postal code. 
For each control, the colon cancer incidence date of the matched patient was assigned 
as cohort entry date.
Drugs were classified according to the WHO ATC coding and grouped on ATC-2 level (i.e. 
ATC A01). Non-therapeutic products (ATC V07) were excluded from the analyses. ATC-2 level 
drugs were counted for cases and controls if there was at least 1 dispensing during the 
year before colon cancer diagnosis or cohort entry date. The number of different drugs on 
ATC-2 level dispensed to cases and controls during the year before colon cancer diagnosis 
or cohort entry date was divided into the following categories: 0, 1-6 or ≥7 drugs. 
Statistical analyses
Differences between cases and controls in the proportion with at least 1 dispensing of each 
drug during the year before colon cancer diagnosis or cohort entry date were calculated 
using Chi2-test or Fisher’s Exact test. 
For the 10 drugs with the highest proportions of colon cancer patients with at least 1 
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dispensing in the total year before colon cancer diagnosis, additional analyses were 
performed: after dividing the study year into quarters, we calculated differences in the 
proportion of cases and controls with at least 1 dispensing during each quarter of the year 
before colon cancer diagnosis or cohort entry date using Chi2-tests. To investigate changes 
over time, differences in the proportions with at least 1 dispensing in the first quarter as 
compared to the last quarter were also calculated, for cases and controls separately. 
Differences in patient and tumor characteristics between patients with and patients without 
a dispensing of each of the 10 drugs were also analyzed using Chi2-tests. Multivariable 
logistic regression was used to assess the independent effect of each patient and tumor 
characteristic on the dispensing of each of these 10 drugs. All odds ratios were adjusted 
for gender, age, socioeconomic status, comorbidity, TNM stage, subsite of the tumor and 
period of cancer diagnosis, but only variables with statistically significant odds ratios were 
reported. For SES and comorbidity, there were 79 (2.9%) and 192 (7.0%) missing values. These 
were included in the analyses as separate categories, but results not shown.
P values below 0.05 were considered statistically significant. SAS/STAT® statistical software 
(SAS system 9.4, SAS Institute, Cary, NC) was used for all analyses.
Results and discussion
The total study population consisted of 2735 elderly colon cancer patients and 2735 
matched cancer-free controls. As a result of the matching procedure, gender, age and 
period distributions for the cases and controls were equal (table 1). Half of the population 
was male. Mean age was 77.8 ± 5.3 years. For 18%, period of diagnosis or cohort entry was 
2000-2003, for 33% 2004-2007 and for 49% 2008-2011. Increasing entrance of patients during 
the study periods was partly related to the increasing incidence of colon cancer, but mostly 
due to the expansion of the PHARMO Database Network within the ECR region.
Drug dispensings and CDS differed between cases and controls (table 1). Drug dispensings 
were higher among cases than among controls (p<0.0001). Among cases, 10% had no drug 
dispensings, 41% had 1-6 drugs with ≥1 dispensing and 49% had ≥7 drugs with ≥1 dispensing. 
For controls, these percentages were 31%, 40% and 29% respectively (table 1). The CDS 
was also higher for cases than for controls (p<0.0001). 18% of cases had a CDS of 0-5 while 
31% of controls had a CDS of 0-5. Among cases, 45% had a CDS of ≥12 while this was 33% 
among controls.
For each drug, the number and proportion of cases and controls with ≥1 dispensing in 
the year before colon cancer diagnosis or cohort entry date are presented in appendix A. 
For 36 drugs, the proportion of cases with ≥1 dispensing was significantly higher than for 
controls. For the other 44 drugs, there was no difference in the proportion of cases and 
controls with ≥1 dispensing. There were no drugs for which the proportion of controls with 
≥1 dispensing was higher as compared to cases.
The 10 drugs with the highest proportions of cases with ≥1 dispensing, were drugs for 
constipation (cases vs. controls 58% vs. 10%), antithrombotics (42% vs. 33%), drugs for acid 
related disorders (35% vs. 22%), antibacterials (34% vs. 24%), renin-angiotensin system (RAS) 
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Table 1 Demographic characteristics, dispensed drugs and chronic disease score for the total study population 
(n=5470)
Cases
n (%)
Controls
n (%)
Gender
   Male
   Female
1377
 1358
(50)
(50)
1377
1358
(50)
(50)
Age
   70-74
   75-79
   80-84
   ≥85
896
892
615
332
(33)
(33)
(22)
(12)
896
892
615
332
(33)
(33)
(22)
(12)
Cohort entry
   2000-2003
   2004-2007
   2008-2011
498
900
1337
(18)
(33)
(49)
498
900
1337
(18)
(33)
(49)
Dispensed drugs in the year prior to cohort entry
   No drugs
   1-6 drugs
   ≥7 drugs
269
1124
1342
(10)
(41)
(49)
848
1082
805
(31)
(40)
(29)
Chronic Disease Score
   0-5
   6-8
   9-11
   ≥12
 
491
450
553
1241
 
(18)
(17)
(20)
(45)
850
425
548
912
(31)
(16)
(20)
(33)
related agents (33% vs. 27%), beta blockers (33% vs. 23%), lipid modifying agents (29% vs. 
22%), diuretics (29% vs. 21%), psycholeptics (25% vs. 18%) and antianemics (23% vs. 6%) 
(p<0.0001 for all).
Figure 1 presents for each of the top 10 drugs the proportion of cases and controls with 
≥1 dispensing in each quarter of the year before colon cancer diagnosis or cohort entry 
date. In each quarter, the proportion of cases with ≥1 dispensing was higher as compared 
to the controls for all 10 drugs. Furthermore, the proportion of cases with ≥1 dispensing 
increased from the first to the last quarter of the year, i.e. the last three months before 
colon cancer diagnosis, with regard to drugs for acid related disorders (from 16% to 27%, 
p<0.0001), drugs for constipation (from 7% to 53%, p<0.0001), antianemics (from 6% to 18%, 
p<0.0001), beta blockers (from 26% to 28%, p=0.048), antibacterials (from 12% to 16%, p<0.0001) 
and psycholeptics (from 15% to 19%, p=0.0002). The proportion of cases with ≥1 dispensing 
did not significantly increase from the first to the last quarter of the year with regard to 
antithrombotics, diuretics, RAS related agents and lipid modifying agents. The proportion 
of controls with ≥1 dispensing did not increase from the first to the last quarter of the year 
for any of the 10 drugs.
Table 2 provides an overview of the crude percentages of elderly colon cancer patients 
with ≥1 dispensing for each of the 10 drugs according to several demographic and clinical 
characteristics. In addition, figure 2 presents the adjusted odds ratios that remained 
significant in multivariable analysis. Drugs for constipation, antithrombotics and lipid 
modifying agents were more often dispensed to male patients than to female patients, 
Drug dispensings in the year before colon cancer diagnosis  |  23
2
  
       











 

 






 


       











 

   




 

    
       











 

 






 


       











 

  




 

  
       











 






 

 
       











 






 

  
       











 






 


       











 






 


       











 






 


       











 






 

Figure 1 Proportion of cases and controls with at least one dispensing of 10 drugs in each quarter of the year 
before colon cancer diagnosis or cohort entry date (n=5470)
RAS: renin-angiotensin system
^ P value Chi2-test cases vs. controls <0.05
* P value Chi2-test cases vs. controls <0.0001
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   
   
  
      
  

    

  
 
  



Figure 2 Odds ratiosa of receiving each of the 10 listed drugs according to patient and tumour characteristics 
among cases (n=2735)
aAll odds ratios are adjusted for gender, age, socioeconomic status (SES), comorbidity, TNM stage, subsite of the 
tumor and period of cancer diagnosis
RAS: renin-angiotensin system
Only variables with statistically significant odds ratios are reported
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while diuretics and psycholeptics were less often dispensed to male patients as compared 
to female patients. Older patients more often had at least 1 dispensing of antithrombotics, 
antianemics, diuretics and psycholeptics but less often had one or more dispensings of 
drugs for constipation and lipid modifying agents. Socioeconomic status was associated 
with dispensing of drugs for acid related disorders, beta blockers and antibacterials. With 
increasing comorbidity, the dispensing of drugs also increased, with the exception of drugs 
for constipation and psycholeptics. In multivariable analysis, TNM stage was not associated 
with any of the drugs. Patients with a tumor located in the distal colon more often had 
at least 1 dispensing of drugs for constipation and RAS related agents, but less often for 
drugs for acid related disorders and antianemics as compared to patients with a tumor 
located in the proximal colon. During the study period, the dispensing of drugs for acid 
related disorders, beta blockers, RAS related agents and lipid modifying agents increased, 
while the dispensing of antibacterials and psycholeptics decreased. The dispensing of 
antithrombotics was higher in 2004-2007 as compared to 2000-2003.
What is new and conclusion
Our study demonstrates a higher proportion of drug dispensing from out-patient pharmacies 
to elderly colon cancer patients during the total year before diagnosis as compared to 
a matched cancer-free control group, which increased even more during the last three 
months before diagnosis. 
Increasing drug dispensing in the months preceding cancer diagnosis is in line with previous 
research12. In our study, drugs for constipation, drugs for acid related disorders, antianemics, 
beta blockers, antibacterials and psycholeptics were dispensed to an increasing proportion 
of cases in the last quarter of the year. Drugs for constipation are probably increasingly 
dispensed for symptom management and as colon preparation agent before a diagnostic 
colonoscopy can take place. Drugs for acid related disorders, especially antacids (i.e. 
magnesium, calcium and aluminium compounds), are often concomitantly prescribed with 
drugs for constipation. Additionally, tumors in the proximal colon may mimic symptoms 
of higher gastrointestinal diseases and this can lead to unjustifiable but explainable 
prescription of acid lowering drugs. The increasing dispensing of antianemics might be 
related to iron deficiency due to blood loss as a symptom of the colon cancer13. Antacids 
can also be described as a pragmatic drug for iron deficiency, during the waiting time of 
diagnostics, when a gastric ulcer is still considered a possible explanation. Antibacterials, 
especially antibiotics, might be increasingly dispensed because an infection is suspected. 
Although our explanation for the increasing dispensing of psycholeptics is very uncertain, 
we hypothesize that for some patients it may perhaps reflect fear and anxiety during the 
diagnostic procedures or in reaction to symptoms. Additionally, it could also suggest that 
patients are anxious or experience delirium due to their colon cancer without being diagnosed 
yet. Although psycholeptics do not interact with colon cancer related chemotherapeutics, 
their use does deserve attention, because of the risk of interactions with other drugs, such 
as for benzodiazepine derivates14. Long-acting benzodiazepines increase the risk of falls 
and fractures with as much as 60%15 and can be found among the inappropriate drugs 
according to the Beers criteria16-18. 
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As stated before, drug dispensing was higher among cases than among controls for the 
total year before diagnosis or cohort entry date. This could be caused by a higher level of 
comorbidity, which was reflected in a higher proportion of cases than controls with a CDS 
≥12. Beta blockers, RAS related agents and diuretics are prescribed for cardiovascular diseases 
such as hypertension. Lipid modifying agents are used in the treatment of diabetes. However, 
higher drug dispensing and especially the underlying symptoms or diseases for which the 
drugs are prescribed could also serve as a warning signal for general practitioners to further 
evaluate the patient. Higher dispensing of laxatives could partly reflect a misinterpretation 
of symptoms in cancer patients12. The elevated dispensing of antithrombotics among cases 
might be explained by the association between venous thromboembolism and cancer19 
and in some cases by the first cancer symptoms. Moreover, the use of antithrombotics 
might also lead to an earlier notice of blood loss and colon cancer diagnosis. Among colon 
cancer patients receiving (adjuvant) chemotherapy with fluorouracil or its oral analogous 
capecitabine, one should be attentive for a potential interaction with antithrombotic agent 
warfarin, which can lead to an increased risk of bleeding20-22.
In general, the elevated dispensing of drugs among cases as compared to controls during 
the total study year is mostly related to comorbidity, as is reflected in our results, which 
show associations between almost all 10 drugs and the presence of comorbidity among 
the colon cancer patients. This association with comorbidity is in part because the elderly 
who develop colon cancer probably have certain risk factors (i.e. overweight, smoking and 
physical inactivity) which make them also more vulnerable for other comorbidities that 
share the same risk factors, but also because patients with comorbidities are under more 
intense medical surveillance. Vice versa, patients who seek medical attention for (cancer) 
symptoms could also be diagnosed with other chronic diseases during the diagnostic 
process. Because only comorbidity present at time of colon cancer diagnosis was registered, 
the exact influence remains uncertain.
The increasing proportion of cases with a dispensing of certain drugs during the year will 
probably be mostly related to the colon cancer, especially drugs for constipation, which 
were not related to comorbidity.
Some of the odds ratios in our study were accompanied by wide confidence intervals. The 
width of the confidence interval depends on the sample size and risk of the event. Although 
these confidence intervals were not centered around 1 (i.e. no effect) and it is therefore 
improbable that there was no effect, it should be acknowledged that the exact strength of 
the effect remains fairly uncertain. Future large scale studies are needed to provide more 
precise estimates of the strength of the effects.
A limitation of our study is that we cannot be certain whether dispensed drugs were actually 
taken. However, because this applies to both cases and controls, possible misclassification 
will be non-differential. Additionally, prescription length was not taken into account, but 
again no difference between cases and controls is expected. Finally, no data from in-hospital 
pharmacies was included.
We acknowledge that it is hard to draw clinical conclusions from our manuscript. As 
expected, drug use is frequent in the time leading up to a colon cancer diagnosis among 
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elderly patients and many patients use multiple drugs. However, we have also provided 
insight into which drugs are commonly used in the year preceding colon cancer diagnosis. 
This may trigger general practitioners and medical specialists to further evaluate the 
patient. Additionally, our study provides starting points for future research, for example, 
for the most frequently used drugs, in-depth analyses can investigate whether distinct 
drug combinations or patterns of drugs use predict subsequent cancer diagnosis.
In conclusion, our study demonstrates that to a substantial proportion of elderly, multiple 
drugs are dispensed in the year before colon cancer diagnosis and, usually, this reflects 
multimorbidity. For drugs that are dispensed to an increasing proportion of cases in the 
months before colon cancer diagnosis, this seems related to symptom management of the 
colon cancer itself. Subsequent cancer treatments with antineoplastic and supportive care 
agents will lead to an even greater complexity and might have an impact on tolerance to and 
effect of these treatments. The effect of specific drugs on cancer treatment (i.e. receiving 
surgery, undergoing adjuvant or palliative chemotherapy, deviations from guidelines) and 
outcome (i.e. complications, toxicity, survival) should be subject of further study.
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Appendix
Appendix A Number and proportion of elderly using ATC-2 level drugs in the year before colon cancer diagnosis 
(cases) or cohort entry date (cancer-free controls) (n=5470)
ATC-2 level code Cases 
n (%)
Controls 
n (%)
P 
value*
A Alimentary tract and metabolism
   A01 Stomatological preparations
   A02 Drugs for acid related disorders
   A03 Drugs for functional gastrointestinal disorder
   A04 Antiemetics and antinauseants
   A05 Bile and liver therapy
   A06 Drugs for constipation
   A07 Antidiarrheals, intestinal anti-inflammatory/anti-infective
   A08 Antiobesity preparations, excluding diet products
   A09 Digestives, including enzymes
   A10 Drugs used in diabetes
   A11 Vitamins
   A12 Mineral supplements
   A14 Anabolic agents for systemic use
37
959
293
6
1
1589
161
2
1
426
76
171
1
(1.4)
(35.1)
(10.7)
(0.2)
(0.1)
(58.1)
(5.9)
(0.1)
(0.1)
(15.6)
(2.8)
(6.3)
(0.1)
37
597
80
2
2
284
53
2
2
365
69
158
1
(1.4)
(21.8)
(2.9)
(0.1)
(0.1)
(10.4)
(1.9)
(0.1)
(0.1)
(13.4)
(2.5)
(5.8)
(0.1)
NS
<0.0001
<0.0001
NS
NS
<0.0001
<0.0001
NS
NS
0.019
NS
NS
NS
B Blood and blood forming organs
   B01 Antithrombotic agents
   B02 Antihemorrhagics
   B03 Antianemic preparations
   B05 Blood substitutes and perfusion solutions
1142
41
640
4
(41.8)
(1.5)
(23.4)
(0.2)
891
16
174
8
(32.6)
(0.6)
(6.4)
(0.3)
<0.0001
0.0009
<0.0001
NS
C Cardiovascular system
   C01 Cardiac therapy
   C02 Antihypertensives
   C03 Diuretics
   C04 Peripheral vasodilators
   C05 Vasoprotectives
   C07 Beta blocking agents
   C08 Calcium channel blockers
   C09 Agents acting on the renin-angiotensin system
   C10 Lipid modifying agents
472
45
783
640
124
888
451
902
796
(17.3)
(1.7)
(28.6)
(23.4)
(4.5)
(32.5)
(16.5)
(33.0)
(29.1)
361
24
574
174
59
625
324
730
604
(13.2)
(0.9)
(21.0)
(6.4)
(2.2)
(22.9)
(11.9)
(26.7)
(22.1)
<0.0001
0.011
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
D Dermatologicals
   D01 Antifungals for dermatological use
   D02 Emollients and protective
   D03 Preparations for treatment of wounds and ulcers
   D04 Antipruritics, including antihistamines, anesthetics, etc.
   D05 Antipsoriatics
   D06 Antibiotics and chemotherapeutics for dermatological use
   D07 Corticosteroids, dermatological preparations
   D08 Antiseptics and disinfectants
   D09 Medicated dressings
   D10 Anti-acne preparations
   D11 Other dermatological preparations
310
256
3
7
32
121
530
20
1
11
23
(11.3)
(9.4)
(0.1)
(0.3)
(1.2)
(4.4)
(19.4)
(0.7)
(0.1)
(0.4)
(0.8)
230
208
3
6
19
95
375
14
0
8
37
(8.4)
(7.6)
(0.1)
(0.2)
(0.7)
(3.5)
(13.7)
(0.5)
(0.0)
(0.3)
(1.4)
0.0003
0.020
NS
NS
NS
NS
<0.0001
NS
NS
NS
NS
G Genito-urinary system and sex hormones
   G01 Gynecological anti-infectives and antiseptics
   G02 Other gynecologicals
   G03 Sex hormones and modulator of the genital system
   G04 Urologicals
12
1
65
265
(0.4)
(0.1)
(2.4)
(9.7)
17
1
62
235
(0.6)
(0.1)
(2.3)
(8.6)
NS
NS
NS
NS
H Systemic hormonal preparations, excluding sex hormones and insulins
   H01 Pituitary and hypothalamic hormones and analogues
   H02 Corticosteroids for systemic use
   H03 Thyroid therapy
   H04 Pancreatic hormones
   H05 Calcium homeostasis
5
262
105
4
65
(0.2)
(9.6)
(3.8)
(0.2)
(2.4)
9
212
78
2
62
(0.3)
(7.8)
(2.9)
(0.1)
(2.3)
NS
0.016
0.042
NS
NS
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Appendix A continued
ATC-2 level code Cases 
n (%)
Controls 
n (%)
P 
value*
J Anti-infectives for systemic use
   J01 Antibacterials for systemic use
   J02 Antimycotics for systemic use
   J04 Antimycobacterials
   J05 Antivirals for systemic use
   J06 Immune sera and immunoglobulins
   J07 Vaccines
924
18
0
29
15
26
(33.8)
(0.7)
(0.0)
(1.1)
(0.6)
(1.0)
650
13
2
12
9
31
(23.8)
(0.5)
(0.1)
(0.4)
(0.3)
(1.1)
<0.0001
NS
NS
0.008
NS
NS
L Antineoplastic and immunomodulating agents
   L01 Antineoplastic agents
   L02 Endocrine therapy
   L03 Immunostimulants
   L04 Immunosuppressants
25
53
0
21
(0.9)
(1.9)
(0.0)
(0.8)
16
16
1
17
(0.6)
(0.6)
(0.1)
(0.6)
NS
<0.0001
NS
NS
M Musculo-skeletal system
   M01 Anti-inflammatory and antirheumatic products
   M02 Topical products for joint and muscular pain
   M03 Muscle relaxants
   M04 Antigout preparations
   M05 Drugs for treatment of bone diseases
   M09 Other drugs for disorders of the musculo-skeletal system
577
13
6
83
180
52
(21.1)
(0.5)
(0.2)
(3.0)
(6.6)
(1.9)
483
10
2
64
148
43
(17.7)
(0.4)
(0.1)
(2.3)
(5.4)
(1.6)
0.001
NS
NS
NS
NS
NS
N Nervous system
   N01 Anesthetics
   N02 Analgesics
   N03 Antiepileptics
   N04 Anti-parkinson drugs
   N05 Psycholeptics
   N06 Psychoanaleptics
   N07 Other nervous system drugs
38
459
103
50
679
202
137
(1.4)
(16.8)
(3.8)
(1.8)
(24.8)
(7.4)
(5.0)
25
374
56
46
493
186
96
(0.9)
(13.7)
(2.1)
(1.7)
(18.0)
(6.8)
(3.5)
NS
0.001
0.0002
NS
<0.0001
NS
0.006
P Antiparasitic products,  insecticides and repellents
   P01 Antiprotozoals
   P02 Anthelmintics
   P03 Ectoparasiticides, including scabicides, insecticides and repellents
30
103
1
(1.1)
(3.8)
(0.1)
17
56
0
(0.6)
(2.1)
(0.0)
NS
0.0002
NS
R Respiratory system
   R01 Nasal preparations
   R02 Throat preparations
   R03 Drugs for obstructive airway diseases
   R05 Cough and cold preparations
   R06 Antihistamines for systemic use
181
1
425
306
139
(6.6)
(0.1)
(15.5)
(11.2)
(5.1)
134
5
361
233
130
(4.9)
(0.2)
(13.2)
(8.5)
(4.8)
0.006
NS
0.014
0.0009
NS
S Sensory organs
   S01 Ophthalmologicals
   S02 Otologicals
582
102
(21.3)
(3.7)
440
75
(16.1)
(2.7)
<0.0001
0.039
V Various
   V03 All other therapeutic products 7 (0.3) 4 (0.2) NS
NS: not significant
* P value indicates significance of the Chi2-test or Fisher’s Exact test where appropriate
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Abstract
Objective: The aim of this study is to identify doctor-related factors determining the 
decision-making for adjuvant chemotherapy for stage III colon cancer patients aged ≥75 
years.
Materials and methods: 21 surgeons and 15 medical oncologists from 10 community hospitals 
were asked to complete a short questionnaire including tick-box questions regarding 
motives for non-referral/non-treatment, consultation of geriatricians, chemotherapy 
schemes prescribed and an open question regarding tolerability of chemotherapy.
Results: 29 medical specialists returned a completed questionnaire (response 81%). The 
motives for non-referral/non-treatment reported most often were comorbidity/bad general 
health condition of the patient; surgical complications; and treatment offered but refused by 
patient/family. 39% of the surgeons and 55% of the medical oncologists reported consultation 
of a geriatrician in 2-30% of their decisions. CAPOX and capecitabine were reported by 
medical oncologists as the most frequently prescribed regimens. Factors that influenced 
the decision for monotherapy or combination therapy were comorbidity; general health 
condition of the patient; and toxicity profile of the chemotherapeutics. In general, medical 
oncologists defined grade ≤2 toxicities as tolerable, with the exception of neuropathy, for 
which grade ≤1 toxicity was accepted.
Conclusions: In case medical oncologists prescribe adjuvant chemotherapy to elderly stage 
III colon cancer patients, the chemotherapy schemes used are in line with clinical guidelines 
and they agree on acceptable levels of toxicity. However, the variation among surgeons 
and medical oncologists in motives for non-referral, non-treatment and consultation of 
geriatricians when deciding on adjuvant chemotherapy for elderly stage III colon cancer 
patients, shows the complexity and need for specific knowledge.
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Introduction
In previous studies, we showed that only a small proportion of elderly patients with stage III 
colon cancer receives adjuvant chemotherapy1 and that there is a large variation between 
hospitals in the southern part of the Netherlands with regard to adjuvant chemotherapy 
administration among these patients, which could not be explained by casemix. 
Additionally, type of prescribed chemotherapy varied, broadly distinguishing between 
oxaliplatin-containing chemotherapy and non-oxaliplatin-containing chemotherapy2. 
The objective of the current study was to identify subjective, doctor-related factors in the 
decision-making on adjuvant chemotherapy in elderly stage III colon cancer patients. 
More specifically, the aim of the study was fourfold. The first goal was to identify which 
motives surgeons and medical oncologists have for non-referral for, or non-treatment 
with, adjuvant chemotherapy of stage III colon cancer patients aged 75 years or older. 
Secondly, we evaluated whether surgeons and medical oncologists consult geriatricians 
in the decision-making process. Thirdly, we investigated which chemotherapy schemes 
medical oncologists prescribe to patients and what motives they have for prescribing 
monotherapy or combination therapy. Finally, we assessed the (grade of) toxicity caused 
by the adjuvant chemotherapy deemed acceptable by medical oncologists.
Materials and methods
36 medical specialists with colorectal cancer as their area of interest and who are directly 
involved in the treatment of colon cancer patients (21 surgeons and 15 medical oncologists) 
were asked to complete a short questionnaire between December 2013 and January 2014. 
The medical specialists represent all 10 community hospitals in the southern part of the 
Netherlands. Eight of these hospitals are also teaching hospitals (seven for surgery, eight 
for internal medicine and four for clinical geriatrics). In 2013, between 75 and 200 colon 
cancer patients were diagnosed in each hospital, of whom 2-15% was 75 years or older and 
diagnosed with stage III disease. Furthermore, all hospitals have multidisciplinary tumour 
boards. More than 90% of the patients are discussed in these multidisciplinary tumour 
boards3. Geriatricians are present in each hospital, but it is unknown whether they are 
available for oncological consultation.
Self-administered questionnaires were developed and discussed with a medical oncologist 
involved in the study for content and relevance. Two slightly different versions (one for 
surgeons and one for medical oncologists) of the questionnaire with room for remarks 
were created. The questionnaire addressed to surgeons included tick-box questions 
regarding motives for non-referral of stage III colon cancer patients aged 75 years or 
older for adjuvant chemotherapy and consultation of a geriatrician in the decision for 
(non-)referral (appendix A). The questionnaire addressed to medical oncologists included 
tick-box questions regarding motives for omitting adjuvant chemotherapy in stage III colon 
cancer patients aged 75 years or older, consultation of a geriatrician in their treatment 
decision, type of chemotherapy schemes the medical oncologists prescribed to these 
patients, and an open question regarding the (grade of) toxicities deemed (un)acceptable 
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(appendix B). Demographic characteristics of the respondent (gender, age) were also 
included in both questionnaires. To increase the number of respondents, the final versions 
of the questionnaires were intentionally kept to a three page maximum, which could be 
completed within 10 minutes.
The medical specialists were requested to return the questionnaire to the Netherlands 
Comprehensive Cancer Organisation (IKNL) in a provided envelope. Returned questionnaires 
contained a study number only. If the questionnaire was not returned within 4 weeks, 
a reminder letter and questionnaire were sent. A second digital reminder and online 
questionnaire were sent 2 weeks after the first reminder.
Results
29 medical specialists from 10 hospitals returned a completed questionnaire (response 81%). 
More specifically, 18 surgeons (response 86%) and 11 medical oncologists (response 73%) 
participated. All hospitals were represented by at least one surgeon (range 1-3) and one 
medical oncologist (range 1-2). A large majority of the respondents was male (25/29, 86%) 
and were in the age groups 40-49 years (10/29, 34%) or 50-59 years (10/29, 34%). In contrast, 
among the non-respondents (3 surgeons, 4 medical oncologists), the majority was female 
(4/7, 57%). Age of the non-respondents was unknown.
Motives for non-referral and non-treatment
Figure 1 presents the proportions of surgeons and medical oncologists reporting each 
listed reason as motive that they have for non-referral or non-treatment with adjuvant 
chemotherapy of patients with stage III colon cancer aged 75 years or older. The motives 
that most surgeons had were comorbidity or bad general health condition of the patient 
(100% of the surgeons); presence of surgical complications (89%); and refusal of adjuvant 
therapy by the patient and/or family (61%). These motives were also reported by most of the 
medical oncologists (91%, 63% and 91% of the medical oncologists, respectively). Medical 
oncologists also frequently reported that they had the motive that expected side effects 
were too severe (63%). Age per se was only an issue in a minority of the surgeons and 
medical oncologists. Two medical oncologists (18%) reported a motive for non-treatment 
which was not in the predefined list, namely non-referral of the patient by the surgeon.
Involvement of geriatricians
When surgeons were asked whether they sometimes consulted a geriatrician in their decisions for 
(non-)referral of elderly patients for adjuvant chemotherapy, less than half of them (n=7, 39%) 
reported to do so, whereas more than half of the medical oncologists (n=6, 55%) reported 
to consult a geriatrician in some of their decisions for (non-)treatment. The consultation 
of geriatricians seemed to be related to the hospital where the medical specialists worked; 
the surgeons reporting consultation of geriatricians originated from five hospitals and the 
medical oncologists reporting consultation of geriatricians originated from these same 
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          
     
   
   
    
  
    
   
   
    
 
     
 

 
Figure 1 Proportions of surgeons and medical oncologists reporting each listed reason as motive that they have 
for non-referral or non-treatment with adjuvant chemotherapy of patients with stage III colon cancer aged 75 
years or older (n=29)
five hospitals and one additional hospital. Amongst them were three of the four teaching 
hospitals for clinical geriatrics.
The percentage of patients for whom those 7 surgeons reported to consult a geriatrician in 
their decision for (non-)referral varied between 2% and 30%, with an outlier of 100%. The latter 
was accompanied by the explanation that all patients are discussed in a multidisciplinary 
team that includes a geriatrician. The percentage of patients for whom the 6 medical 
oncologists reported to consult a geriatrician in their decision for (non-)treatment varied 
from 5% to 25%. 
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(Choice for) chemotherapy schemes
Capecitabine combined with oxaliplatin (CAPOX) and capecitabine monotherapy were both 
reported by 10 out of 11 medical oncologists as chemotherapy schemes that they prescribe 
to elderly patients with stage III colon cancer. Furthermore, 5-fluorouracil, leucovorin and 
oxaliplatin (FOLFOX) was prescribed by three medical oncologists and 5-fluoracil and 
leucovorin (5-FU/LV) by one. No other schemes were reported.
Medical oncologists’ decision for monotherapy versus combination therapy was mostly 
based on comorbid disease(s) (i.e. neurological complaints), general health condition of 
the patient (i.e. poor performance) and toxicity profile of the chemotherapeutics (i.e. risk 
of neuropathy in case of oxaliplatin administration). Other factors, such as quality of life 
and patient preference, were mentioned less often.
(Un)acceptable toxicities
In general, medical oncologists defined grade ≤2 toxicities as acceptable. The one exception 
was neuropathy, which was only deemed acceptable if grade 1, without dysfunction. Grade 
≤2 diarrhea, hand foot syndrome and fatigue were mentioned most often as acceptable 
toxicities. Other acceptable (mild) side effects reported by medical oncologists were hair 
loss, temporary change of taste, anorexia, anaemia, kidney disorders, asthenia and bone 
marrow toxicity.
As unacceptable toxicities, grade ≥3 diarrhoea and hand foot syndrome, and grade ≥2 
neuropathy were listed most often. Other unacceptable toxicities mentioned less often were 
cardiovascular side effects, neutropenia, and leukopenia, if grade ≥3, with a hospitalization 
indication.
Discussion
Our study showed that comorbidity/bad general health condition of the patient, surgical 
complications, and refusal of adjuvant chemotherapy by the patient and/or family, were 
the most frequently reported motives for non-referral and/or non-treatment with adjuvant 
chemotherapy of stage III colon cancer patients aged 75 years or older. Less than half of the 
surgeons and little over half of the medical oncologists consulted a geriatrician for a minority 
of the patients. In case adjuvant chemotherapy was prescribed by medical oncologists, 
the chemotherapy schemes used were according to the clinical guidelines. Comorbidity, 
patients general health condition and toxicity profile were the most frequently reported 
factors on the decision for monotherapy instead of combination therapy. Finally, medical 
oncologists defined grade ≤2 toxicities as acceptable, with the exception of neuropathy, 
which was only deemed acceptable if grade ≤1.
The motives that were most frequently reported in our study for non-referral and 
non-treatment of elderly colon cancer patients are in line with previous research4,5. In a 
Canadian study, comorbidity was also the most common reason for not recommending 
adjuvant chemotherapy based on a chart review. Interestingly, they found that 22% of the 
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patients for whom comorbidity was listed as the motive for non-treatment actually had 
a comorbidity score of 0 based on administrative data. 
Patient or family refusal was another frequently reported motive for non-referral and 
non-treatment. A further elucidation of which reason(s) patients or family had for refusing 
adjuvant chemotherapy was not part of our questionnaire. Therefore, it is unknown whether 
their reasons were justly and based on adequate background information.
The reason of medical oncologists to not treat patients because of non-referral by the surgeon 
has been studied previously. In that study, approximately 20% of the variability in whether a 
stage III colon cancer patient is referred to a medical oncologist is attributable to the surgeon. 
Surgeons with fewer years since graduation, surgeons who practice in a teaching hospital 
and surgeons with a higher volume of colon cancer patients, are more likely to refer patients 
to a medical oncologist6. It is questionable whether surgeons should decide not to refer certain 
patients to the medical oncologist and, additionally, whether patients and/or family should 
refuse adjuvant chemotherapy before consulting a medical oncologist. Non-consultation 
withholds patients from explicit information about chemotherapy treatment and from an 
assessment of their physiological and functional status 6 to 12 weeks after surgery. This 
assessment is usually undertaken before administering chemotherapy and is complex 
among elderly due to their aging process7. Every stage III colon cancer patient, regardless of 
age, should be referred to the medical oncologist, who should weigh the risk for recurrence 
or death against the risk for toxicity of the treatment. In addition, the International Society 
of Geriatric Oncology (SIOG) recommends that for patients with physical or psychological 
comorbidities, a geriatrician should be involved in patient management8. A recent study 
showed both the need for geriatric screening and assessment -revealing problems for 
more than half of older cancer patients, which led to geriatric interventions in a quarter 
of these patients- and the feasibility of including geriatrics in oncology care9. Another 
study showed that the influence of geriatric assessment on treatment decisions is most 
prominent for chemotherapy10. 
In the adjuvant treatment of elderly patients with colon cancer, medical oncologists generally 
agree that grade ≤2 toxicities are acceptable, except for neuropathy (only acceptable if grade 
≤1). Recent studies show that chemotherapy-induced peripheral neuropathy is negatively 
associated with quality of life11 and may continue years after diagnosis among patients 
treated with oxaliplatin12. 
Toxicity of the chemotherapeutics was also one of the most reported factors influencing 
the decision for monotherapy instead of combination therapy. For elderly patients, the use 
of combination regimens and more specifically of oxaliplatin-based chemotherapy should 
also depend on the individual patient’s remaining life expectancy (without recurrence) as the 
gains from oxaliplatin are uncertain in comparison to monotherapy with fluoropyrimidine8. 
On the other hand, the recently published Dutch practice guideline states that for patients 
with a microsatellite instable tumour, only oxaliplatin-containing chemotherapy should 
be offered as the effectiveness of fluoropyrimidine monotherapy is questionable for these 
patients. 
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Variation among surgeons and medical oncologists in deciding on referral for and treatment 
with adjuvant chemotherapy for elderly stage III colon cancer patients can be related to the 
lack of evidence-based guidelines for elderly cancer patients. Although in general adjuvant 
chemotherapy is recommended as the efficacy has been established in clinical trials8, it is 
questionable whether this also applies to elderly cancer patients. Elderly cancer patients 
are often excluded from clinical trials and trial populations may therefore not always be 
representative for elderly patients seen in clinical practice. Furthermore, observational 
studies focusing on overall survival are prone to selection bias. The realization of clinical 
trials especially for elderly cancer patients and of prospective observational studies 
including an extensive description of elderly patient characteristics and with appropriate 
outcome parameters is important to expand the evidence base for the treatment of elderly 
cancer patients.
A limitation of our study is that the study population was relatively small. However, the 
response rate was high and we were able to include medical specialists from 10 different 
hospitals. Additionally, to keep our questionnaire short, we limited the amount of predefined 
motives for (non-)treatment. 
In conclusion, in case adjuvant chemotherapy is prescribed to elderly stage III colon cancer 
patients by medical oncologists, chemotherapy schemes used are in line with clinical 
guidelines and medical oncologists agree on acceptable levels of toxicity. However, variation 
among surgeons and medical oncologists in motives for non-referral, non-treatment and 
consultation of geriatricians when deciding on adjuvant chemotherapy for elderly, shows 
the complexity and need for specific knowledge. We believe that every elderly patient with 
or without comorbidity should be referred to the medical oncologist to receive sufficient 
information and to assess the benefits and risks of adjuvant chemotherapy. In our opinion, 
in case of doubt on vitality or goal setting for individual patients, it is preferable that 
consultation by a geriatrician and geriatric assessment are part of the care pathway.
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Appendices
Appendix A Questions related to (non-)referral posed to surgeons (translated from the original questionnaire)
Which motives do you have for not referring a patient aged 75 years or older with stage III colon 
cancer for adjuvant chemotherapy? (multiple answers possible)
 о Comorbidity/bad general health condition
 о Social circumstances of patient
 о Age of patient
 о Agreed in multidisciplinary team
 о Surgical complications
 о Expected survival benefit too limited
 о Expected side effects too extensive
 о Offered but patient/family refuse treatment
 о Recurrence before start chemotherapy
 о Death before start chemotherapy
 о Other, namely: ………
Do you sometimes involve a geriatrician in your decision to not refer a patient aged 75 years or older 
with stage III colon cancer for adjuvant chemotherapy? If yes; can you give an estimate on how often 
you involve a geriatrician in your decision?
 о No
 о Yes, for approximately ………% of the patients
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Appendix B Questions related to (non-)treatment posed to medical oncologists (translated from the original 
questionnaire)
Which motives do you have for not treating a patient aged 75 years or older with stage III colon cancer 
with adjuvant chemotherapy? (multiple answers possible)
 о Comorbidity/bad general health condition
 о Social circumstances of patient
 о Age of patient
 о Agreed in multidisciplinary team
 о Surgical complications
 о Expected survival benefit too limited
 о Expected side effects too extensive
 о Offered but patient/family refuse treatment
 о Recurrence before start chemotherapy
 о Death before start chemotherapy
 о Other, namely: ………
Do you sometimes involve a geriatrician in your decision to not treat a patient aged 75 years or older 
with stage III colon cancer with adjuvant chemotherapy? If yes; can you give an estimate on how often 
you involve a geriatrician in your decision?
 о No
 о Yes, for approximately ………% of the patients
With which chemotherapy scheme(s) do you treat patients aged 75 years or older with stage III colon 
cancer? (multiple answers possible)
 о 5-FU/LV
 о FOLFOX (5-FU, leucovorin and oxaliplatin)
 о Capecitabine
 о CAPOX / XELOX
 о Uracil / tegafur
 о Other, namely: ………
Which factors play a role in your decision to treat certain patients aged 75 years or older with stage III 
colon cancer with monotherapy and others with combination therapy?
………(multiple answers possible)
What are, in your opinion, acceptable side effects that are to be expected from treatment with (a 
certain type of) adjuvant chemotherapy for patients aged 75 years or older with stage III colon cancer?
………(multiple answers possible)
What are, in your opinion, unacceptable side effects that can arise from treatment with (a certain type 
of) adjuvant chemotherapy for patients aged 75 years or older with stage III colon cancer?
………(multiple answers possible)

Acta Oncologica 2014; 53(7): 975-980
F.N. van Erning
N. Bernards
G.J. Creemers
A. Vreugdenhil
C.J.P.A. Lensen
V.E.P.P. Lemmens
Administration of adjuvant oxaliplatin 
to patients with stage III colon cancer 
is affected by age and hospital
46  |  Chapter 4
To the editor
According to the Dutch clinical practice guideline, the standard adjuvant treatment 
for patients with stage III colon cancer is a combination of fluorouracil, leucovorin and 
oxaliplatin (FOLFOX). Fluorouracil can be replaced by its oral analogue capecitabine, which 
provides similar overall survival, and  is more convenient for the patient. The guideline also 
states that an adjuvant regimen without oxaliplatin, i.e. capecitabine monotherapy, can be 
considered in cases of advanced age or concomitant comorbidity. The efficacy of these 
chemotherapy schemes has been established in clinical trials, which showed improved 
disease-free and overall survival1-3.
Population-based studies have shown that the administration of chemotherapy declines 
with increasing age4-6. For individual patients, there may be valid reasons to deviate from 
standard treatment, however, variations in treatment between hospitals or geographic 
regions after adjustment for patient casemix indicate that arguments for deviating from 
clinical guidelines are interpreted differently across hospitals5-8. 
To date, the type of chemotherapy has often been ignored in population-based studies. 
Therefore, the current study evaluates which factors influence the administration of 
oxaliplatin-based chemotherapy as compared to non-oxaliplatin-based chemotherapy 
for patients with stage III colon cancer treated in daily clinical practice. 
Patients and methods
Data from the Eindhoven Cancer Registry (ECR) were used. The ECR is a population-based 
registry that collects data on all newly diagnosed cancer patients in the southern Netherlands. 
The registry area comprises about 2.4 million inhabitants and encompasses six pathology 
departments, 10 community hospitals, and two radiotherapy institutions. Information 
on patient and tumour characteristics, diagnosis and treatment is routinely extracted 
from the medical records by trained administrators. The anatomical site of the tumour is 
registered according to the International Classification of Disease – Oncology (ICD-O). The 
tumour-node-metastasis (TNM) classification is used for stage notification of the primary 
tumour, according to the edition valid at the time of cancer diagnosis. Socioeconomic status 
(SES), based on individual fiscal data on the economic value of the home and household 
income, is provided at an aggregated level for each postal code. Comorbidities are registered 
according to a slightly modified version of the Charlson Comorbidity index. 
For the present study, patients who underwent resection only or who underwent resection 
and received adjuvant chemotherapy for primary colon cancer stage III (TanyN1-2M0) 
diagnosed between 2008 and 2011 were included. Patients were excluded if they had 
received radiotherapy (n=20), neo-adjuvant chemotherapy (n=6), local chemotherapy (n=3) 
or targeted therapy (n=7). Stage was based on the pathological TNM classification. Tumour 
localisation was categorised into three subsites: proximal colon (C18.0–C18.5), distal colon 
(C18.6–C18.7) and colon other/not otherwise specified (C18.8–C18.9). Patients were divided 
into age groups: <70, 70–74 and ≥75 years. 
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Statistical analyses
Differences in patient and tumour characteristics between patients receiving oxaliplatin-based 
chemotherapy, non-oxaliplatin-based chemotherapy and no chemotherapy were analysed using 
Chi2-tests. Differences in casemix between the hospitals were also analysed using Chi2-tests. 
Patients with unknown SES, comorbidity, T stage, subsite or differentiation grade were 
not excluded from the study population, but were not taken into account in the respective 
Chi2 calculations. 
After stratification by age group, the observed proportions of patients receiving oxaliplatin 
and non-oxaliplatin-based chemotherapy were calculated for each hospital. The expected 
proportions of patients receiving oxaliplatin and non-oxaliplatin-based chemotherapy 
were also calculated after stratification by age group: a multivariable logistic regression 
model was used to calculate the chance of an individual patient receiving oxaliplatin and 
non-oxaliplatin-based chemotherapy, adjusted for gender, age, SES, comorbidity, T stage, 
N stage, subsite, differentiation grade and period of diagnosis. Based on these individual 
chances, the chance of receiving oxaliplatin and non-oxaliplatin-based chemotherapy was 
calculated for each hospital by taking the mean of all chances of the individual patients 
of each hospital. 
After exclusion of patients who did not receive adjuvant chemotherapy, multivariable 
logistic regression analysis was conducted to assess the influence of several patient and 
tumour characteristics and hospital on the probability of the administration of oxaliplatin. 
P values below 0.05 were considered statistically significant. SAS/STAT® statistical software 
(SAS system 9.3, SAS Institute, Cary, NC) was used for all analyses. 
Results
The study population consisted of 1140 patients. Overall, 47% of the patients received 
oxaliplatin-based chemotherapy, 13% received non-oxaliplatin-based chemotherapy and 
40% received no chemotherapy. Table 1 shows the general characteristics of the study 
population by adjuvant treatment. 
With regard to casemix in the hospitals, SES and N stage differed significantly between the 
hospitals (p=0.007 and p=0.048, respectively). Gender, age, comorbidity, subsite, differentiation 
grade and period of diagnosis did not differ significantly between hospitals.
Figure 1 shows the observed and expected proportions of patients receiving oxaliplatin 
and non-oxaliplatin-based chemotherapy by hospital of treatment and stratified according 
to age group. 
For patients aged <70 years, the observed proportions of patients receiving oxaliplatin 
varied from 63% to 87% between the different hospitals (Δ=24%), whereas the expected 
proportions of patients receiving oxaliplatin ranged from 76% to 79% (Δ=3%). Similarly, the 
observed proportions of patients receiving non-oxaliplatin varied between 3% and 20% 
(Δ=17%), whereas the expected proportions ranged from 9% to 10% (Δ=1%).
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Table 1 Characteristics of patients with resected stage III colon cancer, by adjuvant treatment (n=1140)
OX
(n=533)
n (%)
nOX
(n=145)
n (%)
NoCT
(n=462)
n (%)
P value*
Gender
   Male
   Female
302
231 
(57)
(43)
77 
68 
(53)
(47)
228 
234 
(49)
(51)
0.070
Age
   <70
   70-74
   ≥75 
413
84
36
(77)
(16)
 (7)
49 
29 
67 
(34)
(20)
(46)
69 
62 
331 
(15)
(13)
(72)
<0.0001
SES
   Low
   Intermediate
   High
   Institutions
   Unknown
83 
226 
194 
13
17
(16)
(43)
(36)
(2)
(3)
33 
59
39 
4
10
(23)
(40)
(27)
(3)
(7)
142 
151 
119 
27 
23 
(31)
(32)
(26)
(6)
(5)
<0.0001
Comorbidity
   0
   1
   ≥2
   Unknown
231 
144
150 
8 
(43)
(27)
(28)
(2)
43
40
61
1
(30)
(27)
(42)
(1)
84 
98
269
11 
(18)
(21)
(58)
(3)
<0.0001
T stage
   1
   2
   3
   4
   Unknown
7 
56 
395 
41
34 
(1)
(11)
(74)
(8)
(6)
9
14 
104 
12
6
(6)
(10)
(72)
(8)
(4)
7 
37
332
42
44 
(2)
(8)
(72)
(9)
(9)
0.013
N stage
   1
   2
345 
188 
(65)
(35)
100 
45 
(69)
(31)
333
129 
(72)
(28)
0.045
Subsite
   Proximal colon
   Distal colon
   Other/NOS
266 
258 
9 
(50)
(48)
(2)
89 
55 
1 
(61)
(38)
(1)
277 
177 
8 
(60)
(38)
(2)
0.002
Differentiation grade
   Well/moderate
   Poor/undifferentiated
   Unknown
399 
105 
29 
(75)
(20)
(5)
105 
32 
8 
(72)
(22)
(6)
301 
125 
36
(65)
(27)
(8)
0.010
Period of diagnosis
   2008–2009
   2010–2011
263 
270 
(49)
(51)
88 
57 
(61)
(39)
207 
255 
(45)
(55)
0.004
NoCT, no chemotherapy; nOX, non-oxaliplatin-based chemotherapy; OX, oxaliplatin-based chemotherapy. 
* P value indicates significance of the Chi2-test.
In patients aged 70–74 years, the observed proportions receiving oxaliplatin varied from 
15% to 100% between hospitals (Δ=85%), whereas the expected proportions ranged between 
41% and 61% (Δ=20%). Observed proportions receiving non-oxaliplatin ranged from 0% to 
29% (Δ=29%), whereas expected proportions varied between 14% and 18% (Δ=4%).
For patients aged ≥75 years, observed proportions of patients receiving oxaliplatin ranged 
from 0% to 19% (Δ=19%), whereas the expected proportions varied between 7% and 10% (Δ=3%). 
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Figure 1 Observed and expected proportions of patients receiving oxaliplatin-based chemotherapy (dark grey) 
and non-oxaliplatin-based chemotherapy (light grey) among patients with resected stage III colon cancer, by 
hospital of treatment and age group; expected proportions based on casemix adjustment for gender, age, SES, 
comorbidity, T stage, N stage, subsite, differentiation grade and period of diagnosis (A: n=531; B: n=175; C: n=434)
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Table 2 Crude percentages and odds ratiosa for receipt of oxaliplatin-based adjuvant chemotherapy among 
patients with stage III colon cancer treated with adjuvant chemotherapy (n=678)
Crude % Odds ratio (95% CI)
Gender
   Male
   Female
80
77
1.00
1.08
(reference)
(0.69–1.72)
Age
   <70
   70-74
   ≥75
89
74
35
1.00
0.37
0.06
(reference)
(0.21–0.64)
(0.03–0.11)
SES
   Low
   Intermediate
   High
   Institutions
   Unknown
72
79
83
76
63
1.00
1.24
1.47
0.43
0.82
(reference)
(0.68–2.29)
(0.76–2.83)
(0.11–1.62)
(0.27–2.45)
Comorbidity
   0 
   1
   ≥2
   Unknown
84
78
71
89
1.00
0.91
0.86
0.95
(reference)
(0.51–1.61)
(0.49–1.49)
(0.11–8.48)
T stage
   1 
   2
   3
   4
   Unknown
44
80
79
77
85
0.15
1.08
1.00
1.79
1.68
(0.04–0.50)
(0.50–2.36)
(reference)
(0.74–4.33)
(0.54–5.16)
N stage
   1
   2
78
81
1.00
1.18
(reference)
(0.72–1.93)
Subsite
   Proximal colon
   Distal colon
   Other/NOS
75
82
90
1.00
1.40
2.07
(reference)
(0.87–2.26)
(0.22–19.06)
Differentiation grade
   Well/moderate 
   Poor/undifferentiated
   Unknown
79
77
78
1.00
0.90
1.14
(reference)
(0.51–1.60)
(0.42–3.09)
Period of diagnosis
   2008–2009 
   2010–2011
75
83
1.00
2.08
(reference)
(1.26–3.44)
Hospital of treatment
   A
   B
   C
   D
   E
   F
   G
   H
   I
   J
84
90
92
82
75
81
67
74
64
69
0.59
1.82
1.95
1.00
0.54
0.93
0.35
0.53
0.26
0.39
(0.20–1.75)
(0.50–6.59)
(0.70–5.47)
(reference)
(0.22–1.31)
(0.37–2.33)
(0.14–0.85)
(0.22–1.26)
(0.10–0.69)
(0.15–1.04)
a Adjusted for all variables listed.
4Administration of oxaliplatin is affected by age and hospital  |  51
With respect to patients receiving non-oxaliplatin, observed proportions ranged between 
0% and 28% (Δ=28%), whereas the expected proportions varied from 13% to 18% (Δ=5%). 
In the subgroup of patients treated in the adjuvant setting, large inter-hospital variation 
in the addition of oxaliplatin was noted, ranging from 76–96% for patients aged <70 years, 
from 33–100% for patients aged 70–74 years, and from 0–100% for patients aged ≥75 years.
Table 2 presents the crude percentages and adjusted odds ratios for receipt of oxaliplatin 
among patients treated with adjuvant chemotherapy. Patients treated in hospital G and I 
were less likely to receive oxaliplatin than patients treated in hospital C (adjusted OR for 
G vs. C 0.35, 95% CI 0.14–0.85; adjusted OR for I vs. C 0.26, 95% CI 0.10–0.69). Furthermore, 
older patients, patients with a T1 stage and patients diagnosed in 2008-2009 were also less 
likely to receive oxaliplatin. 
Discussion
The current study showed that although the casemix was similar in all hospitals and 
the expected proportions of patients receiving oxaliplatin therefore varied little between 
hospitals, the observed proportions of patients receiving oxaliplatin varied greatly between 
hospitals. In the multivariate analysis, patients from two hospitals had decreased odds of 
receiving oxaliplatin. Although the addition of oxaliplatin improves disease-free and overall 
survival, this improvement is rather limited2,9. Additionally, the administration of oxaliplatin 
is associated with more toxicity and more inconvenience due to the need for intravenous 
administration3. These factors are likely taken into account by medical oncologists. A 
study recently found that physician and hospital characteristics had little influence on 
the receipt of adjuvant oxaliplatin among patients aged ≥65 years10. However, another 
study found that patients in rural regions were less likely to receive oxaliplatin-containing 
chemotherapy than patients from large metropolitan regions8. The wide variation among 
hospitals in chemotherapy administration and type of chemotherapy demonstrated in 
the present study underscores the influence of institutional factors and local practice 
patterns in determining the administration and type of adjuvant chemotherapy. Data on 
the influence of physicians and practice settings on the prescription of adjuvant systemic 
treatment in general are scarce. In 2009, a population-based study showed that elderly 
women with breast cancer treated by oncologists in a private practice were more likely 
to receive adjuvant chemotherapy. This was presumed to be related to patient volume; 
oncologists in private practices generally had a higher patient volume, translating into a 
greater comfort level in treating patients11. Other factors hypothesized by the authors to play 
a role in daily practice are clinical tradition, age of the medical specialists, multidisciplinary 
team meetings, involvement of medical specialists in scientific research and the teaching 
status of the hospital. 
The range of observed proportions of patients receiving oxaliplatin among hospitals was 
found to vary more for patients aged ≥75 years than for patients aged <70 years. Despite 
the significant proportion of elderly patients with colon cancer in clinical practice, the 
elderly are often excluded from clinical trials. Approximately 50% of patients with colon 
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cancer are aged ≥70 years, but only 16% of patients enrolled in trials were ≥70 years12. Since 
data on the effects of adjuvant chemotherapy in patients aged ≥75 years is scarce, it is 
impossible for guidelines to advise on adjuvant chemotherapy for patients over 75 years 
of age and even more complicated to indicate who is eligible for platinum-based regimens, 
leaving this decision up to the physicians’ judgement. However, a pooled analysis using 
data from randomized trials compared the efficacy of adjuvant chemotherapy for elderly 
and non-elderly patients and found that the efficacy of FOLFOX with regard to disease-free 
and overall survival was similar for patients aged less than 70 years and patients aged 70 
years or older12. This confirms that older patients fit enough to meet clinical trial eligibility 
criteria derive the same benefit from adjuvant chemotherapy as younger trial participants. 
However, whether the addition of oxaliplatin offers additional benefit to patients aged 
≥75 years remains unclear, as the available data are conflicting9,12-15. A previous study 
suggested that physicians consider the eligibility criteria of the MOSAIC trial (i.e. age <75 
years, Karnofsky performance score ≥60, and adequate blood counts and liver and kidney 
function) when deciding on the prescription of oxaliplatin16. Uncertainty remains over 
whether the lower rates of oxaliplatin observed in elderly patients represent justified clinical 
judgement or undertreatment. Moreover, this observational study cannot answer to what 
degree the older patients not treated adjuvantly might also have tolerated and benefited 
from the administration of adjuvant chemotherapy.
A limitation of our study is that detailed information on patients’ health status and 
nutritional status is lacking. ECOG performance status, for example, has previously been 
demonstrated to influence the administration of oxaliplatin17. However, the results of 
our study indicate that casemix did not differ between hospitals so this cannot explain 
the large variation in adjuvant (oxaliplatin-based) chemotherapy administration found 
between hospitals. Another limitation of our study is that for those patients receiving 
adjuvant chemotherapy, additional information on the number of (oxaliplatin-based) cycles 
administered, dose schedules used and dose modifications were not available. Previous 
research showed that approximately 30% of stage III colon cancer patients discontinued 
adjuvant therapy after less than three months despite recommendations to continue for 
six months17. Additionally, older patients are more likely than their younger counterparts 
to discontinue oxaliplatin early18. 
In conclusion, the decision to administer oxaliplatin does not only depend on predictable 
factors such as age and T stage, but also on hospital. The impact of hospital variation in 
type of adjuvant chemotherapy on outcomes such as toxicity, disease-free survival and 
quality of life needs to be further elucidated in population-based studies.
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Abstract
Purpose: To provide insight in the use, intensity and toxicity of therapy with capecitabine 
and oxaliplatin (CAPOX) and capecitabine monotherapy (CapMono) among elderly stage 
III colon cancer patients treated in everyday clinical practice.
Methods: Data from the Netherlands Cancer Registry were used. All stage III colon cancer 
patients aged ≥70 years diagnosed in the southeastern part between 2005-2012 and treated 
with CAPOX or CapMono were included. Differences in completion of all planned cycles, 
cumulative dosages and toxicity between both regimens were evaluated.
Results: 193 patients received CAPOX and 164 patients received CapMono. 33% (n=63) of the 
patients receiving CAPOX completed all planned cycles of both agents, whereas 55% (n=90) 
of the patients receiving CapMono completed all planned cycles (p<0.0001). The median 
cumulative dosage capecitabine was lower for patients treated with CAPOX (163,744 mg/m2, 
interquartile range [IQR] 83,397-202,858 mg/m2) than for patients treated with CapMono 
(189,195 mg/m2, IQR 111,667-228,125 mg/m2, p=0.0003). 54% (n=105) of the patients treated 
with CAPOX developed grade III-V toxicity, whereas 38% (n=63) of the patients treated with 
CapMono developed grade III-V toxicity (p=0.0026). After adjustment for patient and tumour 
characteristics, CapMono was associated with a lower odds of developing grade III-V toxicity 
than CAPOX (odds ratio 0.54, 95% confidence interval 0.33-0.89). For patients treated with 
CAPOX, the most common toxicities were gastrointestinal (29%), haematological (14%), 
neurological (11%) and other toxicity (13%). For patients treated with CapMono, dermatological 
(17%), gastrointestinal (13%) and other toxicity (11%) were the most common.
Conclusion: CAPOX is associated with significantly more grade III-V toxicities than CapMono, 
which had a pronounced impact on the cumulative dosage received and completion of all 
planned cycles. In this light, CapMono seems preferable over CAPOX.
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Introduction
In the Netherlands, approximately 55% of the patients newly diagnosed with colon cancer 
are aged ≥70 years at the time of colon cancer diagnosis1. Due to demographic developments 
and the introduction of a screening program for colorectal cancer up to 75 years, the number 
of elderly colon cancer patients will increase even further. Despite colon cancer being a 
disease of the ageing, patients aged 70-75 years were underrepresented in clinical trials 
that established the efficacy of adjuvant chemotherapy in stage III colon cancer. Patients 
aged >75 years may even be excluded as, e.g., in the Multicenter International Study of 
Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) 
trial, Xeloda [capecitabine] in Adjuvant Colon Cancer Therapy (X-ACT) trial and the National 
Surgical Adjuvant Breast and Bowel Project (NSABP) protocol C-07 trial2-4. 
In the X-ACT trial, 83% of patients receiving capecitabine completed their treatment 
course, but 57% required dose modifications. Overall, the toxicity profile of capecitabine 
was superior to the combination of fluorouracil (FU) and leucovorin (LV) with the exception 
of a greater frequency of hand-foot syndrome3. The NSABP C-07 trial showed that serious 
adverse events and treatment discontinuations due to toxicity were more evident with 
oxaliplatin-containing regimens than with a combination of FU and LV alone5. Subgroup 
analyses of these trials showed that patients aged 70-75 years were more likely to discontinue 
treatment prematurely as compared to younger patients4,6. Additionally, dose modifications 
and reductions were required more often4 and grade IV-V toxicity was experienced at 
a higher rate6. Since these trials were not specifically designed for elderly patients, the 
results may not be applicable to unselected elderly patients treated in clinical practice, 
who are often more vulnerable than elderly patients included in randomised clinical trials. 
Observational studies have shown that elderly patients are less often treated with adjuvant 
chemotherapy and less often receive oxaliplatin-containing regimens7-11. Additionally, 
also in population-based studies, dose reductions and treatment discontinuations were 
more frequent among elderly7,10. However, with the exception of the study by Kim et al.9, no 
distinction was made between the different single-agent chemotherapies (i.e. capecitabine 
or FU) and combination therapy (i.e. FULV and oxaliplatin (FOLFOX) or capecitabine and 
oxaliplatin (CAPOX))7,8,10. One population-based study including colon cancer patients from 
all ages showed a rapid shift from the use of FOLFOX to the use of CAPOX from January 
2005 to December 200612. 
To date, little is known about the extent to which elderly patients in daily practice are 
treated with CAPOX or capecitabine monotherapy (CapMono). Moreover, there are hardly 
any population-based studies describing the intensity of and adherence to these adjuvant 
regimens among elderly stage III colon cancer patients in detail. Furthermore, it is unknown 
to what degree unselected elderly develop toxicity from the various regimens. Therefore, 
the aim of the current study is to provide insight in the use, intensity and related toxicity 
of both CAPOX and CapMono among elderly stage III colon cancer patients treated in 
everyday clinical practice.
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Methods
Data collection
Data from the population-based Netherlands Cancer Registry (NCR), more specifically from 
the Eindhoven area, were used. This region collects data on all newly diagnosed cancer 
patients in the southeastern part of the Netherlands. The registry area comprises about 
2.4 million inhabitants (~15% of the Dutch population) and encompasses 10 community 
hospitals. Information on patient and tumour characteristics, diagnosis and treatment is 
routinely extracted from the medical records by trained administrators of the cancer registry. 
Anatomical site of the tumour is registered according to the International Classification 
of Disease – Oncology. The tumour-node-metastasis (TNM) classification is used for 
stage notification of the primary tumour, according to the edition valid at time of cancer 
diagnosis. Comorbidities are registered according to a slightly modified version of the 
Charlson Comorbidity index. The quality of the data is high, due to thorough training of the 
registration team and computerised consistency checks at regional and national levels. 
For the study population, additional data were collected from the medical records by 
experienced registration administrators. This encompassed detailed information on 
adjuvant chemotherapy: regimen and agents, number of cycles received and cumulative 
dosage of each agent. Depending on the hospital in which patients were treated, standard 
treatment with CAPOX consisted of 6 or 8 cycles. Standard dosage for each cycle is 2000 
mg/m2 capecitabine on days 1-14 and 130 mg/m2 oxaliplatin on day 1. The next cycle starts 
at day 21. Standard treatment with CapMono consisted of 6 or 8 cycles with each cycle 
including a dosage of 2000 or 2500 mg/m2 capecitabine on days 1-14 and the next cycle 
starting at day 21. Grade III to V toxicity according to the Common Terminology Criteria 
(CTC) for Adverse Events version 4.0 that appeared after the start of chemotherapy and 
within 3 months after the last day of chemotherapy was also documented. For each toxicity, 
the highest grade that occurred was recorded.
 
Study population
All stage III (pT1-4N1-2M0) colon cancer patients aged ≥70 years who underwent resection and 
were diagnosed between 2005-2012 were included.  Stage was based on the pathological 
TNM classification. Tumour localisation was divided into anatomical subsites: proximal 
colon (C18.0-C18.5), distal colon (C18.6-C18.7) and unknown or overlapping subsites of the 
colon (C18.8-C18.9). 
 
Statistical analyses
Descriptive statistics were used to provide an overview of the study population by adjuvant 
chemotherapy regimen, to give insight in the treatment intensity of both regimens, and 
to present toxicity according to regimen. 
Multivariable logistic regression analysis was used to assess which variables influenced 
receipt of CAPOX versus CapMono. Variables included in the model were gender, age, 
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comorbidity, American Society of Anaesthesiologists (ASA) score, pathological T, pathological 
N, subsite tumour, differentiation grade and period of diagnosis. 
Differences in the number of cycles, cumulative dosages received and completion of all 
planned cycles between both regimens was calculated using Wilcoxon Rank-Sum tests 
and Chi2-tests as appropriate. Multivariable logistic regression was used to assess which 
variables influenced completion of all planned cycles after stratification by regimen. Included 
in this model were grade III-V toxicity and the same patient- and tumour characteristics 
as listed in the model above. 
For each grade III-V toxicity that appeared in more than 10% of the patients, the association 
with treatment characteristics (completion of all planned cycles, number of cycles, 
cumulative dosage) was investigated after stratification by regimen, using Chi2-tests, 
Fisher’s Exact Test and Wilcoxon Rank-Sum tests as appropriate. Multivariable logistic 
regression was used to assess the independent effect of regimen on grade III-V toxicity 
after adjustment for gender, age, comorbidity, ASA score, pathological T, pathological N, 
tumour subsite, differentiation grade and period of diagnosis.
P values below 0.05 were considered statistically significant. SAS/STAT® statistical software 
(SAS System 9.4; SAS Institute, Cary, NC) was used for all analyses.
Results 
A total of 1156 stage III colon cancer patients aged ≥70 years who underwent resection and 
were diagnosed in 2005-2012, were identified (figure 1). Over the total study period, 35% of 
the patients (n=406) received adjuvant chemotherapy. A large majority (88%, n=357) of the 
patients who were treated with adjuvant chemotherapy received CAPOX or CapMono. The 
joint proportion of CAPOX and CapMono versus other regimens increased over time from 
68% in 2005-2006 to 91% in 2007-2008 to 92% in 2009-2010 and to 98% in 2011-2012 (p<0.0001).
Stage III (pT1-4N1-2M0) colon cancer patients
aged ≥70 years, diagnosed in 2005-2012, 
who underwent resection
N=1156
Patients who underwent resection only
N=750
Patients who received adjuvant chemotherapy
N=406
Other/unknown
N=18
FOLFOX
N=31
CapMono
N=164
CAPOX
N=193
Figure 1 Overview of patients included in the study
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Table 1 Crude percentages and adjusted ORsa for receipt of CAPOX versus CapMono among elderly patients with 
stage III colon cancer treated with CAPOX or CapMono (n=357)
Total number 
of patients
Number & percentage 
receiving CAPOX
OR (95% CI) for 
receiving CAPOX
Gender
   Male
   Female
186
171
109 (59)
  84 (49)
1.00
0.73
(reference)
(0.44-1.21)
Age
   70-74 years
   75-79 years
   ≥80 years
194
134
29
142 (73)
 47 (35)
   4 (14)
1.00
0.17
0.05
(reference)
(0.10-0.29)
(0.02-0.17)
Comorbidity
   0 
   1
   ≥2
   Unknown
99
100
149
9
65 (66)
48 (48)
75 (50)
1.00
0.61
0.64
(reference)
(0.31-1.19)
(0.34-1.21)
ASA score
   I-II
   III-IV
   Unknown
230
49
78
133 (58)
  21 (43)
1.00
0.54
(reference)
(0.26-1.15)
Pathological T
   1-2 
   3
   4
46
255
56
  22 (48)
145 (57)
  26 (46)
0.56
1.00
0.62
(0.26-1.20)
(reference)
(0.31-1.24)
Pathological N 
   1
   2
234
123
124 (53)
  69 (56)
1.00
1.51
(reference)
(0.88-2.57)
Subsite tumour
   Proximal colon
   Distal colon
   Other/NOS
202
150
5
100 (50)
 90 (60)
1.00
1.24
(reference)
(0.73-2.11)
Differentiation grade
   Well/moderate 
   Poor/undifferentiated
   Unknown
247
85
25
140 (57)
 42 (49)
1.00
0.73
(reference)
(0.40-1.34)
Period of diagnosis
   2005-2006
   2007-2008
   2009-2010
   2011-2012
63
89
109
96
25 (40)
56 (63)
59 (54)
53 (55)
0.38
1.39
1.07
1.00
(0.17-0.87)
(0.68-2.87)
(0.56-2.03)
(reference)
CI, confidence interval; NOS, not otherwise specified; OR, odds ratio.
Included in the analyses but results not shown for comorbidity unknown, ASA score unknown, subsite other/NOS 
and differentiation grade unknown.
a Adjusted for all variables listed.
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Use and intensity of CAPOX and CapMono
One hundred ninety-three patients received CAPOX and 164 patients received CapMono. 
Table 1 shows the association between several patient and tumour characteristics and 
regimen. Older patients (75-79 years versus 70-74 years: 35% versus 73%, adjusted odds ratio 
[OR] 0.17, 95% confidence interval 0.10-0.29 and ≥80 years versus 70-74 years: 14% versus 
73%, adjusted OR 0.05, 95% CI 0.02-0.17) and patients diagnosed in 2005-2006 (2005-2006 
versus 2011-2012: 40% versus 55%, adjusted OR 0.38, 95% CI 0.17-0.87) were less likely to 
receive CAPOX instead of CapMono. 
Table 2 provides an overview of the number of cycles received and the cumulative dosage 
received according to regimen. Within the CAPOX regimen, the median number of cycles 
capecitabine received was 7, while the median number of cycles oxaliplatin received 
was 5. The median cumulative dosage capecitabine received was 163,744 mg/m2 and the 
median cumulative dosage for oxaliplatin was 604 mg/m2. In the CapMono regimen, the 
median number of cycles received was 8 and the median cumulative dosage was 189,195 
mg/m2. The median number of cycles capecitabine did not differ between both regimens 
(p=0.720), but the median cumulative dosage capecitabine received was lower for patients 
treated with CAPOX than for patients treated with CapMono (p=0.0003).
Completion of all planned cycles differed between CAPOX and CapMono (p<0.0001); 33% 
(n=63) of the patients receiving CAPOX completed all planned cycles of both agents, whereas 
55% (n=90) of the patients receiving CapMono completed all planned cycles. Among the 
elderly who discontinued CAPOX prematurely, 63% discontinued both oxaliplatin and 
capecitabine, 31% discontinued oxaliplatin only and 6% discontinued capecitabine only. 
In a multivariable logistic regression model, only the presence of any grade III-V toxicity 
was independently related to early discontinuation of both CAPOX and CapMono (table 3).
Table 2 Treatment intensity of CAPOX and CapMono among elderly patients with stage III colon cancer treated 
with CAPOX or CapMono
CAPOX
(n=193)
CapMono
(n=164)
Oxaliplatin Capecitabine Capecitabine
Number of cycles received
   Median
   Interquartile range
   Minimum-maximum
   Unknown
n
5
2 - 7
1 - 8
1
n
7
3 - 8
1 - 8
1
n
8
4 - 8
1 - 8
6
Total dosage received 
   Median
   Interquartile range
   Minimum-maximum
   Unknown
mg/m2
604
261 - 768
109 - 1,176
13
mg/m2
163,744
83,397 - 202,858
1,869 - 253,270
13
mg/m2
189,195
111,667 - 228,125
4,980 - 294,329
21
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Table 3 Crude percentages and adjusted odds ratiosa for completing all planned cycles of CAPOX or CapMono 
among elderly patients with stage III colon cancer
CAPOX 
(n=193)
CapMono 
(n=164)
total n n (%) OR (95% CI) total n n (%) OR (95% CI)
Gender
   Male
   Female
109
84
41 (38)
22 (26)
1.00
0.58
(reference)
(0.28-1.19)
77
87
47 (61)
43 (49)
1.00
0.66
(reference)
(0.33-1.32)
Age
   70-74 years
   75-79 years
142
47
47 (33)
16 (34)
1.00
1.24
(reference)
(0.56-2.73)
52
87
31 (60)
46 (53)
1.00
0.61
(reference)
(0.27-1.38)
   ≥80 years 4 0 (0) <0.001 25 13 (52) 0.52 (0.17-1.60)
Comorbidity
   0 
   1
   ≥2
65
48
75
19 (29)
 21 (44)
20 (27)
1.00
1.73
0.74
(reference)
(0.71-4.20)
(0.31-1.78)
34
52
74
17 (50)
31 (60)
40 (54)
1.00
2.38
1.31
(reference)
(0.88-6.45)
(0.50-3.42)
ASA score
   I-II
   III-IV
133
21
48 (36)
  7 (33)
1.00
0.90
(reference)
(0.28-2.84)
97
28
53 (55)
17 (61)
1.00
1.33
(reference)
(0.47-3.73)
Pathological T
   1-2 
   3
   4
22
145
26
  9 (41)
48 (33)
  6 (23)
1.72
1.00
0.48
(0.57-5.14)
(reference)
(0.16-1.43)
24
110
30
16 (67)
59 (54)
15 (50)
1.60
1.00
0.78
(0.56-4.54)
(reference)
(0.31-1.96)
Pathological N 
   1
   2
124
69
41 (33)
22 (32)
1.00
1.27
(reference)
(0.60-2.69)
110
54
60 (55)
30 (56)
1.00
1.28
(reference)
(0.59-2.75)
Subsite tumour
   Proximal colon
   Distal colon
100
90
31 (31)
31 (34)
1.00
1.01
(reference)
(0.49-2.08)
102
60
51 (50)
38 (63)
1.00
1.94
(reference)
(0.88-4.25)
Differentiation grade
   Well/moderate 
   Poor/undifferentiated
140
42
49 (35)
10 (24)
1.00
0.62
(reference)
(0.25-1.55)
107
43
60 (56)
23 (53)
1.00
0.88
(reference)
(0.37-2.05)
Period of diagnosis
   2005-2006
   2007-2008
   2009-2010
   2011-2012
25
56
59
53
 9 (36)
19 (34)
16 (27)
19 (36)
0.79
1.23
0.55
1.00
(0.22-2.77)
(0.50-3.01)
(0.22-1.38)
(reference)
38
33
50
43
18 (47)
21 (64)
26 (52)
25 (58)
0.36
1.08
0.85
1.00
(0.12-1.08)
(0.34-3.39)
(0.33-2.19)
(reference)
Any grade III-V toxicity
   No
   Yes 
88
105
39 (44)
24 (23)
1.00
0.34
(reference)
(0.17-0.68)
101
63
65 (68)
25 (40)
1.00
0.24
(reference)
(0.11-0.52)
CI, confidence interval; OR, odds ratio.
Included in the analyses but results not shown for comorbidity unknown, ASA score unknown, subsite other/not 
otherwise specified and differentiation grade unknown.
a Adjusted for all variables listed.
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Grade III-V toxicity
An overview of the number and proportion of patients with grade III-V toxicity that occurred 
per regimen is presented in table 4. Overall, 54% (n=105) of the patients treated with CAPOX 
developed any grade III-V toxicity, whereas 38% (n=63) of the patients treated with CapMono 
developed any grade III-V toxicity (p=0.0026). Additionally, among patients receiving 
CAPOX as compared to patients receiving CapMono, grade III (53% versus 38%, p=0.0048) 
and grade IV toxicity (8% versus 1%, p=0.0038) occurred more frequently. Only 1 case of 
grade V toxicity was reported. Also in a multivariable logistic regression model, adjusted 
for gender, age, comorbidity, ASA score, pathological T, pathological N, tumour subsite, 
differentiation grade and period of diagnosis, was CapMono associated with a lower odds 
of developing any grade III-V toxicity than CAPOX (adjusted OR 0.54, 95% CI 0.33-0.89). The 
other listed variables were not associated with any grade III-V toxicity (results not shown). 
For patients treated with CAPOX, most common toxicities were gastrointestinal (26%, 
mostly nausea/vomiting and diarrhoea), haematological (14%), neurological (11%) and 
other toxicity (13%, mostly fatigue). For patients treated with CapMono, dermatological 
(17%), gastrointestinal (13%, mostly diarrhoea) and other toxicity (11%, mostly fatigue) were 
most common.
Associations between treatment intensity and toxicity
Table 5 presents the number of cycles and cumulative dosages received for both regimens 
according to the presence or absence of the most common grade III-V toxicity. For patients 
treated with CAPOX, the cumulative dosage received of both capecitabine and oxaliplatin 
was lower for patients with gastrointestinal toxicity. Additionally, the received cumulative 
Table 4 Number and proportion of elderly stage III colon cancer patients with CTC grade III-V toxicities, by 
chemotherapy regimen
CAPOX 
(n=193)
CapMono 
(n=164)
Grade 
III
Grade 
IV
Grade 
V
Total
n (%)
Grade 
III
Grade 
IV
Grade 
V
Total
n (%)
Haematological toxicity 20 7 0 27 (14) 3 0 1 4 (2)
Gastrointestinal toxicity 46 4 0 50 (26) 22 0 0 22 (13)
Cardiovascular toxicity 11 1 0 12 (6) 7 0 0 7 (4)
Pulmonary toxicity 3 0 0 3 (2) 2 0 0 2 (1)
Dermatological toxicity 5 0 0 5 (3) 28 0 0 28 (17)
Neurological toxicity 21 0 0 21 (11) 2 0 0 2 (1)
Renal/genital/urinary toxicity 5 0 0 5 (3) 2 0 0 2 (1)
Other toxicity 22 3 0 25 (13) 17 1 0 18 (11)
Any toxicity* 103 15 0 105 (54) 63 2 1 63 (38)
* In this row, the number of patients in the columns grade III, IV and V do not add up to the number of patients in 
the column total, because patients can have more than one toxicity.
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dosage of capecitabine but not of oxaliplatin was higher for patients with neurological toxicity 
and lower for patients with other toxicity (i.e. fatigue). With regard to the number of cycles 
received, similar results were found, although the number of cycles of capecitabine did 
not differ for patients with or without neurological toxicity, while the number of cycles of 
oxaliplatin received was higher for patients with neurological toxicity. For patients treated 
with CapMono, both the received cumulative dosage of capecitabine and the number of 
cycles was significantly lower for patients with diarrhoea or other toxicity (i.e. fatigue).
Table 5 Number of cycles and total dosage of CAPOX or CapMono received among elderly patients with stage III 
colon cancer, according to grade III-V toxicity
CAPOX 
(n=193)
Capecitabine Oxaliplatin
cycles, n 
(median, IQR)
dosage, mg/m2
(median, IQR)
cycles, n 
(median, IQR)
dosage, mg/m2
(median, IQR)
Haematological toxicity 
   Yes
   No
P value
5 (2-8)
7 (4-8)
0.174
146,618 (59,484-183,178)
164,281 (90,314-204,722)
0.281
3 (2-8)
6 (2-6)
0.555
495 (253-757)
605 (263-768)
0.637
Gastrointestinal toxicity
   Yes
   No
P value
3 (1-8)
8 (6-8)
<0.0001
59,783 (28,292-159,636)
176,232 (135,539-209,184)
<0.0001
2 (1-5)
6 (3-7)
<0.0001
254 (129-633)
647 (380-779)
<0.0001
Neurological toxicity
   Yes
   No
P value
8 (6-8)
7 (3-8)
0.130
181,729 (150,520-218,169)
163,468   (81,492-199,959)
0.038
6 (5-7)
5 (2-6)
0.045
648 (524-803)
586 (258-763)
0.068
Other toxicity
   Yes
   No
P value
4 (2-8)
7 (4-8)
0.013
90,550 (55,197-155,556)
166,179 (115,420-202,879)
0.023
4 (2-7)
6 (2-7)
0.278
540 (256-793)
607 (261-767)
0.584
CapMono 
(n=164)
Capecitabine
cycles, n 
(median, IQR)
dosage, mg/m2
(median, IQR)
Gastrointestinal toxicity
   Yes
   No
P value
4 (2-8)
8 (5-8)
0.006
86,547 (49,018-168,603)
197,862 (144,763-232,555)
0.0002
Dermatological toxicity
   Yes
   No
P value
8 (5-8)
8 (4-8)
0.523
187,314 (145,797-231,579)
189,862 (101,030-228,125)
0.684
Other toxicity
   Yes
   No
P value
5 (2-8)
8 (5-8)
0.024
123,190 (61,222-173,205)
195,654 (139,026-229,150)
0.028
P value indicates significance of the Wilcoxon rank-sum test.
IQR, interquartile range.
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Discussion
The aim of this study was to provide insight in the use, intensity and related toxicity of both 
CAPOX and CapMono among elderly stage III colon cancer patients treated in everyday 
clinical practice. 
This study showed that only 35% of the elderly stage III colon cancer patients received 
adjuvant chemotherapy, which is in line with previous population-based studies from the 
Netherlands8,13 but somewhat lower than the 40-50% reported in other international studies7,14. 
In the years included in this study (2005-2012), adjuvant chemotherapy consisted of CAPOX 
or CapMono in 87%, while FU-based regimens were prescribed sparsely. In contrast, 87% 
received FULV in the previous period (1997-2004)15. The use of capecitabine instead of FU in 
the Netherlands is high in comparison to other countries. A population-based study from 
France including patients from all ages showed that almost 95% of the patients receiving 
chemotherapy, was treated with either FOLFOX or FULV in 2004-200916. Another French 
study that only included the year 2009, showed higher proportions of capecitabine, especially 
among elderly11. Additionally, a single-centre retrospective study suggests that in Canada, 
regardless of age, FOLFOX was prescribed more often than CAPOX in the years 2006-201117. 
The shift towards capecitabine-based regimens in the Netherlands over the last decade 
is related to the fact that capecitabine-based regimens are non-inferior to and less toxic 
than FU-based regimens3,4, are more convenient for the patient and have a more favourable 
reimbursement policy for hospitals. On the other hand, especially among elderly cancer 
patients in which polypharmacy is common, possible drug interactions with capecitabine 
should be taken into account when deciding on capecitabine administration. For example, 
interaction with anticoagulant coumarin derivates have been previously shown18. However, 
in practice, oral anticoagulants are often replaced by dalteparin instead of that the use of 
capecitabine is waived. 
Patients aged ≥70 years were less likely to receive CAPOX instead of CapMono, which 
is in line with previous studies showing that elderly patients were less likely to receive 
oxaliplatin-containing regimens7-11. This most likely reflects the highly debated additional 
benefit from adding oxaliplatin to fluoropyrimidine chemotherapy in elderly patients19-21. 
One trial in which the effect of the different chemotherapy regimens on 3-year disease-free 
survival are compared among elderly patients with colon cancer is now ongoing22.
Elderly patients receiving CAPOX less frequently completed all planned cycles compared 
to patients receiving CapMono (33% versus 55%, p<0.0001). Although the median number 
of capecitabine cycles did not differ between regimens, the median cumulative dosage 
of capecitabine was lower for patients who received CAPOX compared to patients who 
received CapMono. This is probably related to the fact that the standard dosage for 
capecitabine is lower in the CAPOX regimen compared to the CapMono regimen (2000 
versus 2500 mg/m2). In addition, increased toxicity with the CAPOX regimen can also 
have impacted the cumulative dosage of capecitabine. The fact that patients treated with 
CAPOX received a lower median cumulative dosage capecitabine than patients treated 
with CapMono seems counterproductive, as it has been suggested that the main benefit 
from adjuvant treatment is derived from the fluoropyrimidine. 
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The proportions of patients completing their adjuvant treatment as described in our study 
are mostly lower compared to currently available studies. Not only in comparison to large 
phase III trials such as the X-ACT trial4 in which 74% of the patients aged 70-75 years 
completed their treatment course but also compared to other population-based studies 
including elderly. In the study by Kim et al., 51% of patients aged ≥65 years treated with 
CAPOX or FOLFOX and 23% of the patients aged ≥65 years treated with either CapMono 
or FU-LV completed less than 75% of their cycles9. Results from the study by Laurent et al. 
showed that among patients aged ≥70 years and treated with FOLFOX, early discontinuation 
(i.e. <12 cycles) was present in 33% for 5-FU and in 69% for oxaliplatin23. In yet another 
population-based study, 40% of patients aged ≥65 years discontinued chemotherapy7. No 
distinction was made in type of adjuvant chemotherapy. We found that only the presence 
of any grade III-V toxicity was independently related to early discontinuation of both 
CAPOX and CapMono. The relationship between toxicity and treatment discontinuation 
was not often investigated in previous studies, except for the study by Kim et al., in which 
differences in treatment discontinuation between patients treated with monotherapy 
(capecitabine + FU) or combination chemotherapy (CAPOX + FOLFOX) according to the 
presence of non-haematological and haematological toxicity was investigated9. A difference 
was found between both types of chemotherapy in discontinuation due to haematological 
toxicity (3% versus 17% respectively, p=0.0004) but no difference in discontinuation due to 
non-haematological toxicity (28% versus 34% respectively, p=0.20)9.
Especially for elderly patients with competing causes of death, adjuvant treatment should 
lead to gains in quality of life, symptom control and preserved functional status beyond 
survival benefit24. In this light, and given the uncertain effect of the addition of oxaliplatin 
on (overall) survival in elderly patients19-21, is it important to consider the prevalence of 
chemotherapy-induced toxicity. Grade III-V toxicity was more evident with CAPOX (54%) 
than with CapMono (38%). This is in line with previous studies showing higher toxicity rates 
with oxaliplatin-containing regimens5,9. Previous studies have shown that the incidence 
of severe toxicity is not only determined by the chemotherapeutic agents itself but also 
by patient characteristics. The study by Extermann et al.25 showed that the risk of severe 
toxicity is significant for any older patient receiving chemotherapy.  Patient differences 
in Eastern Cooperative Oncology Group performance status, nutritional status and mental 
status contributed two to three times more than chemotherapy differences to the risk of 
non-haematological toxicity25. The study by Hurria et al. described the importance of a 
scoring system dominated by patient characteristics (based upon a geriatric assessment) in 
predicting chemotherapy toxicity26. Other studies have also shown the impact of geriatric 
factors on patient selection for (type of) chemotherapy and risk of toxicity. These factors 
included for example malnutrition and functional and cognitive impairment27,28.
Among patients treated with CAPOX, mostly oxaliplatin-related toxicity occurred. Especially 
grade III-IV neurological toxicity, i.e. neuropathy, which occurred in 11%, can have a disabling 
and prolonged effect with a major influence on quality of life24,29. In a previous study we 
reported that among patients treated with oxaliplatin, neuropathy-related symptoms are 
still reported 2 to 11 years after diagnosis30. 
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Another toxicity of concern in the CAPOX regimen is diarrhoea. In our study the rate of 
gastrointestinal toxicity was twice as high with CAPOX compared with CapMono. In a trial 
comparing continuous or intermittent chemotherapy (COIN), which included patients with 
metastatic colorectal cancer, has shown that the incidence of grade III-IV diarrhoea was 
also higher among patients receiving CAPOX ± cetuximab compared to patients receiving 
FOLFOX ± cetuximab31,32. Additionally, another trial in the metastatic setting which included 
exclusively frail and elderly patients (the Fluorouracil, Oxaliplatin, CPT11 [irinotecan]: Use 
and Sequencing 2 (FOCUS2) trial) reported that the overall risk of grade ≥III toxicity was 
higher with capecitabine compared to FU, with specifically higher rates of nausea, vomiting, 
diarrhoea, anorexia and hand-foot syndrome33. As studies in the adjuvant setting showed 
a favourable toxicity profile for capecitabine3,34, literature data are discordant. 
In the X-ACT trial, grade III hand-foot syndrome occurred in 17% of the patients receiving 
capecitabine4. In our study, 17% of the patients receiving CapMono developed dermatological 
complications such as hand-foot syndrome. In contrast, only 3% of the patients treated with 
CAPOX developed dermatological complications. This presumably reflects the lower dosage 
of capecitabine in the CAPOX regimen in comparison with the monotherapy regimen.
The current study also investigated the associations between the most common grade 
III-V toxicity and the median number of cycles and cumulative dosage received. In general, 
toxicity that occurred rapidly was associated with a lower median number of cycles and 
cumulative dosage received, such as gastrointestinal toxicity (i.e. nausea/vomiting and 
diarrhoea). Other toxicity was cumulative, appeared in a later stage during the treatment 
course and did not result in lower median number of cycles and cumulative dosages 
received, such as haematological toxicity, neuropathy and hand-foot syndrome. It is also 
possible that, when these toxicities occur and need to be mitigated, cycles are delayed 
instead of the dosage being reduced or cycles prematurely discontinued. 
A limitation of our study is that only grade ≥III toxicity was recorded. Kalsi et al. previously 
showed that  even low grade toxicities can lead to treatment modification and early 
discontinuation in older patients35. 
In conclusion, still only one third of stage III colon cancer patients aged ≥70 years received 
adjuvant chemotherapy. CAPOX is associated with more grade III-IV toxicities than CapMono, 
which had a pronounced impact on treatment intensity as patients receiving CAPOX more 
often discontinued treatment before all planned cycles were completed and received a 
lower cumulative dosage capecitabine as compared to patients receiving CapMono. As 
the main benefit from adjuvant therapy arises from fluoropyrimidine agents, CapMono 
seems preferable over CAPOX in elderly patients. 
Of course, effects on recurrence-free survival and quality of life should be taken into 
account as well. Nonetheless, the current study provides new insights that will help medical 
oncologists to discuss more adequately the benefits and drawbacks of the regimens with 
elderly patients.
68  |  Chapter 5
References
1. Netherlands Cancer Registry. Cijfers over kanker. 
Retrieved from www.cijfersoverkanker.nl on 18-11-
2015.
2. Andre T, Boni C, Navarro M, Tabernero J, Hickish 
T, Topham C, et al. Improved overall survival with 
oxaliplatin, fluorouracil, and leucovorin as adjuvant 
treatment in stage II or III colon cancer in the MOSAIC 
trial. J Clin Oncol 2009;27:3109-3116.
3. Twelves C, Wong A, Nowacki MP, Abt M, Burris 
H, 3rd, Carrato A, et al. Capecitabine as adjuvant 
treatment for stage III colon cancer. N Engl J Med 
2005;352:2696-2704.
4. Twelves C, Scheithauer W, McKendrick J, Seitz JF, 
Van Hazel G, Wong A, et al. Capecitabine versus 
5-fluorouracil/folinic acid as adjuvant therapy for 
stage III colon cancer: final results from the X-ACT 
trial with analysis by age and preliminary evidence 
of a pharmacodynamic marker of efficacy. Ann Oncol 
2012;23:1190-1197.
5. Kuebler JP, Colangelo L, O’Connell MJ, Smith RE, 
Yothers G, Begovic M, et al. Severe enteropathy 
among patients with stage II/III colon cancer 
treated on a randomized trial of bolus 5-fluorouracil/
leucovorin plus or minus oxaliplatin: a prospective 
analysis. Cancer 2007;110:1945-1950.
6. Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, 
Colangelo LH, Petrelli NJ, et al. Oxaliplatin as 
adjuvant therapy for colon cancer: updated results 
of NSABP C-07 trial, including survival and subset 
analyses. J Clin Oncol 2011;29:3768-3774.
7. Kahn KL, Adams JL, Weeks JC, Chrischilles EA, 
Schrag D, Ayanian JZ, et al. Adjuvant chemotherapy 
use and adverse events among older patients with 
stage III colon cancer. JAMA 2010;303:1037-1045.
8. van Erning FN, Bernards N, Creemers GJ, Vreugdenhil 
A, Lensen CJ, Lemmens VE. Administration of 
adjuvant oxaliplatin to patients with stage III colon 
cancer is affected by age and hospital. Acta Oncol 
2014;53:975-980.
9. Kim CA, Spratlin JL, Armstrong DE, Ghosh S, Mulder 
KE. Efficacy and safety of single agent or combination 
adjuvant chemotherapy in elderly patients with 
colon cancer: a Canadian cancer institute experience. 
Clin Colorectal Cancer 2014;13:199-206.
10. Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt 
JA, Schrag D, et al. Patterns of adjuvant chemotherapy 
use in a population-based cohort of patients with 
resected stage II or III colon cancer. J Clin Oncol 
2011;29:3255-3262.
11. Doat S, Thiebaut A, Samson S, Ricordeau P, Guillemot 
D, Mitry E. Elderly patients with colorectal cancer: 
treatment modalities and survival in France. 
National data from the ThInDiT cohort study. Eur J 
Cancer 2014;50:1276-1283.
12. van Gils CW, Koopman M, Mol L, Redekop WK, 
Uyl-de Groot CA, Punt CJ. Adjuvant chemotherapy 
in stage III colon cancer: guideline implementation, 
patterns of use and outcomes in daily practice in The 
Netherlands. Acta Oncol 2012;51:57-64.
13. van Erning FN, Creemers GJ, De Hingh IH, Loosveld 
OJ, Goey SH, Lemmens VE. Reduced risk of distant 
recurrence after adjuvant chemotherapy in patients 
with stage III colon cancer aged 75 years or older. 
Ann Oncol 2013;24:2839-2844.
14. Sanoff HK, Carpenter WR, Sturmer T, Goldberg 
RM, Martin CF, Fine JP, et al. Effect of adjuvant 
chemotherapy on survival of patients with stage 
III colon cancer diagnosed after age 75 years. J Clin 
Oncol 2012;30:2624-2634.
15. Hoeben KW, van Steenbergen LN, van de Wouw 
AJ, Rutten HJ, van Spronsen DJ, Janssen-Heijnen 
ML. Treatment and complications in elderly stage 
III colon cancer patients in the Netherlands. Ann 
Oncol 2013;24:974-979.
16. Hamza S, Bouvier AM, Rollot F, Lepage C, Faivre J, 
Bedenne L. Toxicity of oxaliplatin plus fluorouracil/
leucovorin adjuvant chemotherapy in elderly 
patients with stage III colon cancer: a population-
based study. Ann Surg Oncol 2014;21:2636-2641.
17. Loree JM, Mulder KE, Ghosh S, Spratlin JL. CAPOX 
associated with toxicities of higher grade but 
improved disease-free survival when compared 
with FOLFOX in the adjuvant treatment of stage III 
colon cancer. Clin Colorectal Cancer 2014;13:172-177.
18. Camidge R, Reigner B, Cassidy J, Grange S, Abt M, 
Weidekamm E, et al. Significant effect of capecitabine 
on the pharmacokinetics and pharmacodynamics 
of warfarin in patients with cancer. J Clin Oncol 
2005;23:4719-4725.
19. McCleary NJ, Meyerhardt JA, Green E, Yothers G, de 
Gramont A, Van Cutsem E, et al. Impact of age on the 
efficacy of newer adjuvant therapies in patients with 
stage II/III colon cancer: findings from the ACCENT 
database. J Clin Oncol 2013;31:2600-2606.
20. Tournigand C, Andre T, Bonnetain F, Chibaudel B, 
Lledo G, Hickish T, et al. Adjuvant therapy with 
fluorouracil and oxaliplatin in stage II and elderly 
patients (between ages 70 and 75 years) with colon 
cancer: subgroup analyses of the Multicenter 
International Study of Oxaliplatin, Fluorouracil, and 
Leucovorin in the Adjuvant Treatment of Colon 
Cancer trial. J Clin Oncol 2012;30:3353-3360.
5Intensity adjuvant chemotherapy regimens and grade III-V toxicities  |  69
21. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont 
A, Tournigand C, Andre T, et al. Pooled analysis of 
safety and efficacy of oxaliplatin plus fluorouracil/
leucovorin administered bimonthly in elderly 
patients with colorectal cancer. J Clin Oncol 
2006;24:4085-4091.
22. Aparicio T, Francois E, Cristol-Dalstein L, Carola E, 
Maillard E, Paillaud E, et al. PRODIGE 34 - FFCD 1402 
- ADAGE: Adjuvant chemotherapy in elderly patients 
with resected stage III colon cancer: A randomized 
phase 3 trial. Dig Liver Dis 2016;48:206-207.
23. Laurent M, Des Guetz G, Bastuji-Garin S, Culine S, 
Caillet P, Aparicio T, et al. Chronological Age and 
Risk of Chemotherapy Nonfeasibility: A Real-Life 
Cohort Study of 153 Stage II or III Colorectal Cancer 
Patients Given Adjuvant-modified FOLFOX6. Am J 
Clin Oncol 2015; Epub ahead of print.
24. McCleary NJ, Dotan E, Browner I. Refining the 
Chemotherapy Approach for Older Patients With 
Colon Cancer. J Clin Oncol 2014;32:2570-2580.
25. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, 
DeFelice J, et al. Predicting the risk of chemotherapy 
toxicity in older patients: the Chemotherapy Risk 
Assessment Scale for High-Age Patients (CRASH) 
score. Cancer 2012;118:3377-3386.
26. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, 
Gross CP, et al. Predicting chemotherapy toxicity in 
older adults with cancer: a prospective multicenter 
study. J Clin Oncol 2011;29:3457-3465.
27. Caillet P, Canoui-Poitrine F, Vouriot J, Berle M, 
Reinald N, Krypciak S, et al. Comprehensive geriatric 
assessment in the decision-making process in 
elderly patients with cancer: ELCAPA study. J Clin 
Oncol 2011;29:3636-3642.
28. Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil 
F, Le Brun-Ly V, et al. Geriatric factors predict 
chemotherapy feasibility: ancillary results of FFCD 
2001-02 phase III study in first-line chemotherapy 
for metastatic colorectal cancer in elderly patients. 
J Clin Oncol 2013;31:1464-1470.
29. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, 
Colangelo LH, et al. Neurotoxicity from oxaliplatin 
combined with weekly bolus fluorouracil and 
leucovorin as surgical adjuvant chemotherapy for 
stage II and III colon cancer: NSABP C-07. J Clin 
Oncol 2007;25:2205-2211.
30. Mols F, Beijers T, Lemmens V, van den Hurk CJ, 
Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-
induced neuropathy and its association with quality 
of life among 2- to 11-year colorectal cancer survivors: 
results from the population-based PROFILES registry. 
J Clin Oncol 2013;31:2699-2707.
31. Adams RA, Meade AM, Madi A, Fisher D, Kay E, 
Kenny S, et al. Toxicity associated with combination 
oxaliplatin plus fluoropyrimidine with or without 
cetuximab in the MRC COIN trial experience. Br J 
Cancer 2009;100:251-258.
32. Madi A, Fisher D, Wilson RH, Adams RA, Meade 
AM, Kenny SL, et al. Oxaliplatin/capecitabine vs 
oxaliplatin/infusional 5-FU in advanced colorectal 
cancer: the MRC COIN trial. Br J Cancer 2012;107:1037-
1043.
33. Seymour MT, Thompson LC, Wasan HS, Middleton 
G, Brewster AE, Shepherd SF, et al. Chemotherapy 
options in elderly and frail patients with metastatic 
colorectal cancer (MRC FOCUS2): an open-label, 
randomised factorial trial. Lancet 2011;377:1749-1759.
34. Scheithauer W, McKendrick J, Begbie S, Borner M, 
Burns WI, Burris HA, et al. Oral capecitabine as an 
alternative to i.v. 5-fluorouracil-based adjuvant 
therapy for colon cancer: safety results of a 
randomized, phase III trial. Ann Oncol 2003;14:1735-
1743.
35. Kalsi T, Babic-Illman G, Fields P, Hughes S, Maisey 
N, Ross P, et al. The impact of low-grade toxicity in 
older people with cancer undergoing chemotherapy. 
Br J Cancer 2014;111:2224-2228.

Clinical Colorectal Cancer 2016; Epub ahead of print
F.N. van Erning
M.L.G. Janssen-Heijnen
J.A. Wegdam
G.D. Slooter
J.H. Wijsman
G. Vreugenhil
A.J.M. Beijers
L.V. van de Poll-Franse
V.E.P.P. Lemmens
The course of neuropathic symptoms 
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among elderly patients with stage III 
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Abstract
Introduction: Among the elderly, the impairment of functional capacities due to neuropathy 
can have a significant impact. The aim of the present study was to investigate the course 
of neuropathic symptoms among elderly patients with stage III colon cancer treated with 
CAPOX, capecitabine monotherapy or no adjuvant chemotherapy.
Materials and methods: The Netherlands Cancer Registry was used to select patients 
with stage III colon cancer and aged ≥70years. Questionnaires were sent after 
resection (T1) and six (T2) and twelve months (T3) later. Neuropathy was measured 
using the European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20. Logistic generalized 
estimating equations analyses were used to evaluate the effect of chemotherapy on the 
course of neuropathic symptoms.
Results: Of 155 eligible patients, 117 (76%) completed the T1 questionnaire, and 69 and 
59 completed the T2 and T3 questionnaires, respectively. The course of the sensory 
symptoms tingling fingers or hands; tingling toes or feet; numbness in fingers or hands; 
and numbness in toes or feet was significantly unfavorable for patients treated with 
adjuvant chemotherapy (CAPOX or capecitabine) compared with that for patients who 
had not received adjuvant chemotherapy. The course of numbness in toes or feet also 
differed significantly between patients treated with CAPOX (T1, 7%; T2, 50%; T3, 42%) and 
patients treated with capecitabine (T1, 17%; T2, 31%; T3, 8%). Additionally, patients treated 
with capecitabine reported significantly less tingling toes or feet (T1, 6%; T2, 25%; T3, 7%) 
compared with patients treated with CAPOX (T1, 0%; T2, 50%; T3, 58%). 
Conclusion: The course of several sensory symptoms over time was less favorable for elderly 
patients with colon cancer treated with chemotherapy. Moreover, CAPOX was associated 
with more symptoms in toes and feet compared with capecitabine. It is important to inform 
patients of these risks to enable informed decision-making.
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Introduction
The adjuvant treatment for patients with pathological stage III colon cancer after resection 
of the primary tumor is chemotherapy (CTx). Oxaliplatin combined with a fluoropyrimidine 
(i.e. capecitabine or 5-fluorouracil/leucovorin) is the standard regimen for these patients, 
although the benefit of oxaliplatin on recurrence-free and overall survival is uncertain 
in elderly patients1-5. In the case of contraindications for oxaliplatin, adjuvant treatment 
should consist of capecitabine monotherapy (CapMono)6. 
CTx-induced peripheral neuropathy (CIPN) is increasingly recognized as an important 
toxicity which compromises treatment plans. Although peripheral neuropathy is a very 
rare complication of capecitabine7, it is a common adverse effect of oxaliplatin. Oxaliplatin 
can cause both an acute, mainly cold-triggered neuropathy and a chronic neuropathy8,9. 
Symptoms can differ: most symptoms are sensory, although motor and autonomic 
dysfunction can also occur10,11. In general, acute neuropathy is characterized by paresthesia 
and dysesthesia of the hands and feet and reverses within a week, while chronic neuropathy 
mainly consists of symptoms of hypoesthesia and is only partly reversible9,12,13. Acute 
neuropathy occurs in 80 to 90% of patients treated with oxaliplatin10,14-16 and chronic 
neuropathy affects 30 to 60% of patients10,15. 
The prevention and treatment of CIPN remain difficult17. Because CIPN interferes with 
many aspects of daily life and is negatively associated with health-related quality of life, 
this is of major concern18,19. Particularly for the growing population of elderly patients, the 
impairment of functional capacities can have a significant effect on their lives. Having 
information about the effects of different CTx regimens on neuropathic symptoms can 
help patients and clinicians in deciding on a suitable treatment course. 
The aim of the present study was to gain insight into differences in the course of neuropathic 
symptoms among elderly patients with stage III colon cancer subsequently treated with 
a combination of capecitabine and oxaliplatin (CAPOX), CapMono or no adjuvant CTx in 
daily clinical practice. First, the interaction between treatment and time was investigated. 
Subsequently, the main effect of treatment on neuropathic symptoms was investigated. 
We expected that patients treated with CAPOX would experience neuropathic symptoms 
more often and that the course of their symptoms would be less favorable than that of 
patients treated with CapMono or no CTx. 
Materials and methods
Data collection and study population
Data were collected within the PROFILES database (Patient Reported Outcomes Following 
Initial treatment and Long term Evaluation of Survivorship)20. PROFILES is linked to clinical 
data from the population-based Netherlands Cancer Registry (NCR). The NCR records the 
data for all patients with newly diagnosed cancer in the Netherlands. Information on 
patients and tumor characteristics, diagnosis and treatment is routinely extracted from the 
medical records by trained administrators of the NCR. The anatomic tumor site is registered 
according to the International Classification of Diseases – Oncology. The pathologic TNM 
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classification is used for staging of the primary tumor, according to the edition valid at 
the cancer diagnosis. Socioeconomic status (SES), based on individual fiscal data on the 
economic value of the home and household income, is provided at an aggregated level 
for each postal code. The number of comorbid conditions at time of cancer diagnosis is 
registered using a slightly modified version of the Charlson comorbidity index. 
The NCR was used to identify patients with stage III (pT1-4N1-2M0) colon cancer aged ≥70 years 
who had undergone resection. Questionnaire data were collected for patients diagnosed in 
nine hospitals in the southeastern part of the Netherlands between March 2013 to October 
2014. The treating physicians verified the status of each eligible patient before the patient 
was approached for study participation (e.g. patients with serious cognitive impairment were 
excluded). All eligible patients received an invitation letter from their attending surgeon 
and both a paper questionnaire and a login account and password to complete the survey 
online. After two weeks, reminders were sent to patients who had not responded to the 
survey. The first questionnaire was sent after resection (T1) and the respondents received 
subsequent questionnaires six months (T2) and twelve months (T3) later.
A certified medical ethics committee approved the present study, and all patients provided 
written informed consent for participation in the study and agreed to the linkage of the 
questionnaire data with the sociodemographic and clinical information in the NCR.
Study measures
Peripheral neuropathy was measured using the European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral 
Neuropathy 20 (EORTC QLQ-CIPN20)21, which contains 20 items assessing sensory, motor 
and autonomic symptoms. All items are measured on a four point Likert scale ranging 
from 1 (not at all) to 4 (very much). 
Diabetes, osteoarthritis or rheumatoid arthritis are comorbid conditions that are known 
to be associated with neuropathy-like symptoms. The presence of these conditions at 
completion of the first questionnaire was self-reported by the patients and assessed using 
the adapted Self-Administered Comorbidity Questionnaire22.
Statistical analyses
Differences in the characteristics between the respondents and non-respondents were 
assessed using Chi2-tests and Fisher’s Exact tests as appropriate. Differences between 
respondents completing 1 questionnaire and respondents completing ≥2 questionnaires 
and differences between respondents treated with CAPOX, CapMono or no CTx were 
analyzed similarly.
For the group of respondents subsequently treated with CAPOX, CapMono or no CTx, 
the number and percentages of patients who experienced mild to severe neuropathic 
symptoms at T1 were reported per individual item of the EORTC QLQ-CIPN20. The severity of 
neuropathic symptoms was dichotomized as in a previous report23 as follows: the response 
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categories ‘a little’, ‘quite a bit’ and ‘very much’ were grouped as mild to severe neuropathic 
symptoms and the response category ‘not at all’ as no neuropathic symptoms. Multivariable 
logistic regression analyses were performed to evaluate differences between treatment 
groups in the proportion of patients reporting mild to severe neuropathy symptoms at T1. 
Adjustments were made for age category (70-74, 75-79 and ≥80 years), and the presence 
of osteoarthritis and diabetes.
For the subgroup of patients completing ≥2 questionnaires and treated with CAPOX, 
CapMono or no CTx, the number and percentages of patients who experienced mild 
to severe neuropathic symptoms at T1, T2 and T3 were reported per individual item of 
the EORTC QLQ-CIPN20. Because neuropathic symptoms were repeatedly measured 
in the same patients and observations of one patient were not independent of each 
other, logistic Generalized Estimating Equations (GEE) analyses with an exchangeable 
correlation structure were used. Both the interaction between treatment and time (i.e. T1 
to T2 to T3) and the main effect of treatment on neuropathic symptoms were evaluated. 
First, the interaction between receipt of CTx (yes vs. no, regardless of regimen) and time 
was evaluated. Second, the interaction between the CTx regimen received and time was 
assessed. In all logistic GEE-analyses, adjustments were also made for time, age category, 
osteoarthritis and diabetes.
P values below 0.05 were considered statistically significant. SAS/STAT® statistical software 
(SAS system 9.4, SAS Institute, Cary, NC) was used for all analyses.
Results
Study population
Of the 155 elderly patients with stage III colon cancer eligible for participation, 117 completed 
the first questionnaire (T1), resulting in a response rate of 76%. Subsequently, 69 patients 
completed the second questionnaire (T2) and 59 patients the third questionnaire (T3) (figure 1).
No significant differences between the respondents and non-respondents were present, 
except for older age at the cancer diagnosis among the non-respondents (table 1). For the 
respondents, the mean interval between the date of resection of the primary tumor and 
the date of completing the first questionnaire was 40 ± 18 days. Additionally, among the 
respondents treated with adjuvant CTx, 88% completed the first questionnaire before or 
during cycle 1 and 12% during cycle 2. The patients receiving CAPOX were younger than 
those receiving CapMono or no CTx, and the patients treated without CTx more often had 
osteoarthritis compared with those receiving CAPOX or CapMono (table 2).
Analyses between the respondents who completed one and those who completed ≥2 
questionnaires showed no significant differences in gender, age, SES, number of comorbid 
conditions, diabetes or adjuvant treatment (data not shown). Osteoarthritis was less common 
among respondents completing ≥2 questionnaires than among respondents completing 
1 questionnaire (19% vs. 35%, p=0.0434). 
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Figure 1 Flowchart of the data collection process
180 stage III colon cancer patients aged ≥70 years, 
from 9 hospitals in the southeastern part of the 
Netherlands, diagnosed between March 2013 and 
October 2014, were selected from the NCR
7 patients were excluded due to other 
ongoing research
The status of 173 patients were checked against NCR 
and hospital records
155 patients were eligible for participation and 
received a questionnaire
38 (24.5%) patients actively refused 
or did not return the questionnaire
117 (75.5%) patients completed the questionnaire from 
wave 1
2 patients died, 31 patients 
discontinued participation, 1 patient 
had an unverifiable address
83 patients were invited for wave 2
14 (16.9%) patients actively refused 
or did not return the questionnaire
69 (83.1%) patients completed the questionnaire from 
wave 2
4 patients died, 3 patients 
discontinued participation
62 patients were invited for wave 3
3 (4.8%) patients actively refused or 
did not return the questionnaire
59 (95.2%) patients completed the questionnaire from 
wave 3
2 patients died prior to the study start, 
15 patients were cognitively impaired, 
1 patient had an unverifiable address
6Course of neuropathic symptoms in relation to adjuvant chemotherapy  |  77
Neuropathic symptoms at baseline (T1)
Among the group of T1 respondents subsequently treated with CAPOX, CapMono or no 
CTx, the neuropathy symptoms that bothered >20% of the patients at baseline included 
trouble getting or maintaining an erection (80% of men), trouble opening a jar or bottle 
due to loss of strength in hands (36%), trouble walking stairs or standing up from a chair 
due to weakness in legs (29%), trouble handling small objects (e.g. buttoning a blouse, 27%), 
trouble hearing (25%), dizziness after standing up (25%) and tingling fingers or hands (24%).
After adjustment for age category, osteoarthritis and diabetes, patients (subsequently) 
treated with CAPOX less often reported trouble walking stairs or standing up from a chair 
due to weakness in legs compared with patients (subsequently) treated with CapMono 
(crude percentages 7% vs. 36%, adjusted p=0.0266) and compared with patients who did 
not receive adjuvant CTx (crude percentages 7% vs. 36%, adjusted p=0.0418) (table 3). No 
other differences were found among the groups.
Table 1 Characteristics of respondents (completing ≥1 questionnaire) and non-respondents
Respondents
n=117 (76%)
n (%)
Non-respondents
n=38 (24%)
n (%)
P valueb
Gender
   Male
   Female
58
59
(50)
(50)
17
21
(45)
(55)
0.6043
Agea
   70-74 years
   75-79 years
   ≥80 years
32
44
41
(27)
(38)
(35)
13
6
19
(34)
(16)
(50)
0.0417
Socioeconomic status
   Low
   Intermediate
   High
   Institutions
   Unknown
29
41
28
4
15
(25)
(35)
(24)
(3)
(13)
11
14
11
1
1
(29)
(36)
(29)
(3)
(3)
0.4562
Number of comorbid conditionsa
   0
   1
   ≥2
   Unknown
18
37
62
0
(15)
(32)
(53)
(0)
5
7
25
1
(13)
(18)
(66)
(3)
0.1278
Adjuvant chemotherapy
   None
   Capecitabine + oxaliplatin 
   Capecitabine monotherapy
   Other regimen
58
27
28
4
(50)
(23)
(24)
(3)
18
7
13
0
(47)
(18)
(34)
(0)
0.5290
a At time of cancer diagnosis
b P value indicates significance of the Chi2-test or Fisher’s exact test as appropriate
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Course of neuropathic symptoms by adjuvant treatment (T1-T2-T3)
The data from patients who completed ≥2 questionnaires are listed in table 4, which 
includes an overview of the number and percentages of patients who reported mild to 
severe neuropathic symptoms at T1, T2 and T3 by adjuvant treatment. 
Logistic GEE analyses showed a significant interaction between the receipt of CTx (yes 
vs. no) and time (T1, T2, T3) for the items tingling fingers or hands (p=0.0017); tingling toes 
or feet (p=0.0060); numbness in fingers or hands (p=0.0118); and numbness in toes or feet 
(p=0.0073). This indicates that the course of these neuropathic symptoms differed between 
patients treated with and without CTx. Additionally, for the item numbness in toes or 
feet, a significant interaction was also present between CTx regimen and time (p=0.0152), 
indicating that the course of this symptom differed between patients receiving CAPOX 
and patients receiving CapMono. A graph of these four sensory neuropathic symptoms 
is depicted in figure 2.
In the subgroup of patients receiving CTx, a main effect of CTx regimen was found for 
the item tingling toes or feet (p=0.0199): patients receiving CapMono had a lower odds of 
Table 2 Characteristics of respondents completing ≥1 questionnaire and treated with capecitabine + oxaliplatin 
(CAPOX), capecitabine monotherapy (CapMono) or no adjuvant chemotherapy (no CTx)
CAPOX
n=27 (24%) 
n (%)
CapMono
n=28 (25%)
n (%)
No CTx
n=58 (51%)
n (%)
P valuec
Gender
   Male
   Female
16
11
(59)
(41)
15
13
(54)
(46)
26
32
(45)
(55)
0.4315
Agea
   70-74 years
   75-79 years
   ≥80 years
16
9
2
(59)
(33)
(8)
6
11
11
(22)
(39)
(39)
6
24
28
(10)
(42)
(48)
<0.0001
Socioeconomic status
   Low
   Intermediate
   High
   Institutions
   Unknown
7
10
7
0
3
(26)
(37)
(26)
(0)
(11)
10
10
5
0
3
(36)
(36)
(18)
(0)
(10)
12
18
16
4
8
(21)
(31)
(27)
(7)
(14)
0.7329
Number of comorbid conditionsa
   0
   1
   ≥2
7
10
10
(26)
(37)
(37)
2
5
21
(7)
(18)
(75)
8
20
30
(14)
(34)
(52)
0.0606
Diabetesb
   No
   Yes
24
3
(89)
(11)
21
7
(75)
(25)
48
10
(83)
(17)
0.3763
Osteoarthritisb
   No
   Yes
24
3
(89)
(11)
24
4
(86)
(14)
37
21
(64)
(36)
0.0148
a At time of cancer diagnosis
b At time of first questionnaire
c P value indicates significance of the Chi2-test or Fisher’s exact test as appropriate
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Figure 2 Graphical representation of the course of percentages of patients who experienced mild to severe 
neuropathic symptomsa over time among respondentsb treated with capecitabine + oxaliplatin, capecitabine 
monotherapy or no adjuvant chemotherapy
a Mild to severe symptoms reflect the response categories: ‘a little’, ‘quite a bit’ and ‘very much’
b Only respondents completing ≥2 questionnaires were included
  
  











  
  













 
  
  











  
  











reporting tingling toes or feet compared with patients receiving CAPOX (odds ratio 0.18, 
95% confidence interval 0.04-0.76). 
For all other neuropathic symptoms, no significant interaction between adjuvant treatment 
and time was found, indicating that the course of these neuropathic symptoms over time 
was similar among the treatment groups. 
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Discussion
The present longitudinal study of real world elderly patients with stage III colon cancer 
provided insight into the course of neuropathic symptoms of patients receiving treatment 
with CAPOX, CapMono or no CTx.
Because peripheral neuropathy is a very rare complication of capecitabine7, we were 
surprised that the course of some sensory symptoms was less favorable for all patients 
receiving adjuvant CTx, regardless of whether the patients had received CAPOX or CapMono. 
A possible explanation might be found in another toxicity often caused by capecitabine: 
palmar-plantar erythrodysesthesia or ‘hand-foot syndrome’ (HFS)24. Initial symptoms of HFS 
are dysesthesia and tingling in the palms, fingers and soles of the feet. These symptoms 
can progress in a few days to burning pain with erythema and swelling25-28. The symptoms 
caused by HFS are therefore partly comparable to the symptoms caused by neuropathy. We 
expect that patients treated with CapMono scored these complaints on the questionnaires.
The finding that patients treated with CAPOX more often reported tingling toes or feet 
than patients treated with CapMono could have been because in HFS, the palms of the 
hands are more frequently affected than the soles of the feet25,26,28. Additionally, another 
study that used the EORTC QLQ-CIPN20 sensory subscale to measure CIPN reported more 
numbness, tingling and burning pain in toes or feet than in fingers or hands29.
Studies on patient-reported neuropathic symptoms are limited. In both the XELOXA trial and 
MOSAIC trial, neuropathic symptoms were monitored and graded according to the National 
Cancer Institute Common Toxicity Criteria for Adverse Events30,31. In the XELOXA trial, all 
grade neurosensory toxicity was common (78%) but mild to moderate in severity (i.e. 10-12% 
grade III-IV) among patients treated with CAPOX30. In the MOSAIC trial, 92% of the patients 
treated with FOLFOX developed peripheral sensory neuropathy (PSN) of any grade during 
treatment and respectively 41%, 30% and 15% had residual PSN six months, one year and 
four years after treatment31. The frequency of grade III PSN at these time points was 13%, 2%, 
1% and <1% respectively. For patients treated with FULV, grade III PSN during treatment was 
reported for <1%31. In the NSABP C-07 trial, self-reported neurotoxicity was included for a 
subgroup of the trial population and measured using the Functional Assessment of Cancer 
Therapy/Gynecologic Oncology Group Oxaliplatin-specific Neurotoxicity questionnaire32. 
Among patients without symptoms at baseline, the most often reported symptoms during 
the second cycle of treatment with oxaliplatin were cold-induced pain in the hands and 
feet (severity ‘quite a bit’ or ‘very much’ for 26%) and hand numbness/tingling (20%). By 
6 months after the start of CTx, cold-induced hand/foot pain had diminished (8%), but 
hand numbness/tingling remained high (17%), and foot numbness/tingling (17%) and foot 
discomfort (10%) increased. Foot numbness/tingling remained high (14%) after 18 months32. 
Of note, both in this trial and the previously mentioned MOSAIC trial, oxaliplatin was 
administered in a regimen with 5-fluorouracil instead of the oral analogue capecitabine. 
Another study showed that although the incidence of acute neuropathy seemed comparable 
between CAPOX and FOLFOX, chronic peripheral neuropathy appeared to be more common 
with CAPOX15.
In contrast to previous studies on patient reported neuropathic symptoms, only patients 
6Course of neuropathic symptoms in relation to adjuvant chemotherapy  |  83
aged ≥70 years were included in the present study. A comparison of the neuropathic 
symptoms as reported in our study with a younger patient population would be valuable 
to establish whether elderly experience neuropathic symptoms to a smaller, similar or 
greater extent. Unfortunately data for a direct comparison are not available. However, the 
symptoms reported in our study were similar to those reported in earlier studies, suggesting 
that the elderly experience neuropathic symptoms comparable to that of their younger 
counterparts, although comparisons are difficult because these studies included patients 
2 to 11 years after diagnosis and the data were not longitudinal33,34.
The present study also showed that at baseline several neuropathic symptoms were 
already present and bothered more than 20% of the patients. These symptoms were in 
the sensory, motor and autonomic domains. Previous research has shown that subclinical 
peripheral neuropathy is a common finding in patients with colorectal cancer prior to 
CTx, indicating that the cancer itself is a contributing factor35. Moreover, many symptoms 
could also be related to the aging process instead of to the cancer or its treatment36. With 
the exception of weakness in legs, which was less often reported by patients treated with 
CAPOX, no differences in symptoms were found at T1 among the treatment groups. That 
the patients treated with CAPOX were younger and less often had osteoarthritis suggests 
that confounding by indication might have played a role. 
Previous studies have shown that the benefit of oxaliplatin on recurrence-free and overall 
survival is uncertain in elderly patients with stage III colon cancer1-5. To help clinicians and 
patients decide on a desirable course of treatment, not only information on the survival 
benefit associated with different treatment regimens is important, but also information on 
the possible short- and long-term side-effects. CIPN might impair functional capacities and 
affect health-related quality of life, both during and after adjuvant treatment18,19. Neuropathy 
is only partly reversible and, as also shown in previous research, chronic neuropathy is 
still present in many patients ≥1 year after the termination of therapy12. Even as long as 
11 years after diagnosis, neuropathic symptoms have still been reported by colorectal 
cancer patients, especially sensory symptoms in the toes and feet among those treated 
with oxaliplatin33. As the effect of oxaliplatin on survival is uncertain among elderly and 
the results of the present study indicate that the elderly treated with CAPOX compared 
with CapMono reported more sensory symptoms in toes/feet that are known to persist 
long term, the addition of oxaliplatin might not be justified. At the very least, the present 
results do not provide support for the addition of oxaliplatin to adjuvant CTx for elderly 
patients with stage III colon cancer. 
Previous studies have shown that a higher cumulative dose of oxaliplatin seems to 
be a predictive factor for the development of chronic peripheral neuropathy12,34. This 
chronic peripheral neuropathy occurs after a cumulative dose of ~750-800 mg/m2 of 
oxaliplatin16. Unfortunately, the number of patients in our study was too small to perform 
analyses according to the cumulative dose received. The present study also had some other 
limitations. Although we achieved a high response rate at T1 despite the timing shortly after 
major cancer surgery, the sample size at T2 and T3 was relatively small. At T1, in addition 
to informed consent, patients were able to indicate that they discontinued participation for 
the next 2 questionnaires. It is conceivable that patients would have decided differently if 
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asked after six months. Additionally, not all patients receiving adjuvant CTx had completed 
the first questionnaire before the start of adjuvant CTx. However, a large majority had 
completed the questionnaire before the start of the second cycle, during which the first 
toxicity might occur16,37. It is possible that the differences were underestimated as a result. 
Furthermore, the scores for each item were dichotomized, thereby impeding the possibility 
to investigate differences in the severity of symptoms among the treatment groups. Previous 
research has shown that even low grade toxicities can lead to treatment alterations in older 
patients38. Another limitation was that it was unknown why non-respondents declined 
participation. This could be caused by neuropathic symptoms or other problems. However, 
we were able to compare respondents and non-respondents on sociodemographic and 
clinical characteristics and only found differences in age at the time of cancer diagnosis.
Despite these limitations, the current study provides an important contribution to the limited 
data available on self-reported neuropathic symptoms according to CTx regimen among 
elderly patients with stage III colon cancer. The strong points of the present study include 
the longitudinal design with a baseline measurement and the adjustment for comorbid 
conditions (i.e. osteoarthritis and diabetes) also associated with neuropathic symptoms. 
Although rheumatoid arthritis is also associated with neuropathy-like complaints, only 3 
patients in our study had rheumatoid arthritis; therefore, no adjustments were made for 
this comorbid condition.
Conclusions
Our results have shown that the course of some sensory symptoms over time is less 
favorable for all patients undergoing adjuvant chemotherapy, regardless of the regimen. 
Additionally, patients treated with CAPOX more often reported symptoms in toes and feet 
than patients treated with CapMono. While improving survival is important, evaluating 
the harms of treatment will determine the functional effectiveness of the treatment. It 
is of paramount importance to inform patients on the risk of developing CIPN to enable 
patients to make an informed decision. 
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Abstract
Background: Little is known about the effects of adjuvant chemotherapy on the risk of 
distant recurrence in elderly with stage III colon cancer, treated in daily practice. 
Patients and methods: One thousand two hundred and ninety-one stage III colon cancer 
patients diagnosed in the southern Netherlands between 2003 and 2008 were included. 
Propensity score matching was applied to create a subsample to reduce bias caused by 
differences between patients receiving adjuvant chemotherapy and patients not receiving 
adjuvant chemotherapy.  For both the total study population and the propensity score 
matched sample, Cox regression analysis was used to discriminate independent risk 
factors for distant recurrence.
Results: Adjuvant chemotherapy (CT) was correlated with a reduced risk of distant recurrence 
in both the total study population [hazard ratio (HR) CT versus nCT 0.55, 95% confidence 
interval (CI) 0.42-0.70] and in the propensity score matched sample (HR CT versus nCT 0.46, 
95% CI 0.33-0.63). In separate analyses for patients aged <75 years and ≥75 years, the effect 
of adjuvant chemotherapy on the risk of distant recurrence remained comparable for both 
age groups (HR CT versus nCT 0.50, 95% CI 0.37-0.68 and 0.57, 95% CI 0.36-0.90 respectively). 
Conclusion: Distant recurrence risks at higher age definitely warrant consideration of 
adjuvant chemotherapy for elderly stage III colon cancer patients. This decision should 
be based on a multidisciplinary and functional assessment of the patient, not on age.
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Introduction
The primary treatment for stage III colon cancer is surgery, followed by adjuvant 
chemotherapy consisting of 5-fluorouracil (5-FU) often in combination with oxaliplatin1,2. 
The efficacy of adjuvant chemotherapy has been established in clinical trials, which 
showed improved disease-free and overall survival3-8. However, despite the significant 
proportion of elderly patients in clinical practice, elderly are often excluded in clinical 
trials. Approximately half of the patients with colon cancer is aged ≥70 years, but only 16% 
of patients enrolled in trials was ≥70 years9.
More recently, studies have compared the efficacy of adjuvant chemotherapy for elderly 
and nonelderly patients using pooled data from randomized trials. One study found that 
for selected elderly, adjuvant treatment (5-FU plus leucovorin or levamisole) had the same 
significant positive effect on overall survival and time to recurrence as for their younger 
counterparts10. In another pooled analysis, the efficacy of FOLFOX was similar for patients 
aged <70 years and patients aged ≥70 years with regard to disease-free and overall survival9. 
These pooled analyses confirm that older patients fit enough to meet clinical trial eligibility 
criteria derive the same benefit from adjuvant therapy as younger trial participants.
Population-based studies have shown that despite its apparent efficacy in older patients, 
chemotherapy usage declines rapidly with age2,11-18. As a result, it is difficult to determine 
whether the efficacy realized in trials applies for elderly in daily practice. Therefore, 
population-based studies should offer additional insight in the effectiveness of adjuvant 
chemotherapy in elderly patients.  
To date, most population-based studies focused on overall survival, which is prone to 
selection bias (e.g. the fittest patients receiving adjuvant chemotherapy thereby by definition 
exhibiting better survival). Little is known about the risk of distant recurrence in daily 
clinical practice. Therefore, the aim of this study is to gain more insight in the effect of 
adjuvant chemotherapy on the risk of distant recurrence in patients with stage III colon 
cancer, using population-based data from clinical practice. Furthermore, it is investigated 
whether patients aged ≥75 years treated in clinical practice derive comparable benefit from 
adjuvant chemotherapy as their younger counterparts. 
Methods 
Data collection
Data from the Eindhoven Cancer Registry (ECR) were used. The ECR is a population-based 
registry which collects data on all newly diagnosed cancer patients in the southern 
Netherlands. The registry area comprises about 2.4 million inhabitants and encompasses 
6 pathology departments, 10 community hospitals, and 2 radiotherapy institutions. 
Information on patient and tumour characteristics, diagnosis and treatment is routinely 
extracted from the medical records by trained administrators of the cancer registry. 
Anatomical site of the tumour is registered according to the International Classification 
of Disease–Oncology (ICD-O). The TNM (tumour-node-metastasis) classification is used 
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for stage notification of the primary tumour, according to the edition valid at time of 
cancer diagnosis. Comorbidities are registered according to a slightly modified version 
of the Charlson Comorbidity index. Socioeconomic status, based on individual fiscal data 
on the economic value of the home and household income, is provided at an aggregated 
level for each postal code. The quality of the data is high, due to thorough training of the 
registration team and computerized consistency checks at regional and national levels. 
Additional data on the development of distant recurrences and the date of diagnosis of 
distant recurrences was collected from the medical records by experienced registration 
administrators, encompassing all patients with stage I-III (TanyNanyM0) colorectal cancer 
diagnosed between 2003 and 2008. In the present study, distant recurrence is defined as 
a distant metastasis of primary colon cancer in other organs, regional lymph nodes not 
included, after a primary diagnosis of M0 disease.
 
Study population
For the present study, all patients with resected stage III (TanyN1-2M0) primary colon cancer 
diagnosed in the south of the Netherlands in the period 2003-2008 were included.  Stage 
was based on the pathological TNM classification. If pathological stage was unknown, 
clinical stage was used (n=4). Tumour localization was divided into anatomical subsites: 
proximal colon (C18.0-C18.5), distal colon (C18.6-C18.7) and unknown or overlapping subsites 
of the colon (C18.8-C18.9). The study period was divided into categories: 2003-2005 and 
2006-2008. Patients were divided into age groups (<75/≥75 years). 
Propensity score matched sample
Due to the population-based nature of the data, comparing patients who received adjuvant 
chemotherapy with non-recipients, raises the question of potential endogeneity bias caused 
by differences between both groups. Therefore, a subsample was created through the 
application of propensity score matching. Propensity scores were determined on the basis 
of a logistic regression model in which the dependent variable was the variable of interest 
(adjuvant chemotherapy receipt) and the independent variables were factors potentially 
associated with the variable of interest (sex, age, socioeconomic status, comorbidity, 
T stage, N stage, differentiation grade, subsite and period of diagnosis). The propensity score 
represented the probability that a patient would not receive adjuvant chemotherapy. On the 
basis of propensity scores, patients who did not receive adjuvant chemotherapy were then 
matched to patients who did receive adjuvant chemotherapy using the nearest available 
pair matching method. Individuals were matched within tight bounds of the propensity 
scores; predicted probability could vary by no more than 0.01 (1%) on a scale of 0 to 1.
Statistical analyses
For both the total study population and the propensity score matched sample, differences 
between age groups and differences between patients receiving versus not receiving 
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adjuvant chemotherapy were analysed by means of Chi2-tests. Furthermore, crude 5-year 
percentages for distant recurrence were calculated based on Kaplan-Meier curves to correct 
for differences in follow-up time and Cox regression analyses were used to discriminate 
independent risk factors for distant recurrence. Time to distant recurrence was defined as 
the time from first diagnosis to distant recurrence. Patients without a distant recurrence 
were censored at time of death or last follow-up date, whichever occurred first.
P values below 0.05 were considered statistically significant. SAS/STAT® statistical software 
(SAS system 9.3, SAS Institute, Cary, NC) was used for all analyses. 
Results
One thousand two hundred ninety-one patients were included in the study of whom 56% 
received adjuvant chemotherapy and 31% developed a distant recurrence. 37% of the study 
population was aged ≥75 years. Median follow-up time was 32 months. In the propensity 
score matched sample, 466 patients (36%) of the original study population could be included, 
with an equal proportion of patients receiving and not receiving adjuvant chemotherapy. 
32% was aged ≥75 years and 34% developed a distant recurrence. Median follow-up time 
was 29 months.
Table 1 shows the demographic distribution and the proportion of patients receiving 
adjuvant chemotherapy according to age group, for both the total study population and the 
propensity score matched sample. In the total study population, patients aged ≥75 years 
received significantly less adjuvant chemotherapy than patients aged <75 years (p<0.0001). 
Furthermore, patients aged ≥75 years were more often female (p<0.0001) and had more 
comorbidities (p<0.0001) than patients aged <75 years. Patients aged ≥75 years also had more 
poor or undifferentiated tumours (p=0.020) and more proximal located tumours (p<0.0001) 
in comparison to patients aged <75 years. Finally, patients aged ≥75 years and patients 
aged <75 years differed with regard to socioeconomic status (p<0.0001). Within the group of 
patients aged <75 years, patients receiving adjuvant chemotherapy were younger (p<0.0001), 
had less comorbidities (p<0.0001) and had higher socioeconomic status (p=0.004) than 
non-recipients. Among patients aged ≥75 years, patients receiving adjuvant chemotherapy 
were less often female (p=0.028), were younger (p<0.0001), had higher socioeconomic status 
(p=0.034) and had more N2 stage (p=0.048) than non-recipients.
In the propensity score matched sample, patients aged ≥75 years had more comorbidities 
(p=0.015) than patients aged <75 years. Both in the group of patients aged <75 years as in 
the group of patients aged ≥75 years, patients receiving adjuvant chemotherapy did not 
differ from non-recipients. 
Table 2 shows the crude 5-year percentages and adjusted hazard ratios (HRs) for distant 
recurrence. For the total study population, multivariate analysis showed that after adjustment 
for relevant patient and tumour characteristics, the risk of recurrence was correlated with 
adjuvant chemotherapy receipt [HR CT versus nCT 0.55, 95% confidence interval (CI) 0.42-0.70]. 
In addition, lower T stage, lower N stage and a well or moderate differentiation grade all 
reduced the recurrence risk. Age did not significantly influence the recurrence risk. When 
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Table 1 Demographic distribution and proportion of patients receiving adjuvant chemotherapy by age group, for 
the total study population (n=1291) and for the propensity score matched sample (n=466)
Total study
population
Propensity score
matched sample
<75 years ≥75 years <75 years ≥75 years
n % CT n % CT n % CT n % CT
Total 816 78 475 17 317 50 149 51
Sex
   Male
   Female
434
382
78
79
195
280
22
14
166
151
45
54
72
77
53
49
Age (years)
   <65
   65-69
   70-74
   75-79
   ≥80
401
191
224
87
77
64
220 
255
32
5
110
79
128
52
46
50
123
26
51
50
Comorbidity
   0
   1
   ≥2 
   Unknown
319
223
212
  62
87
77
68
77
  83
121
241 
30
18
22
17
3
87
93
110
27
51
45
51
56
29
45
70
5
48
51
54
20
Socioeconomic status
   Low
   Intermediate
   High
   Institutions
   Unknown
188
338
254
 21
  15
74
82
80
57
53
162
136
118
  48
  11
13
21
22
8
36
83
119
98
10
7
51
52
51
20
14
44
47
49
4
5
48
53
45
100
80
T stage
   1-2
   3
   4
  68
603
145
75
80
75
  37
360
  78
19
16
24
28
231
58
46
51
45
14
109
26
50
48
65
N stage
   1
   2
572
244
77
81
345
130
15
23
236
81
51
46
101
48
49
56
Differentiation grade
   Well/moderate
   Poor/undifferentiated
   Unknown
574
196
  46
79
76
76
304
148
  23
18
15
26
211
84
22
48
51
55
95
45
9
52
49
56
Subsite
   Proximal
   Distal
   Other/NOS
419
380
  17
79
79
65
306
166
     3
15
21
33
165
144
8
50
50
25
83
63
3
53
49
33
Distant recurrence
   Yes
   No
264
552
77
79
142
333
20
16
107
210
45
52
50
99
48
53
Period of diagnosis
   2003-2005
   2006-2008
358
458
79
78
220
255
15
20
137
180
52
48
66
83
47
54
CT, adjuvant chemotherapy; n, number of patients.
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Table 2 Crude 5 year percentages and hazard ratiosa of developing a distant recurrence after resection for stage III 
colon cancer for the total study population (n=1291), and for the propensity score matched sample (n=466)
Total study 
population
Propensity score 
matched sample
Crude 
5-year %
Hazard ratio 
(95% CI)
Crude 
5-year %
Hazard ratio
(95% CI)
Sex
   Male
   Female
40
37
1.00 (reference)
0.91 (0.75-1.12)
44
39
1.00 (reference)
0.87 (0.62-1.22)
Age (years)
   <65 
   65-69
   70-74
   75-79
   ≥80 
37
40
39
41
38
1.00 (reference)
1.04 (0.76-1.41)
1.10 (0.81-1.48)
1.02 (0.74-1.41)
0.81 (0.56-1.17)
44
35
39
44
37
1.00 (reference)
0.79 (0.47-1.33)
1.08 (0.69-1.71)
0.89 (0.57-1.39)
0.53 (0.22-1.28)
SES
   Low 
   Intermediate
   High
38
42
37
0.80 (0.61-1.05)
1.05 (0.82-1.33)
1.00 (reference)
40
41
41
0.78 (0.50-1.21)
0.97 (0.66-1.44)
1.00 (reference)
Comorbidity
   0 
   1
   ≥2
   Unknown
37
39
38
46
1.00 (reference)
1.07 (0.82-1.39)
1.06 (0.82-1.38)
1.36 (0.94-1.98)
39
40
41
58
1.00 (reference)
0.98 (0.62-1.54) 
1.11 (0.71-1.72) 
1.70 (0.93-3.09)
T stage
   1-2 
   3
   4
22
38
51
0.56 (0.35-0.90)
1.00 (reference)
1.63 (1.28-2.08)
20
41
55
0.40 (0.17-0.91)
1.00 (reference)
1.57 (1.06-2.32)
N stage
   1
   2
34
52
1.00 (reference)
1.96 (1.59-2.42)
38
51
1.00 (reference)
1.53 (1.06-2.21)
Subsite
   Proximal colon
   Distal colon
   Other/NOS
38
38
65
1.00 (reference)
1.09 (0.89-1.34)
1.80 (0.96-3.35)
43
39
38
1.00 (reference)
1.15 (0.81-1.63) 
0.78 (0.24-2.57)
Differentiation grade
   Well/moderate 
   Poor/undifferentiated
   Unknown
35
46
48
1.00 (reference)
1.43 (1.14-1.79)
1.52 (1.01-2.28)
35
54
51
1.00 (reference)
2.02 (1.40-2.91) 
1.59 (0.85-2.97)
Period of diagnosis
   2003-2005 
   2006-2008
41
35
1.00 (reference)
0.87 (0.71-1.06)
41
41
1.00 (reference)
1.10 (0.79-1.54)
Adjuvant chemotherapy
   No
   Yes
42
36
1.00 (reference)
0.55 (0.42-0.70)
50
34
1.00 (reference)
0.46 (0.33-0.63)
a Adjusted for all variables listed. 
CI, confidence interval; NOS, not otherwise specified.
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the analysis was repeated for patients aged <75 years and ≥75 years separately, the effect of 
adjuvant chemotherapy on the recurrence risk remained comparable for both age groups 
(HR CT versus nCT 0.50, 95% CI 0.37-0.68 and 0.57, 95% CI 0.36-0.90, respectively).
For the propensity score matched sample, comparable results were found. The strength 
of the effect of adjuvant chemotherapy on the development of distant recurrence even 
increased (HR 0.46, 95% CI 0.33-0.63).
Discussion
Given the increasing life expectancy, the number of elderly patients in oncologic practice 
will increase substantially in the near future19. 
In line with previous research2,11-18, the current study shows older patients are less likely 
to receive adjuvant chemotherapy. The use of chemotherapy declines with age due to, 
e.g. comorbidity, frailty, lack of a supportive care system or decreased acceptance of side 
effects leading to more patient refusal15. Additionally, medical specialists (surgeons, medical 
oncologists) might not consider older patients suitable candidates11.
Our study suggests older patients derive comparable benefits from adjuvant chemotherapy 
as their younger counterparts with regard to risk of recurrence20,21. Another study with a 
follow-up of 8 years found that adjuvant chemotherapy reduces the risk of recurrence 
within the first 2 years, suggesting adjuvant chemotherapy eradicates micrometastases21. 
Moreover, a recent pooled analysis of trials demonstrated that adjuvant chemotherapy 
did not have an effect on post-relapse survival, indicating that improved disease-free 
and overall survival after adjuvant chemotherapy are not endangered by deteriorated 
post-relapse survival22.
The present study also shows the risk of recurrence is  influenced to a large extent by the 
tumour characteristics T stage, N stage and differentiation grade, in line with results from 
previous studies6,20,23.
Besides the analyses carried out for the total study population, which provide externally 
valid analyses, a propensity score matched sample was used to provide more internally 
valid analyses by reducing presence of heterogeneity between treatment groups. The 
results of the matched sample are comparable with the overall results, further supporting 
the equally beneficial effect of adjuvant chemotherapy on risk of recurrence for patients 
aged <75 years and patients aged ≥75 years. Moreover, the effects found in the current 
study are even stronger than the effects found in pooled analyses of trials, in which HRs for 
recurrence and recurrence-free survival for patients treated with adjuvant chemotherapy 
versus non-recipients were around 0.65-0.70, regardless of age9,10.
It is acknowledged that, due to the observational character, this study has limitations 
and bias in treatment selection factors cannot be completely ruled out. It is unknown to 
what extent the positive effect of adjuvant treatment was caused by selection of the ‘fitter’ 
patients for adjuvant chemotherapy or other factors not included in the analysis. 
Another limitation of this study is that it is unknown which chemotherapy scheme patients 
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received. Previous studies have shown that usage of especially oxaliplatin-based schemes 
decrease with rising age18,24, making it likely that also in this study the chemotherapy 
schemes that were received by patients aged <75 years and patients aged ≥75 years are 
different. Whether the addition of oxaliplatin offers additional benefit to patients aged 
≥75 years is unclear, as data has been conflicting9,18,19,25. However, one pooled analysis of 
trial data found that the benefit of oxaliplatin was modestly diminished in patients aged 
≥70 years, but a significant effect was found regardless of age26. 
Furthermore, chemotherapy schemes have also changed over time. During the first half of 
the study period (2003-2005), patients mostly received a combination of 5-FU and leucovorin. 
Since the second half of the study period (2006-2008), oxaliplatin has become the standard 
adjuvant chemotherapy in combination with 5-FU or capecitabine.
An important factor contributing to the risk-benefit ratio with respect to adjuvant 
chemotherapy are treatment-related side-effects. In pooled analyses of randomized trials, 
it was found that no significant increase in toxic effects was found in elderly patients as 
compared to their younger counterparts from both fluorouracil-based and FOLFOX adjuvant 
therapy9,10. For the present study, no data on toxicity was available.
Future prospective studies should investigate how adjuvant chemotherapy affects the quality 
of life of elderly patients, which is of paramount importance in treatment decisions among 
elderly patients. To date, few studies have specifically addressed the effect of chemotherapy 
on quality of life in elderly patients. However, it seems likely that a substantial degree of 
undertreatment exists which reflects assumptions about age which might not be in line 
with current evidence on effectiveness of adjuvant chemotherapy11.
Overall, the results of the present study underline that consideration of adjuvant 
chemotherapy is definitely warranted for all patients aged ≥75 years with resected stage 
III colon cancer, as they derive comparable benefit from adjuvant chemotherapy as their 
younger counterparts. However, it remains important to realize that in certain circumstances, 
withholding adjuvant chemotherapy from elderly may be appropriate, for example in case of 
short  life expectancy (<1-2 years) or increased risk of serious side-effects. The assessment 
of older patients is complex and should include considerations of comorbidities, activities 
of daily living, socioeconomic conditions, clinical geriatric assessment, polypharmacy 
and nutritional status.
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Abstract
The aim of this study is to investigate the effects of CAPOX and capecitabine on 
recurrence-free survival (RFS) and overall survival (OS) among elderly stage III colon 
cancer patients and to evaluate the effect of (non-)completion. Patients aged ≥70 years who 
underwent resection only or who were subsequently treated with CAPOX or capecitabine 
in 10 large non-academic hospitals were included. RFS and OS were analyzed with 
Kaplan-Meier curves and multivariable Cox regression adjusted for patient and tumor 
characteristics. 982 patients were included: 630 underwent surgery only, 191 received 
CAPOX and 161 received capecitabine. Five-year RFS and OS did not differ between 
capecitabine and CAPOX (RFS: 63% vs. 60% (p=0.91), adjusted HR=0.99 (95% CI 0.68-1.44); OS: 
66% vs. 66% (p=0.76), adjusted HR=0.93 (95% CI 0.64-1.34)). After resection only, RFS was 38% 
and OS 37%. Completion rates were 48% for CAPOX and 68% for capecitabine. Three-year 
RFS and OS did not differ between patients who discontinued CAPOX early and patients 
who completed treatment with CAPOX (RFS: 61% vs. 69% (p=0.21), adjusted HR=1.42 (95% 
CI 0.85-2.37); OS: 68% vs. 78% (p=0.41), adjusted HR=1.17 (95% CI 0.70-1.97)). Three-year RFS 
and OS differed between patients who discontinued capecitabine early and patients who 
completed treatment with capecitabine (RFS: 54% vs. 72% (p=0.01), adjusted HR=2.07 (95% 
CI 1.11-3.84); OS: 65% vs. 80% (p=0.01), adjusted HR=2.00 (95% CI 1.12-3.59)). Receipt of CAPOX 
or capecitabine is associated with improved RFS and OS. The advantage does not differ 
by regimen. The addition of oxaliplatin might not be justified in elderly stage III colon 
cancer patients.
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Introduction
Adjuvant chemotherapy is standard care for patients with stage III colon cancer. Several 
randomized controlled trials have been performed to compare the effectiveness of a 
number of agents in this setting. In the X-ACT trial, oral capecitabine demonstrated to be as 
effective as 5FU/LV, with an improved safety profile except for more hand-foot syndrome1,2. 
The MOSAIC trial and NSABP C-07 study showed that oxaliplatin in combination with 
5-flourouracil/leucovorin (FOLFOX) provided an additional ~4% survival gain compared to 
5FU/LV alone, but at the cost of higher toxicity rates, especially significant neurotoxicity3-6. In 
the XELOXA trial, the combination of oxaliplatin with capecitabine (CAPOX) also improved 
disease-free and overall survival compared with bolus fluorouracil/folinic acid (FU/FA) and 
was shown to provide an alternative treatment option, but with higher rates of grade III-IV 
neurotoxicity and grade III hand-foot syndrome7-9. Up to date, no randomized controlled 
trial compared FOLFOX and CAPOX head to head in the adjuvant setting and therefore 
both are considered standard care. 
Despite the fact that patients aged ≥70 years account for more than half of the patients with 
colon cancer10, only a small part of this group is included in clinical trials. Subgroup analyses 
of trials by age group have shown that oral capecitabine maintained its effectiveness in 
older patients and that the prevalence of grade ≥3 chemotherapy-related toxicities did 
not differ by age (<65 vs. ≥65 years)2,11. However, regarding the beneficial survival effect of 
adding oxaliplatin to 5FU-based regimens, inconsistent results were found12,13. Furthermore, 
although results were inconclusive, differences in toxicity suggested that older patients 
may be more prone to develop oxaliplatin-related toxicity12. The XELOXA trial showed an 
overall higher rate of grade III-IV toxicity with CAPOX for patients aged ≥65 years versus 
younger patients (65% versus 57% respectively)9.
One pooled analysis found that FOLFOX was equally efficient in selected elderly as compared 
to younger patients14, while other pooled analyses reported that elderly experienced 
reduced benefit from adding oxaliplatin to FU/LV or capecitabine15,16. Oxaliplatin-related 
grade III-IV toxicity was not elevated among elderly16. However, these subgroup and pooled 
analyses can only provide information on elderly who are fit enough to meet clinical trial 
eligibility criteria. Whether unselected elderly patients in daily clinical practice derive 
benefit is unclear. So far, population-based studies among elderly mostly included 5FU/LV 
and FOLFOX and provided inconsistent results regarding the additional benefit provided 
by the addition of oxaliplatin to chemotherapy17-20. 
Nowadays, in the Netherlands CAPOX and capecitabine monotherapy (CapMono) are the 
mostly prescribed regimens for elderly stage III colon cancer patients treated in daily clinical 
practice. A significant part of the elderly treated with adjuvant chemotherapy however do 
not complete all planned cycles21. Previous studies have shown that patients who failed to 
complete chemotherapy treatment with FU/LV exhibited a worse cancer-specific survival 
than those who completed treatment22-24, while early discontinuation of FOLFOX did not 
affect disease-free and overall survival25. 
Therefore, the aim of the current study is twofold. The first aim is to investigate the effects 
of the regimens CAPOX and CapMono on recurrence-free and overall survival and to assess 
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whether oxaliplatin provides additional benefit among elderly stage III colon cancer patients 
treated in clinical practice. The second aim is to investigate the effects of (non-)completion 
of both regimens on recurrence-free and overall survival.
Methods
Data collection
Data from the population-based Netherlands Cancer Registry (NCR), more specifically from 
the Eindhoven area, were used. This region collects data on all newly diagnosed cancer 
patients in the southeastern part of the Netherlands. The registry area comprises about 
2.4 million inhabitants (~15% of the Dutch population) and encompasses 10 community 
hospitals. Information on patient and tumor characteristics, diagnosis and treatment is 
routinely extracted from the medical records by trained administrators of the cancer registry. 
Anatomical site of the tumor is registered according to the International Classification of 
Disease – Oncology (ICD-O). The TNM (tumor-node-metastasis) classification is used for 
stage notification of the primary tumor, according to the edition valid at time of cancer 
diagnosis. Comorbidities are registered according to a slightly modified version of the 
Charlson Comorbidity index. The quality of the data is high, due to thorough training of the 
registration team and computerized consistency checks at regional and national levels. 
For the present study, additional data were collected from the medical records by experienced 
registration administrators in 2013 and 2014. This encompassed more detailed information 
on which adjuvant chemotherapy regimen patients received, whether all planned cycles 
were completed and on the development and diagnosis of recurrences. Depending on the 
hospital in which patients were treated with adjuvant chemotherapy, standard treatment 
with CAPOX consisted of 6 or 8 cycles. Standard dosage for each cycle is 2000 mg/m2 
capecitabine on days 1-14 and 130 mg/m2 oxaliplatin on day 1. The next cycle starts at day 
21. Standard treatment with CapMono consisted of 6 or 8 cycles with each cycle including 
a dosage of 2000 or 2500 mg/m2 capecitabine on days 1-14 and the next cycle starting at 
day 21. Recurrence as defined for this study encompasses local and/or regional recurrence 
and/or distant metastases of colon cancer, after a primary diagnosis of stage III disease. 
In the Netherlands, studies with anonymized patient records do not fall under the scope 
of the Medical Research Involving Human Subjects Act. This study is therefore exempt 
from medical ethics review.
Study population
For the present study, patients with primary stage III (pT1-4N1-2M0) colon cancer aged ≥70 
years who were diagnosed between 2005 and 2012 and who underwent resection only 
or who were subsequently treated with adjuvant chemotherapy consisting of CAPOX or 
CapMono were included. Surgery consisted of an oncologic resection of the primary tumor 
and regional lymph nodes. Stage was based on the pathological TNM classification. Tumor 
8Recurrence-free and overall survival with CAPOX or capecitabine  |  105
localization was divided into anatomical subsites: proximal colon (C18.0-C18.5), distal colon 
(C18.6-C18.7) and unknown or overlapping subsites of the colon (C18.8-C18.9).
Patients who did not survive the first 90 days after surgery were excluded (N=125), since 
deaths within 90 days after surgery were expected to limit the feasibility and gains of 
adjuvant chemotherapy administration and to overcome the effect of postoperative 
mortality on long-term survival.
Patients who received 6-8 cycles of adjuvant chemotherapy were categorized as patients 
who completed all planned cycles. Patients who received 1-5 cycles were categorized as 
patients who discontinued treatment before all planned cycles were completed.
Statistical analyses
Descriptive statistics were used to provide an overview of the study population by treatment 
modality. Differences in patient and tumor characteristics between treatment modalities 
were calculated using Chi2-test or Fisher’s Exact test as appropriate. After stratification by 
regimen, differences in patient and tumor characteristics between patients who completed 
all planned cycles and patients who discontinued treatment prematurely were also 
calculated using Chi2-test or Fisher’s Exact test, while differences in median total dosage 
received were calculated using Wilcoxon Rank-Sum test.
Differences in recurrence-free survival (RFS) and overall survival (OS) according to treatment 
modality and according to chemotherapy regimen and completion of all planned cycles 
were visualized by means of Kaplan-Meier curves and tested with Log-Rank tests and 
multivariable Cox regression analyses. To minimize immortal time bias, different starting 
points were used in these comparisons. In the comparison of RFS according to treatment 
modality, RFS time was defined as the time between the date of resection of the primary 
tumor to the date of diagnosis of recurrence or date of death. In the comparison of RFS 
according to chemotherapy regimen and completion of all planned cycles, RFS time was 
defined as the time between the last date of chemotherapy to the date of diagnosis of 
recurrence or date of death. In both comparisons, patients without a recurrence or death 
were censored at time of last follow-up date. Last follow-up date for recurrence differed 
between patients and was dependent on last patient contact and ascertainment of 
recurrence status. For OS, the same starting points were used. Date of death was completed 
until 31 December 2014. Variables included in the multivariable analysis were gender, age, 
comorbidity, ASA score, pathological T, pathological N, tumor subsite, differentiation grade 
and period of diagnosis.
To investigate whether the effects of the treatment modalities on RFS and OS differed 
according to patient characteristics, interaction tests were performed between treatment 
modality and respectively age, gender and comorbidity, using multivariable Cox regression.
P values below 0.05 were considered statistically significant. SAS/STAT® statistical software 
(SAS system 9.4, SAS Institute, Cary, NC) was used for all analyses.
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Results 
The final study population consisted of 982 elderly colon cancer patients: 630 patients 
(64%) underwent surgery only, 191 patients (20%) received CAPOX and 161 patients (16%) 
received CapMono (figure 1). Table 1 provides an overview of the patient and tumor 
characteristics of the study population by treatment modality. Mean age of the patients 
who underwent resection only was 79.8 years, while this was 73.2 years and 75.9 years 
respectively for patients treated with CAPOX and CapMono. On average, patients who 
underwent resection only had the highest number of comorbid conditions and the highest 
ASA score. The proportion pathological N2 was higher among the patients treated with 
adjuvant chemotherapy. In 2005-2006, the proportion of patients treated with CAPOX 
was still relatively low, but increased in the next periods. In separate analyses comparing 
patients who received CAPOX to patients who received CapMono, differences were found 
with regard to age, comorbidity and period of diagnosis (table 1).
Among patients receiving CAPOX, 92 patients (48%) completed all planned cycles. For 
these patients, the median cumulative dosage received per patient was 191,894 mg/m2 
for capecitabine and 765 mg/m2 for oxaliplatin. 96 patients (50%) did not complete all 
planned cycles of CAPOX. For this group, the median number of cycles was 4 (range 1-8) 
for capecitabine and 2 (range 1-8) for oxaliplatin. The median cumulative dosages received 
for capecitabine and oxaliplatin were therefore significantly lower: 88,004 mg/m2 and 
263 mg/m2 respectively (p<0.0001 for both). For the remaining 3 patients (2%) who received 
CAPOX, the number of cycles was unknown. Among patients receiving CapMono, the 
Figure 1 Overview of patients included in the study
Stage III (pT1-4N1-2M0) colon cancer patients 
aged ≥70 years, diagnosed in 2005-2012, 
who underwent resection
N=1156
Patients who underwent resection only
N=750
Death <90 days 
after resection
N=120
CAPOX
N=193
FOLFOX   N=31
Other/unknown  N=18
CapMono
N=164
Death <90 days 
after resection
N=2
Death <90 days 
after resection
N=3
CAPOX
N=191
CapMono
N=161
Resection only
N=630
Patients who received adjuvant chemotherapy
N=406
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completion rate was higher with 109 (68%) patients completing all planned cycles (p<.0001). 
The median cumulative dosage received was 212,029 mg/m2 for these patients. 46 patients 
(28%) did not complete all planned cycles. The median number of cycles among patients 
who discontinued treatment early was 2 (range 1-5) and the median cumulative dosage 
received was significantly lower (63,580 mg/m2) than for patients who completed treatment 
(p<0.0001). For 6 patients (4%), the number of capecitabine cycles was unknown. Table 2 
provides an overview of the patient and tumor characteristics of the patients treated with 
Table 1 Patient and tumor characteristics of the study population, according to treatment modality
Resection 
only
n (%)
Resection 
+ CAPOX
n (%)
Resection 
+ CapMono
n (%) P value* P value#
Gender
   Male
   Female
284
346
(45)
(55)
108 
83
(57)
(43)
75
86
(47)
(53)
0.02 0.06
Age
   70-74 years
   75-79 years
   ≥80 years
108
197
325
(17)
(31)
(52)
140
47
4
(73)
(25)
(2)
52
84
25
(32)
(52)
(16)
<.0001 <.0001
Comorbidity
   0 
   1
   ≥2
   Unknown
97
135
377
21
(15)
(22)
(60)
(3)
65
48
74
4
(34)
(25)
(39)
(2)
33
52
72
4
(21)
(32)
(45)
(2)
<.0001 0.04
ASA score
   I-II
   III-IV
   Unknown
257
224
149
(41)
(35)
(24)
131
21
39
(69)
(11)
(20)
95
27
39
(59)
(17)
(24)
<.0001 0.14
Pathological T
   1-2 
   3
   4
61
452
117
(10)
(72)
(18)
22
144
25
(12)
(75)
(13)
24
107
30
(15)
(66)
(19)
0.14 0.18
Pathological N 
   1
   2
478
152
(76)
(24)
124
67
(65)
(35)
107
54
(66)
(34)
0.0026 0.76
Subsite tumor
   Proximal colon
   Distal colon
   Other/NOS
393
230
7
(62)
(37)
(1)
98
90
3
(51)
(47)
(2)
99
60
2
(62)
(37)
(1)
0.08 0.16
Differentiation grade
   Well/moderate 
   Poor/undifferentiated
   Unknown
428
163
39
(68)
(26)
(6)
139
41
11
(73)
(21)
(6)
105
42
14
(65)
(26)
(9)
0.48 0.28
Period of diagnosis
   2005-2006
   2007-2008
   2009-2010
   2011-2012
139
153
154
184
(22)
(24)
(25)
(29)
24
56
59
52
(13)
(29)
(31)
(27)
38
33
49
41
(24)
(21)
(30)
(25)
0.03 0.03
* P value indicates significance of the Chi2-test or Fisher’s Exact test between all groups
# P value indicates significance of the Chi2-test or Fisher’s Exact test between patients receiving CAPOX and 
patients receiving CapMono
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Median follow-up time for all patients treated with CAPOX or CapMono was 35 months 
for RFS and 65 months for OS, while median follow-up time for the patients treated with 
CAPOX or CapMono and for whom it was known whether all planned cycles were completed 
was 39 months for RFS and 59 months for OS. Because the number of patients at risk 
after 36 months was <10 in the group of patients that did not complete CapMono, survival 
adjuvant chemotherapy by completion of all planned cycles, after stratification by regimen. 
Male patients more often completed all planned cycles of CAPOX than female patients. 
Table 2 Patient and tumor characteristics of the patients who received adjuvant chemotherapy, according to 
regimen and completion of all planned cycles
CAPOX, 
complete
n (%)
CAPOX, 
incomplete
n (%) P value*
CapMono, 
complete
n (%)
CapMono, 
incomplete
n (%) P value*
Gender
   Male
   Female
61
31
(66)
(34)
46
50
(48)
(52)
0.01
53
56
(49)
(51)
20
26
(43)
(57)
0.56
Age
   70-74 years
   75-79 years
   ≥80 years
70
21
1
(76)
(23)
(1)
69
25
2
(72)
(26)
(2)
0.75
40
54
15
(37)
(49)
(14)
9
27
10
(19)
(59)
(22)
0.09
Comorbidity
   0 
   1
   ≥2
   Unknown
30
27
32
3
(33)
(29)
(35)
(3)
34
21
40
1
(35)
(22)
(42)
(1)
0.43
21
39
45
4
(19)
(36)
(41)
(4)
10
12
24
0
(22)
(26)
(52)
(0)
0.37
ASA score
   I-II
   III-IV
   Unknown
70
9
13
(76)
(10)
(14)
59
11
26
(61)
(11)
(27)
0.07
62
20
27
(57)
(18)
(25)
30
5
11
(65)
(11)
(24)
0.47
Pathological T
   1-2 
   3
   4
11
70
11
(12)
(76)
(12)
10
72
14
(10)
(75)
(15)
0.84
17
75
17
(16)
(68)
(16)
7
27
12
(15)
(59)
(26)
0.30
Pathological N 
   1
   2
61
31
(66)
(34)
61
35
(64)
(36)
0.69
74
35
(68)
(32)
28
18
(61)
(39)
0.40
Subsite tumor
   Proximal colon
   Distal colon
   Other/NOS
45
46
1
(49)
(50)
(1)
51
43
2
(53)
(45)
(2)
0.67
65
43
1
(60)
(39)
(1)
30
15
1
(65)
(33)
(2)
0.47
Differentiation grade
   Well/moderate 
   Poor/undifferentiated
   Unknown
72
16
4
(78)
(18)
(4)
66
23
7
(69)
(24)
(7)
0.32
74
28
7
(68)
(26)
(6)
25
14
7
(54)
(30)
(15)
0.14
Period of diagnosis
   2005-2006
   2007-2008
   2009-2010
   2011-2012
10
31
24
27
(11)
(34)
(26)
(29)
13
24
34
25
(14)
(25)
(35)
(26)
0.39
23
26
31
29
(21)
(24)
(28)
(27)
10
7
17
12
(22)
(15)
(37)
(26)
0.59
* P value indicates significance of the Chi2-test or Fisher’s Exact test
Excluded from the analyses were patients for whom completion of all planned cycles was unknown (CAPOX: 3 
patients, CapMono: 6 patients)
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curves were limited to 3 years in the analyses of survival by chemotherapy regimen and 
completion of all planned cycles. The interaction tests between treatment modality and 
age for RFS and OS were not significant (p=0.73 and p=0.73 respectively). Similarly, no 
significant interaction was found between treatment and gender for RFS (p=0.74) and OS 
(p=0.47) and between treatment and comorbidity for RFS (p=0.45) and OS (p=0.11). 
In the analyses regarding survival according to treatment modality, crude 5-year RFS 
and OS did not differ between patients treated with CapMono and patients treated with 
CAPOX (RFS: 63% vs. 60% (p=0.91); OS: 66% vs. 66% (p=0.76)). For patients who underwent 
resection only, RFS was 38% and OS was 37% (figure 2). As shown in figure 4, both the risk of 
Figure 2 Recurrence-free survival (A) and overall survival (B) according to treatment modality among elderly 
stage III colon cancer patients
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recurrence/death (model 1A) and the risk of death alone (model 1B) were similar for patients 
treated with CapMono as compared to patients treated with CAPOX after adjustment for 
casemix (RFS: HR=0.99 (95% CI 0.68-1.44); OS: HR=0.93 (95% CI 0.64-1.34)).
In the analyses regarding survival according to chemotherapy regimen and completion 
of all planned cycles, crude 3-year RFS and OS did not differ between patients who did not 
complete all planned cycles of CAPOX and patients who did complete all planned cycles of 
Figure 3 Recurrence-free survival (A) and overall survival (B) according to adjuvant chemotherapy regimen and 
completion of all planned cycles among elderly stage III colon cancer patients
Excluded from the analyses were patients for whom completion of all planned cycles was unknown (CAPOX: 3 
patients, CapMono: 6 patients)
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CAPOX (RFS: 61% vs. 69% (p=0.21); OS: 68% vs. 78% (p=0.41)). However, for patients who did 
not complete all planned cycles of CapMono, crude 3-year RFS and OS was lower than for 
patients who completed all planned cycles of CapMono (RFS: 54% vs. 72% (p=0.01); OS: 65% 
vs. 80% (p=0.01)) (figure 3). As shown in figure 4, both the risk of recurrence/death (model 
2A) and the risk of death alone (model 2B) were similar for patients who did not complete 
all planned cycles of CAPOX as compared to patients who did complete all planned cycles 
of CAPOX in multivariable analysis (RFS: HR=1.42 (95% CI 0.85-2.37); OS: HR=1.17 (95% CI 
0.70-1.97)). Among patients treated with CapMono, both the risk of recurrence/death (model 
2A) and the risk of death alone (model 2B) were higher for patients who did not complete 
all planned cycles as compared to patients who did complete all planned cycles (RFS: 
HR=2.07 (95% CI 1.11-3.84); OS: HR=2.00 (95% CI 1.12-3.59)).
Figure 4 Adjusted hazard ratios for recurrence or death (A) or death alone (B) according to treatment modality 
(models 1, n=982) or adjuvant chemotherapy regimen and completion of all planned cycles (models 2, n=343) 
among elderly stage III colon cancer patients
Hazard ratios adjusted for gender, age, comorbidity, ASA score, pathological T, pathological N, tumor subsite, 
differentiation grade and period of diagnosis
Excluded from models 2 were patients for whom completion of all planned cycles was unknown (CAPOX: 3 
patients, CapMono: 6 patients)
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Discussion
In this population-based study, we investigated the effects of the chemotherapy regimens 
CAPOX and CapMono on recurrence-free and overall survival among elderly stage III 
colon cancer patients. Additionally, we evaluated the effect of (non-)completion of both 
regimens on survival. We found a 5-year RFS of 60% for patients treated with CAPOX and 
63% for patients treated with CapMono. In subgroup analysis of the NSABP C-07 trial with 
patients aged ≥70 years and treated with either FU/LV or bolus FU and oxaliplatin (FLOX), 
a 5-year disease-free survival rate of approximately 55% was reported for both groups12. 
The difference is in part related to differences in the definition of disease-free survival 
versus recurrence-free survival. In the NSABP C-07 trial, besides recurrence and death, 
also second primary cancers were taken into account12. Additionally, patients in trials 
are monitored more closely for recurrences. Similarly, among patients aged 70-75 years 
included in the X-ACT trial and treated with CapMono, 5-year disease-free survival was 
58%11. In line with the current study, no benefit was found with the addition of oxaliplatin in 
the NSABP C-07 subgroup analysis12. Also in the subgroup of patients aged 70-75 years from 
the MOSAIC trial did treatment with FOLFOX not improve disease-free survival compared 
to treatment with FU/LV13. The 5-year disease-free survival rates in that study were 69% 
and 66% respectively13, probably somewhat higher compared to our study because patients 
with stage II disease were also included and patients over the age of 75 years were not. 
In contrast, the 5-year OS rates of 66% for both patients treated with CAPOX and patients 
treated with CapMono as found in the present study were lower than the 5-year OS rates of 
~76% as reported in the MOSAIC and NSABP C-07 subgroup analyses12,13. However, also in 
these trials, no difference in OS was found with the addition of oxaliplatin. Importantly, it 
should be acknowledged that the MOSAIC trial was underpowered for subgroup analyses13. 
In fact, in both the NSABP C-07 trial and the MOSAIC trial, the subgroup analyses by age 
group were exploratory only12,13. 
Our study suggests that optimal treatment with adjuvant chemotherapy comprises not 
merely the administration of chemotherapy, but also the completion of all planned cycles. 
In the current study, the cut-off for treatment completion was set at ≥6 cycles, irrespective 
of treatment protocol, which could also be 8 cycles. Less than half of the patients treated 
with CAPOX and approximately two third of the patients treated with CapMono completed 
all planned cycles. Except for the finding that male patients more often completed all 
planned cycles of CAPOX than female patients, no other differences in patient and tumor 
characteristics were found between patients who completed all planned cycles and patients 
who did not complete all planned cycles, for both CAPOX and CapMono. In a previous study 
from our group, we found that only the presence of any grade III-V toxicity was related 
to early treatment discontinuation for both CAPOX and CapMono21. The completion rates 
are lower than those found in other studies. The population-based study by Kumar et al. 
showed that 69% of the patients aged ≥70 years completed at least 10 cycles of the FOLFOX 
regimen25. In the subgroup of patients aged 70-75 included in the X-ACT trial, 74% completed 
the planned course of treatment with CapMono11. 
Especially for patients treated with CapMono, recurrence-free and overall survival were 
worse when patients did not complete all planned cycles. This is in line with previous 
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studies that showed that patients who failed to complete 5FU-based chemotherapy 
had worse cancer-specific survival than those who completed treatment. In line with 
a previous study on FOLFOX, for patients treated with CAPOX, no statistical significant 
differences were found in RFS and OS according to completion of all planned cycles. 
Our results however did suggest a trend towards lower crude 3-year recurrence-free and 
overall survival among the patients who did not complete all planned cycles of CAPOX as 
compared to their counterparts. The lack of statistical significance could just be the result 
of an underpowered analysis. Due to the relatively small number of patients in our study, 
we were only able to report 3-year recurrence-free survival rates in the strata according to 
both regimen and completion of all planned cycles. We acknowledge that this is relatively 
short follow-up period. However, previous studies showed that most recurrences occur 
within this time period26,27.
A limitation of the current study is the observational design. In general, randomized 
controlled trials (RCTs) are considered the gold standard in evaluating the efficacy of 
treatments. As participants are randomly assigned to a treatment or control group -thereby 
equalizing both groups with respect to all features except the treatment-, RCTs have superior 
internal validity and enable establishment of causality28. As this observational study 
includes patients treated in everyday clinical practice, it is likely that the fitter patients 
were selected for adjuvant chemotherapy. This is also reflected in the differences in ASA 
scores and in the number of comorbid conditions between the patients who underwent 
surgery only and the patients who received adjuvant chemotherapy. We cannot rule 
out that residual confounding is partly responsible for the positive effect of adjuvant 
chemotherapy. Importantly, we did not find a recurrence-free and overall survival benefit 
for the patients treated with CAPOX as compared to the patients treated with CapMono, 
despite the fact that the patients receiving CAPOX were younger and had less comorbid 
conditions than the patients receiving CapMono. This strengthens the conclusion that 
oxaliplatin might not provide an additional benefit in this study population. However, as 
the observational nature of the current study limits in establishing causality, the results 
should be interpreted with caution. The realization of RCTs designed for elderly patients 
remains important to expand the evidence-base. A trial in which the effect of the different 
chemotherapy regimens on 3-year disease-free survival is compared among elderly colon 
cancer patients is now ongoing29.
On the other hand, RCTs also have disadvantages as these are often restricted to relatively 
healthy patients, thereby limiting the generalizability of results28. Especially for patient groups 
who do not meet the eligibility criteria from RCTs, such as a large part of the elderly treated 
in everyday clinical practice, observational studies are important to provide information 
on outcomes in the real world.
In conclusion, among elderly stage III colon cancer patients treated in clinical practice, 
receipt of adjuvant chemotherapy consisting of CAPOX or CapMono is associated with 
improved RFS and OS. Since completion of all planned cycles was of more importance than 
the regimen used, the addition of oxaliplatin might not be justified, although interpretation 
should be cautious due to the observational nature of the study.
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Timing of adjuvant chemotherapy and 
its relation to survival among patients 
with stage III colon cancer
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Abstract
Background: Currently available data suggest that delaying the start of adjuvant 
chemotherapy in colon cancer patients has a detrimental effect on survival. We analysed 
which factors impact on the timing of adjuvant chemotherapy and evaluated the influence 
on overall survival (OS).
Patients and methods: Stage III colon cancer patients who underwent resection and received 
adjuvant chemotherapy between 2008 and 2013 were selected from the Netherlands Cancer 
Registry. Timing of adjuvant chemotherapy was subdivided into: ≤4, 5-6, 7-8, 9-10, 11-12 and 
13-16 weeks post-surgery. Multivariable regressions were performed to asses the influence 
of several factors on the probability of starting treatment within 8 weeks post-surgery and 
to evaluate the association of timing of adjuvant chemotherapy with 5-year OS.
Results: 6620 patients received adjuvant chemotherapy, 14% commenced after 8 weeks. 
Factors associated with starting treatment after 8 weeks were older age (Odds ratio (OR) 
65-74 versus <65 years 1.3  (95% confidence interval (CI): 1.14-1.58); OR ≥75 versus <65 years 1.6 
(1.25-1.94)), emergency resection (OR 1.8 (1.41-2.32)), anastomotic leakage (OR 8.1 (6.14-10.62)), 
referral to another hospital for adjuvant chemotherapy (OR 1.9 (1.36-2.57)) and prolonged 
postoperative hospital admission (OR 4.7 (3.30-6.68)). Starting 5-8 weeks post-surgery 
showed no decrease in OS compared to initiation within 4 weeks (Hazard ratio (HR) 5-6 
weeks 0.9 (0.79-1.11); HR 7-8 weeks 1.1 (0.91-1.30)). However, commencing beyond 8 weeks 
was associated with decreased OS compared to initiation within 8 weeks (HR 9-10 weeks 
1.4 (1.21-1.68); HR 11-12 weeks 1.3 (1.06-1.59); HR 13-16 weeks 1.7 (1.23-2.23)).
Conclusion: Our data support initiating adjuvant chemotherapy in stage III colon cancer 
patients within 8 weeks post-surgery.
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Introduction
Adjuvant chemotherapy has been shown to decrease recurrence rates and improve 
overall survival (OS) after surgical resection for patients with stage III colon cancer1-3. The 
time interval from surgery to the initiation of chemotherapy has been proposed as an 
important factor that could affect the overall outcome4-6. In most clinical trials adjuvant 
chemotherapy was generally allowed to initiate within 4-8 weeks, routinely providing 
time for wound healing; however, results showed that in daily clinical practice delays in 
commencing treatment may occur7-9.
The guidelines from the European Society for Medical Oncology (ESMO) recommend 
adjuvant chemotherapy should start as early as possible starting from the fourth week up 
to a maximum of 8-12 weeks post-surgery. If the start of adjuvant chemotherapy is delayed 
for more than 12 weeks, treatment should be given on the basis of an individual decision 
taking into account the relatively limited likelihood of benefit against the potential toxicity10. 
The Dutch guideline for the treatment of colorectal cancer (CRC) 2014 recommends that 
adjuvant chemotherapy should start between 6 and 8 weeks after surgical resection, and 
certainly within 12 weeks following surgical resection11.
Several population-based studies have shown that a delayed initiation of adjuvant 
chemotherapy is associated with an unfavourable long-term OS, cancer-specific survival 
and disease-free survival12-17. Results from a meta-analysis has indicated that the relative 
OS decreased by every 4-week delay in the administration of adjuvant chemotherapy18. 
However, in this meta-analysis there was heterogeneity among the different studies 
in the cut-off points for the timing of adjuvant chemotherapy, ranging from 8 weeks to 
more than 12 weeks, as well as in the primary location (colon versus rectum) and stage 
of disease (2 versus 3).
Various patient and tumour characteristics may act as influencing factors for timing 
of adjuvant chemotherapy, including age, comorbidity, tumour grade, tumour size and 
postoperative complications19. Identification of these factors can propose modifiable 
parameters to minimise delay in initiation of adjuvant chemotherapy.
Due to the absence of randomised data, it has not been firmly established whether there is 
a time window beyond which adjuvant chemotherapy is of little or no value for long-term 
outcomes. On the other hand, there is also no evidence that starting adjuvant chemotherapy 
early (i.e. 4-6 weeks post-surgery) is associated with better outcomes than starting somewhat 
later, giving the patient more time to recover from surgery. Irrespective of these uncertainties, 
the timing of adjuvant chemotherapy is often used as a quality indicator20. 
We analysed data from a large, population-based cancer registry of patients who are known 
to benefit most from adjuvant chemotherapy, i.e. with stage III colon cancer. Using these 
data, we investigated factors affecting timing of adjuvant chemotherapy and evaluated 
its influence on OS.
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Patients and methods
Data from the nationwide Netherlands Cancer Registry (NCR) were used, managed by the 
Netherlands Comprehensive Cancer Organisation (IKNL). The NCR is a population-based 
registry based on notification of all newly diagnosed malignancies in the Netherlands 
by the automated pathological archive (PALGA) and the National Registry of Hospital 
Discharge Diagnosis (LMR). 
Information on patient and tumour characteristics, diagnosis and treatment is routinely 
extracted from the medical records. The quality of the data is high due to thorough training 
of the registration team and computerised consistency checks at regional and national level. 
Anatomical site of the tumour is registered according to the International Classification of 
Disease – Oncology (ICD-O)21. The TNM (tumour-node-metastasis) classification is used for 
stage notification of the primary tumour, according to the edition valid at time of cancer 
diagnosis22. Furthermore, detailed information was available on: urgency of the resection 
(emergency resection <24h after presentation); surgical procedure (laparoscopic versus 
open resection) and anastomotic leakage as a surgical complication. Data on type of 
chemotherapy (oxaliplatin-based versus non-oxaliplatin-based) were available for patients 
diagnosed in the South-eastern part of The Netherlands. Data on prolonged postoperative 
hospital admission (>14 days; yes/no) were available for patients diagnosed in 2012-2013. 
Prolonged postoperative hospital admission after surgical resection served as a proxy for 
a complicated postoperative period. 
Study population
We selected all patients with colon cancer and lymph node metastases, but without distant 
metastases at presentation (stage III), diagnosed in The Netherlands in 2008-2013 who 
underwent surgical resection and received adjuvant chemotherapy (figure 1). Patients were 
excluded if they had received local chemotherapy (n=4) or neo-adjuvant chemotherapy 
(n=31). In addition, patients were excluded if the date of chemotherapy initiation was 
missing (n=1051) or if chemotherapy was started more than 16 weeks after the surgical 
resection to ensure that treatment was for adjuvant therapy (n=49).  The timing to adjuvant 
chemotherapy was calculated from the date of surgical resection to the date of initiation 
of adjuvant chemotherapy. The timing of adjuvant chemotherapy was subdivided into six 
categories: within 4 weeks, 5-6 weeks, 7-8 weeks, 9-10 weeks, 11-12 weeks and 13-16 weeks 
from surgical resection. Information on type of adjuvant chemotherapy was available for a 
subgroup of patients (n=725) who were included in a subgroup analysis. Patients of whom 
information on prolonged postoperative hospital admission was available (n=2584) were 
included in a subgroup analysis. Additionally, patients who underwent surgical resection 
without receiving adjuvant chemotherapy were included in the crude survival analyses 
to show OS of this group (n=4899; total n=11,519).
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Stage was based on the pathological TNM classification. Tumour localisation was categorised 
into three subsites: proximal colon (C18.0-C18.5), distal colon (C18.6-C18.7) and colon 
other/not otherwise specified (C18.8-C18.9). Patients were divided into age groups: <65, 
65-74 and ≥75 years. The study period was divided biannually into three time periods in 
order to calculate a possible trend over the years in timing of adjuvant chemotherapy.
Statistical analyses
Differences in clinical, pathological and treatment-related characteristics across the 
different timings of adjuvant chemotherapy were evaluated using Chi2-tests. Multivariable 
logistic regression analysis was conducted to assess the independent influence of several 
patient and clinical characteristics on the probability of starting adjuvant chemotherapy 
beyond 8 weeks post-surgery. Similar methods were used in a subgroup analysis to evaluate 
differences in type of chemotherapy across the different timings of adjuvant chemotherapy.
Survival was defined as the date of resection to death or last follow-up date (1st January 
2015) for patients who were still alive. Crude 5-year OS was estimated for the different 
groups using the Kaplan-Meier method and differences in OS outcomes were assessed 
with the log-rank test. 
Colon cancer patients stage III (TanyN1-2M0)
diagnosed between 2008-2013
n=12,718
Patients who underwent resection
n=12,654
Patients who received 
chemotherapy
n=7,755
 1,135  Excluded
4 HIPEC treatment
31 Neo-adjuvant chemotherapy
49 Start adjuvant chemotherapy >16 weeks
1,051 Date of adjuvant chemotherapy unknown
Patients who received 
adjuvant chemotherapy
n=6,620
Patients who received no 
chemotherapy (resection only)
n=4,899
Figure 1 Consort diagram of patient selection
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A multivariable Cox proportional hazards regression model was used to evaluate the 
relationship between timing of adjuvant chemotherapy and OS, with adjustment for clinical, 
pathological and treatment-related characteristics. P values below 0.05 were considered 
statistically significant. SAS/STAT® statistical software (SAS system 9.4, SAS Institute, Cary, 
NC) was used for all analyses. 
Results
Over the period 2008-2013, 6620 patients underwent surgical resection for stage III 
(TanyN1-2M0) colon cancer, and received adjuvant chemotherapy. Mean age of the population 
was 70 (standard deviation 7.8) years, 14% was ≥75 years of age and 53% was male. The 
median timing of adjuvant chemotherapy was 5.6 weeks post-surgery. A total of 1106 
patients (17%) commenced treatment within 4 weeks after resection. The majority of the 
patients (n=4512, 69%) started chemotherapy between 5 and 8 weeks after resection. A 
total of 1002 patients (14%) started treatment after 8 weeks, of whom 165 patients (16%, 2% 
of total) started treatment between 13 and 16 weeks after resection. Figure 2 presents the 
distribution of timing of adjuvant chemotherapy in weeks.
               

















    


 
 



Figure 2 Distribution of the time (in weeks) after surgical resection to the start of adjuvant chemotherapy, for 
patients diagnosed with stage III colon cancer in the Netherlands, 2008-2013 (n=6620)
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Factors associated with timing of adjuvant chemotherapy
In univariable analyses, age, period of diagnosis, T-stage, tumour location, surgical procedure, 
urgency of resection, presence of an anastomotic leakage and being referred to another 
hospital for adjuvant chemotherapy all had a significant impact on the timing of adjuvant 
chemotherapy. In addition, in the subgroup of patients (diagnosed in 2012-2013), a higher 
proportion of patients with prolonged postoperative hospital admission was found when 
adjuvant chemotherapy was started beyond 6 weeks (table 1) (p<0.0001). Gender, N stage, 
differentiation grade and histology of the primary tumour were not associated with timing 
of adjuvant chemotherapy (table 1). Type of chemotherapy was not associated with timing 
of adjuvant chemotherapy in the subgroup of patients for whom information on type of 
chemotherapy was available (p=0.918).
In a multivariable logistic regression model (table 2), elderly patients (≥65 years of age) 
(Odds Ratio (OR) 65-74 versus <65 years 1.3 (95% confidence interval (CI) 1.14-1.58) and OR 
≥75 versus <65 years 1.6 (1.25-1.94)), patients who underwent an emergency resection (OR 
1.8 (1.41-2.32)), patients who suffered from an anastomotic leakage (OR 8.1 (6.14-10.62)) and 
patients who were referred to another hospital for adjuvant chemotherapy (OR 1.9 (1.36-2.57)) 
were more likely to start chemotherapy later than 8 weeks post-surgery. Furthermore, in the 
subgroup of patients (diagnosed in 2012-2013) with information on prolonged postoperative 
hospital admission, the latter was also associated with a timing of adjuvant chemotherapy 
of more than 8 weeks (OR 4.7 (3.30-6.68)). Furthermore, patients undergoing a laparoscopic 
resection (OR 0.5 (0.43-0.61)) were more likely to start adjuvant chemotherapy earlier. Time 
to start of adjuvant chemotherapy did not differ according to type of chemotherapy in the 
subgroup of patients with information on type of chemotherapy (OR 1.1 (0.65-1.55)).
Timing of adjuvant chemotherapy and survival
Median follow-up time was 60 months. Figure 3 shows the crude 5-year OS rates according 
to the initiation of adjuvant chemotherapy within 4 weeks, 5-6 weeks, 7-8 weeks, 9-10 weeks, 
11-12 weeks or 13-16 weeks. The crude observed 5-year OS rates were 75%, 76%, 72%, 64%, 61% 
and 54%, respectively, while the proportion of 5-year OS among patients who underwent 
surgery only (n=4899) was 39%. To overcome immortal time bias between patients who 
received adjuvant chemotherapy and patients who underwent resection only; only patients 
who survived the first 16 weeks after the date of resection were included in a subgroup 
analysis. Similar results for OS were found  (data not shown). 
After case-mix adjustment (table 3), timing of adjuvant chemotherapy beyond 8 weeks 
was associated with an increased hazard of death (Hazard Ratio (HR) 9-10 versus ≤8 weeks 
1.4 (1.21-1.68); HR 11-12 versus ≤8 weeks 1.3 (1.06-1.59) and HR 13-16 versus ≤8 weeks 1.7 
(1.23-2.23)). In addition, initiation of adjuvant chemotherapy between 5 and 8 weeks post-
surgery showed no decrease in OS compared to initiation within 4 weeks (HR 5-6 versus 
≤4 weeks 0.9 (0.79-1.11) and HR 7-8 versus ≤4 weeks 1.1 (0.91-1.30)). After stratification, no 
effect of age on hazard ratios of death for timing of adjuvant chemotherapy beyond 8 
weeks was found (data not shown).
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Table 2 Crude percentages and adjusted odds ratiosa for timing of adjuvant chemotherapy beyond 8 weeks 
post-surgery among resected stage III colon cancer patients receiving adjuvant chemotherapy (n=6620)
 
Timing of AC >8 weeks
Crude %
Multivariable analysis
OR (95% CI)
Gender
   Male
   Female
15
15
1.0
1.0
(reference)
(0.87-1.18)
Age
   <65 years
   65-74 years
   ≥75 years
14
16
17
1.0
1.3
1.6
(reference) 
(1.14-1.58)
(1.25-1.94)
Period of diagnosis
   2008-2009
   2010-2011
   2012-2013
16
15
15
1.0
0.9
0.9
(reference) 
(0.78-1.15)
(0.71-1.04)
T stage 
   T1
   T2
   T3
   T4
10
14
14
16
1.0
1.2
1.1
1.2
(reference) 
(0.65-3.52)
(0.65-3.23)
(0.62-3.23)
N stage
   N1
   N2
15
15
1.0
0.9
(reference) 
(0.78-1.08)
Tumour location
   Proximal colon
   Distal colon
   Other/NOS
15
15
20
1.0
1.0
1.5
(reference) 
(0.83-1.14)
(0.94-2.44)
Differentiation grade*
   Well/moderated
   Poor /undifferentiated
14
17
1.0
1.2
(reference) 
(0.98-1.44)
Histology of primary tumour*
   Non-mucinous adenocarcinoma
   Mucinous adenocarcinoma
15
17
1.0
1.2
(reference) 
(0.91-1.62)
Surgical procedure 
   Open resection
   Laparoscopic resection
18
10
1.0
0.5
(reference) 
(0.43-0.61)
Urgency of resection* 
   Elective
   Emergency
14
26
1.0
1.8
(reference) 
(1.41-2.32)
Anastomotic leak*
   No
   Yes
13
50
1.0
8.1
(reference) 
(6.14-10.62)
Hospital AC equal to hospital resection
   No
   Yes
15
25
1.0
1.9
(reference) 
(1.36-2.57)
Prolonged hospital admission (>14 days)†
   No
   Yes
11
47
1.0
4.7
(reference) 
(3.30-6.68)
AC, adjuvant chemotherapy; CI, confidence interval; OR, odds ratio.
a Adjusted for all variables listed.
* Included in the analysis but results not shown tumour grade unknown, histology of primary tumour unknown, 
urgency of resection unknown and anastomotic leak unknown.
† Included patients diagnosed in 2012-2013 (n=2584).
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Figure 3 Crude overall survival according to whether adjuvant chemotherapy was initiated within 4 weeks, 5-6 
weeks, 7-8 weeks, 9-10 weeks, 11-12 weeks, 13-16 weeks (n=6620) or patients undergoing surgery only (n=4899)
AC, adjuvant chemotherapy.
Table 3 Crude 5-year overall survival and adjusted hazard ratiosa for death among stage III resected colon cancer 
patients receiving adjuvant chemotherapy (n=6620)
Crude 5-year survival (%) Multivariable analysis
HR (95% CI)
Timing of AC
   ≤4 weeks
   5-6 weeks
   7-8 weeks
   ≤8 weeks
   9-10 weeks
   11-12 weeks
   13-16 weeks
75
76
72
74
64
61
54
1.0
0.9
1.1
1.0
1.4
1.3
1.7
(reference)
(0.79-1.11)
(0.91-1.30)
(reference)
(1.21-1.68)
(1.06-1.59)
(1.23-2.23)
AC, adjuvant chemotherapy; CI, confidence interval; HR, hazard ratio.
a Adjusted for gender, age, period of diagnosis, T stage, N stage, tumour location, differentiation grade, histology of 
tumour, surgical procedure, urgency of resection, anastomotic leak, hospital AC equal to hospital resection.
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Discussion
Currently available data suggest that a start of adjuvant chemotherapy later than 8 
weeks post-surgery in stage III colon cancer patients is associated with poorer survival. 
We identified factors that influenced the probability of starting adjuvant chemotherapy 
beyond 8 weeks, and studied the effect of the timing of adjuvant chemotherapy on survival. 
We found that initiating adjuvant chemotherapy beyond 8 weeks was associated with a 
decrease in OS, even when relevant prognostic factors were taken into account. However, 
the timing of adjuvant chemotherapy had no effect on OS when this was started anytime 
within 8 weeks of surgery.
Different cut-offs for the initiation of adjuvant chemotherapy were used in previous studies 
leading to different definitions of a delayed start of chemotherapy2,23, ranging from 8 to 12 
weeks. Other studies also included rectal cancer patients18,24,25 or high-risk stage II colon 
cancer patients26. Since the benefit of adjuvant chemotherapy in patients with stage II 
colon cancer and in rectal cancer is less obvious or even questionable, the effect of timing 
of adjuvant chemotherapy on outcome may be diluted or masked in studies that included 
these patients. In our study, only 14% of the patients started adjuvant chemotherapy beyond 
8 weeks of surgery, which is less compared to the 19-42% which has been observed in 
studies performed in other countries14,27. 
Patient age, emergency resection, surgical procedure (laparoscopic versus open resection), a 
complicated postoperative recovery (suffering from anastomotic leakage and/or prolonged 
postoperative hospital stay) and receiving adjuvant chemotherapy in a different hospital than 
in which surgery was performed were all identified as factors that have an impact on timing 
of adjuvant chemotherapy. These findings are comparable with other studies6,17,28. Hendren 
et al. found that the presence of surgical complications was related to a delayed start and 
omission of adjuvant chemotherapy in stage III CRC patients29. In a study including rectal 
cancer patients, the duration of postoperative hospital stay was also strongly associated 
with a delayed start of adjuvant chemotherapy26. In line with previous studies of Poylin et 
al.30 and Lacy et al.31, we found a lower odds for starting adjuvant chemotherapy beyond 
8 weeks when patients underwent a laparoscopic resection instead of an open resection.
The timing of adjuvant chemotherapy had no effect on OS when this was started anytime 
within 8 weeks of surgery. This is in accordance with a study of Hershman et al. who found 
no survival gain in patients receiving adjuvant chemotherapy within 4 weeks compared 
to patients receiving adjuvant chemotherapy between 5 and 8 weeks14. The 5-year survival 
proportion of patients starting adjuvant chemotherapy between 13 and 16 weeks was 
54% in our study, while the proportion of 5-year survival among patients who underwent 
surgery only was 39%. 
Previous studies have shown similar results using population-based data on a regional 
and/or hospital level. This is the first large nationwide observational study to describe 
the effect of timing of adjuvant chemotherapy in resected stage III colon cancer patients 
on long-term survival. An important limitation of this study however is its observational 
nature. The effects observed may be highly susceptible to selection bias, e.g. less fragile 
patients receiving adjuvant chemotherapy first. Although we adjusted for several patient and 
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tumour characteristics, data about functional status, specific postoperative complications 
other than anastomotic leakage and comorbidity were not available. Therefore an analysis 
of the effect of timing of adjuvant chemotherapy on long-term outcomes may be subject 
to residual confounding. We hypothesise that patients starting chemotherapy beyond 8 
weeks post-surgery were in worse general health, have had more surgical complications 
and had an inherently worse prognosis, which may have influenced the results. Another 
limitation of our study is that for 1051 patients date of chemotherapy initiation was missing 
and were therefore excluded. However, results of our study indicate that casemix did not 
differ between this group and included patients.
We did not find a negative effect on survival of initiating adjuvant chemotherapy between 5 
and 8 weeks post-surgery compared to initiation within 4 weeks. Therefore we hypothesise 
the presence of a time window in which patients can recover from surgery and give them 
physically and emotionally more time to prepare for the next step in the treatment process. 
A prospective cohort study in which patients are followed over time, and in which more 
information about unmeasured confounders and modification of the identified factors 
is available, would be valuable. A national population-based colorectal cancer registry is 
currently in development in The Netherlands.
Our data support the inclusion of the timing of adjuvant chemotherapy as a quality indicator 
for cancer treatment. It is important that multidisciplinary teams (MDTs) should seek for the 
optimal timing of adjuvant chemotherapy taking social and frailty aspects of the patients 
into account32. Efforts should be made to ensure that the process of adjuvant chemotherapy 
treatment is based on shared decision-making between patients and providers whenever 
possible and appropriate. 
In conclusion, our data support the initiation of adjuvant chemotherapy in stage III colon 
cancer within 8 weeks of surgery.
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In this chapter, the main findings of the studies included in this thesis will be summarized and 
subsequently discussed in a broader context. Next, several methodological considerations 
are highlighted that should be taken into account when interpreting the results of the 
studies. Implications for clinical practice and future research are discussed as well.
Summary of the main findings
This thesis started with an overview of drugs dispensed to elderly colon cancer patients in 
the year before colon cancer diagnosis in comparison with an age- and gender-matched 
control group without cancer (chapter 2). The study demonstrated a higher proportion of drug 
dispensing from out-patient pharmacies to elderly colon cancer patients during the year 
before diagnosis as compared to a matched cancer-free control group, which increased even 
more during the last three months before diagnosis. In general, the elevated dispensing of 
drugs among cases as compared to controls during the total study year was mostly related 
to comorbidity, while the drugs that were dispensed to an increasing proportion of cases 
in the months before colon cancer diagnosis were probably mostly related to (symptom 
management of) the colon cancer. Insight into which drugs are commonly used in the year 
preceding colon cancer diagnosis may trigger general practitioners and medical specialists 
to further evaluate the patient’s medication and should be considered in subsequent cancer 
treatment planning as this might impact on the tolerance and effect of these treatments. 
The objective of the next study was to identify subjective, doctor-related factors in the 
decision-making on adjuvant chemotherapy in elderly stage III colon cancer patients 
(chapter 3). Short questionnaires were sent to surgeons and medical oncologists. 
Surgeons most often reported the following motives for non-referral: comorbidity or bad 
general health condition of the patient; presence of surgical complications and refusal of 
adjuvant chemotherapy by the patient. Medical oncologists also reported these motives 
for non-treatment, and additionally reported that expected side effects were too severe. 
Less than half of the surgeons and little over half of the medical oncologists reported to 
consult a geriatrician for a minority of the patients. The decision of medical oncologists 
for monotherapy or combination therapy is based on the presence of comorbidity, the 
general health condition of the patient and the toxicity profile of the chemotherapeutic 
agents. Medical oncologists agree on acceptable levels of toxicity: in general, grade ≤II 
toxicity was defined as acceptable, with the exception of neuropathy, which was only 
deemed acceptable if grade I. The variation among surgeons and medical oncologists in 
motives for non-referral, non-treatment and consultation of geriatricians when deciding 
on adjuvant chemotherapy for elderly stage III colon cancer patients might be related to 
the lack of evidence-based guidelines for, and complexity of, these patients. 
Subsequently, patient and tumour characteristics influencing the administration of 
oxaliplatin-based chemotherapy (FOLFOX and CAPOX) as compared to non-oxaliplatin-based 
chemotherapy (5-fluorouracil/leucovorin or capecitabine) and variation in the administration 
of both types between hospitals (chapter 4) were evaluated. For this study, 1140 patients 
originating from 10 community hospitals in the southeast part of the Netherlands and 
diagnosed between 2008 and 2011 were included. The median age of the patients receiving 
10
General discussion  |  135
oxaliplatin was 64 years, and the median ages of patients receiving non-oxaliplatin-based 
chemotherapy or no chemotherapy were 74 and 79 years respectively. A large inter-hospital 
variation in the administration of oxaliplatin-based and non-oxaliplatin-based chemotherapy 
was noted, which could not be entirely explained by patient casemix. Oxaliplatin-based 
chemotherapy administration ranged from 63% to 87% for patients aged <70 years, from 
15% to 100% for patients aged 70-74 years, and from 0% to 19% for patients aged 75 years or 
older. For non-oxaliplatin-based chemotherapy, these proportions ranged from 3% to 20%, 
from 0% to 29% and from 0% to 28% for the respective age groups. In an analysis including 
only patients receiving adjuvant chemotherapy, the addition of oxaliplatin was affected 
by age, T stage, period of diagnosis and hospital of treatment. 
Hardly any previous population-based studies among elderly stage III colon cancer patients 
described the exact regimens used in daily practice; the intensity of and adherence to these 
regimens; and the degree unselected elderly develop toxicity from these regimens. The aim 
of chapter 5 was therefore to provide insight in the completion of all planned cycles and 
received cumulative dosages for the most commonly used regimens in everyday clinical 
practice and to investigate the association with grade III-V toxicity. Additional data was 
collected within the Netherlands Cancer Registry for all stage III colon cancer patients 
aged ≥70 years diagnosed in the ten hospitals in the southeast part of the Netherlands 
between 2005 and 2012. The study showed that a large majority (88%) of the patients who 
were treated with adjuvant chemotherapy received CAPOX or capecitabine monotherapy 
(CapMono). The joint proportion of CAPOX and CapMono versus other regimens was as high 
as 98% in the most recent study period (2011-2012). The proportion of patients completing 
all planned cycles was lower for patients receiving CAPOX (33%) than for patients receiving 
CapMono (55%). The median cumulative dosage of capecitabine received was also lower 
for patients treated with CAPOX (163,744mg/m2) than for patients treated with CapMono 
(189,195mg/m2). Additionally, CAPOX was associated with significantly more grade III-V 
toxicity than CapMono (54% versus 38%), also after adjustment for patient and tumour 
characteristics. For patients treated with CAPOX, the most common toxicities were 
gastrointestinal (mainly diarrhoea and nausea/vomiting, 29%), haematological (14%), 
neurological (i.e. neuropathy, 11%) and other toxicity (mainly fatigue, 13%). For patients 
treated with CapMono, dermatological (i.e. hand-foot syndrome, 17%), gastrointestinal 
(mainly diarrhoea, 13%) and other toxicity (mostly fatigue, 11%) were the most common. The 
study also investigated the associations between the most common grade III-V toxicity 
and the median number of cycles and cumulative dosage received. In general, toxicity that 
occurred rapidly was associated with a lower median number of cycles and cumulative 
dosage received, such as gastrointestinal toxicity. Other toxicity was cumulative, appeared 
in a later stage during the treatment course and did not result in lower median number of 
cycles and cumulative dosages received, such as neuropathy and hand-foot syndrome.
Chemotherapy-induced peripheral neuropathy (CIPN) is increasingly recognized as an 
important toxicity which compromises treatment plans. The next study focused on 
differences in the course of neuropathic symptoms between patients who were treated 
with CAPOX, CapMono, or no adjuvant chemotherapy (chapter 6). For this longitudinal 
study, patients were invited to complete the first questionnaire after resection and 
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subsequent questionnaires six and twelve months later. The number and percentages of 
patients who experienced mild to severe neuropathic symptoms were measured using 
the EORTC QLQ-CIPN20. A total of 117 patients completed T1 (response rate 76%), and 69 
and 59 patients completed T2 and T3 respectively. Over time, the course of several sensory 
symptoms was less favourable for the patients treated with adjuvant chemotherapy. 
Additionally, the course of numbness in toes/feet differed significantly between patients 
treated with CAPOX (T1 7%, T2 50%, T3 42%) and patients treated with CapMono (T1 17%, 
T2 31%, T3 8%). Furthermore, patients treated with CapMono reported significantly less 
tingling toes/feet (T1 6%, T2 25%, T3 7%) than patients treated with CAPOX (T1 0%, T2 50%, 
T3 58%). As neuropathic symptoms may impair functional capacities and are negatively 
associated with health-related quality of life during and after treatment, it is of paramount 
importance to inform elderly on these risks to enable them to make an informed decision 
on a suitable course of treatment.
In chapter 7, the association between adjuvant chemotherapy and the risk of distant 
recurrence was investigated. It was also evaluated whether the association was similar 
for patients aged ≥75 years and their younger counterparts. Patients diagnosed with 
stage III colon cancer between 2003 and 2008 in the southeast of the Netherlands were 
included as data on the development of metachronous distant recurrences was available 
for these years. Propensity score matching was applied to create a subsample to reduce 
bias caused by differences between patients receiving adjuvant chemotherapy and patients 
not receiving adjuvant chemotherapy. Adjuvant chemotherapy (CTx) was correlated with 
a reduced risk of distance recurrence in both the total study population (crude five-year 
percentages for CTx versus no CTx 36% vs. 42%, adjusted HR 0.55, 95% CI 0.42-0.70) and 
in the propensity score matched sample (34% vs. 50%, adjusted HR 0.46, 95% CI 0.33-0.63). 
In separate analyses for patients aged <75 years and ≥75 years, the effect of adjuvant 
chemotherapy on the risk of distant recurrence remained comparable for both age groups 
(adjusted HR 0.50, 95% CI 0.37-0.68 and adjusted HR 0.57, 95% CI 0.36-0.90 respectively). These 
results suggest that older patients derive comparable benefit from adjuvant chemotherapy 
as their younger counterparts with regard to the risk of distant recurrence. Consideration 
of adjuvant chemotherapy is therefore warranted.
In the next study, the associations of the adjuvant chemotherapy regimens CAPOX and 
CapMono with recurrence-free survival (RFS) and overall survival (OS) among elderly 
stage III colon cancer patients were investigated (chapter 8). Moreover, this study also 
evaluated the effects of (non-)completion of both regimens on RFS and OS. Recurrence 
as defined for this study encompassed local and/or regional and/or distant recurrence(s). 
Five-year RFS and five-year OS did not differ between CapMono and CAPOX (RFS: 63% vs. 
60%, adjusted HR 0.99, 95% CI 0.68-1.44; OS: 66% vs. 66%, adjusted HR 0.93, 95% CI 0.64-1.34). 
After resection only, five-year RFS was 38% and five-year OS 37%. Completion of treatment 
(defined as ≥6 cycles) was achieved for 48% among patients treated with CAPOX and for 
68% among patients treated with CapMono. Three-year RFS and OS did not differ between 
patients who discontinued CAPOX early and patients who completed treatment with 
CAPOX (RFS: 61% vs. 69%, adjusted HR 1.42, 95% CI 0.85-2.37; OS: 68% vs. 78%, adjusted HR 1.17, 
95% CI 0.70-1.97). Three-year RFS and OS differed between patients who discontinued 
CapMono early and patients who completed treatment with CapMono (RFS: 54% vs. 72%, 
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adjusted HR 2.07, 95% CI 1.11-3.84; OS: 65% vs. 80%, adjusted HR 2.00, 95% CI 1.12-3.59). In 
other words, administration of CAPOX or CapMono is associated with improved RFS and 
OS. Since the advantage does not differ by regimen, the addition of oxaliplatin might not 
be justified in elderly stage III colon cancer patients treated in everyday clinical practice.
The last study included in this thesis investigated which demographic and clinical 
variables were associated with the timing of adjuvant chemotherapy and how this timing 
was associated with overall survival (chapter 9). In this nationwide study, data from the 
Netherlands Cancer Registry for all stage III colon cancer patients who underwent resection 
and received adjuvant chemotherapy between 2008 and 2013 was included. The median 
timing of adjuvant chemotherapy was 5.6 weeks post-surgery. Fourteen percent of the 
patients commenced adjuvant chemotherapy more than 8 weeks after surgery. Factors 
associated with starting treatment after 8 weeks post-surgery were older age (65-74 years 
vs. <65 years: adjusted OR 1.3, 95% CI 1.14-1.58; ≥75 years vs. <65 years: adjusted OR 1.6, 
95% CI 1.25-1.94), emergent surgery, anastomotic leakage, referral to another hospital 
for adjuvant chemotherapy and prolonged postoperative hospital admission. The crude 
five-year overall survival rates according to initiation of adjuvant chemotherapy within 4, 
5-6, 7-8, 9-10, 11-12 or 13-16 weeks were 75%, 76%, 72%, 64%, 61% and 54% respectively. After 
adjustment for casemix, starting 5-8 weeks post-surgery showed no decrease in overall 
survival compared to initiation within 4 weeks after surgery. However, commencing 
beyond 8 weeks post-surgery was associated with decreased overall survival compared 
to initiation within 8 weeks. These results support initiation of adjuvant chemotherapy 
in stage III colon cancer within 8 weeks post-surgery, while also providing a time window 
in which patients can recover from surgery.
General discussion
Elderly represent a substantial part of the colon cancer patients and this will increase even 
further in the near future due to demographic developments1. This provides a significant 
challenge to cancer specialists, as many uncertainties still remain regarding the optimal 
treatment for this heterogeneous patient population. This thesis intended to realise a more 
evidence-based use of the existing adjuvant treatment options for elderly patients with 
stage III colon cancer. 
The administration of adjuvant chemotherapy declines with increasing age2-10. Approximately 
one third of the elderly stage III colon cancer patients receives adjuvant chemotherapy. 
Several reasons were identified for this low treatment rate. The most frequently reported 
motives by surgeons for non-referral and by medical oncologists for non-treatment were 
comorbidity/bad general health condition of the patient, surgical complications, and refusal 
by the patient and/or family. In line with the first reported motive, patients who received 
adjuvant chemotherapy had less comorbid conditions and a lower ASA score than patients 
who underwent resection alone11-16. The use of biological age as opposed to chronological 
age is desirable in deciding on (contra-)indications for adjuvant chemotherapy.
The variation among surgeons and medical oncologists in motives for non-referral, 
non-treatment and consultation of geriatricians, as well as the variation in treatment 
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between hospitals after adjustment for patient casemix, show the complexity of an 
adequate selection of patients that will benefit from adjuvant chemotherapy. As this thesis 
showed that the older patients who were treated with adjuvant chemotherapy derived 
comparable benefits from adjuvant chemotherapy as their younger counterparts with 
regard to the risk of recurrence, a further investigation and refinement of this selection 
is of paramount importance. Some promising advances have been made, such as the 
exploration of immunological criteria that could be included in tumour staging. Tumour 
infiltration by specific types of immune cells has been associated with tumour dissemination, 
recurrence and survival17-22. Additionally, several other markers have been identified that 
can be used for prognostic stratification of patients and which might help select patients 
for adjuvant chemotherapy23. These markers include for example perineural invasion and 
lymphovascular invasion24, microsatellite instability (MSI)25,26, BRAF mutations27,28 and 
KRAS mutations29,30. Mutations in BRAF and KRAS have been independently associated 
with reduced disease-free and overall survival. Especially interpreted in the context of MSI 
status and tumour location are they of great value. The highest risk of recurrence is found 
in BRAF-mutated microsatellite stable (MSS) left-sided tumours23,31. These advances will 
challenge researchers and clinicians to develop even more complex and individualized 
treatment strategies.
For elderly, the inclusion of geriatrics and geriatric assessments provides additional 
opportunities for further refinement of the selection of elderly who could benefit from 
adjuvant chemotherapy. The International Society of Geriatric Oncology (SIOG) recommends 
that for patients with physical or psychological comorbidities, a geriatrician should be 
involved in patient management32. The need for geriatric screening and assessment and the 
feasibility of including geriatrics in oncology care was previously shown33. Problems were 
revealed for more than half of older cancer patients, which led to geriatric interventions in 
a quarter of these patients33. Recently, psychological stress, neuropsychological problems 
and the number of prescriptive drugs taken were found to be predictive for the feasibility 
of chemotherapy34. 
For a patient to receive sufficient information about the treatment with adjuvant 
chemotherapy and for an assessment of a patient’s functional status and possible risks 
and benefits of treatment with adjuvant chemotherapy, every elderly stage III colon cancer 
patient should have a consultation with a medical oncologist. On the other hand, it should 
also be acknowledged that adjuvant chemotherapy may not be desirable for every elderly 
stage III colon cancer patient, for example in case of a short remaining life expectancy. In case 
of doubt on vitality or goal setting for individual patients, it is preferable that consultation 
by a geriatrician and geriatric assessment are part of the care pathway.
In case an elderly patient is treated with adjuvant chemotherapy, another challenge is to 
select an appropriate regimen for each individual patient. Current guidelines recommend 
oxaliplatin-containing chemotherapy as the standard of care, with exceptions in which a 
fluoropyrimidine monotherapy is preferable32,35. In clinical practice, elderly patients are less 
often treated with oxaliplatin-containing regimens than their younger counterparts5,36-38. 
Comorbidity, patients general health condition and toxicity profile were the most frequently 
reported factors on the decision for monotherapy instead of combination therapy. Again, 
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there was a large variation between hospitals in the southern part of the Netherlands 
with regard to the type of adjuvant chemotherapy (that is, combination therapy versus 
monotherapy) administered to these patients, which could not be explained by casemix. 
Nowadays, CAPOX and capecitabine monotherapy (CapMono) are the mostly prescribed 
regimens for elderly stage III colon cancer patients treated in daily clinical practice. In the 
included years (2005-2012), adjuvant chemotherapy consisted of CAPOX or CapMono in 
87%, while FU-based regimens were prescribed sparsely. In contrast, 87% received FULV in 
the previous period (1997-2004)16. A population-based study including colon cancer patients 
from all ages showed a rapid shift from the use of FOLFOX to the use of CAPOX from January 
2005 to December 200639. The use of capecitabine instead of FU in the Netherlands is high 
in comparison to other countries. The shift towards capecitabine-based regimens in the 
Netherlands over the last decade is related to the fact that capecitabine-based regimens 
are non-inferior to and less toxic than FU-based regimens40,41, are more convenient for the 
patient and have a more favourable reimbursement policy for hospitals. 
This thesis showed that elderly patients receiving CAPOX less frequently completed all 
planned cycles compared to patients receiving CapMono (33% versus 55%). Although 
the median number of capecitabine cycles did not differ between regimens, the median 
cumulative dosage of capecitabine was lower for patients who received CAPOX compared 
to patients who received CapMono. This is probably related to the fact that the standard 
dosage for capecitabine is lower in the CAPOX regimen compared to the CapMono regimen 
(2000 versus 2500 mg/m2). In addition, increased toxicity with the CAPOX regimen can 
also have impacted the cumulative dosage of capecitabine. However, the fact that patients 
treated with CAPOX received a lower median cumulative dosage capecitabine than patients 
treated with CapMono seems counterproductive, as it has been suggested that the main 
benefit from adjuvant treatment is derived from the fluoropyrimidine. 
When deciding on the dosage of fluoropyrimidine, an important consideration is the 
presence of dihydropyrimidine dehydrogenase (DPD) deficiency, encoded by the gene DPYD. 
DPYD variants DPYD*2A, c.1679T>G, c.2846A>T and c.1236G>A/HapB3 have been shown to 
be predictive for severe and life-threatening fluoropyrimidine-associated (haematological 
and gastrointestinal) toxicity42,43. Dose reductions of 50% for the first two variants and 25% 
for the latter variant are now recommended43,44. For one of the most well established DPYD 
variants, DPYD*2A, genotype-guided dosing has been shown to significantly improve 
safety. Additionally, prospective screening for DPYD*2A was proven to be feasible and cost 
saving in daily clinical practice45.
The 5-year recurrence-free and overall survival rates for patients treated with CAPOX (60% 
and 66% respectively) and for patients treated with CapMono (63% and 66% respectively) 
were comparable, despite the fact that the patients receiving CAPOX were younger and had 
less comorbid conditions than the patients receiving CapMono. In other words, oxaliplatin 
did not provide benefit. 
Additionally, grade III-V toxicity was more evident with CAPOX (54%) than with 
CapMono (38%). This is in line with previous studies showing higher toxicity rates with 
oxaliplatin-containing regimens36,46. Other research has shown that the incidence of 
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severe toxicity is not only determined by the chemotherapeutic agents itself but also by 
patient characteristics. The study by Extermann et al.47 showed that the risk of severe 
toxicity is significant for any older patient receiving chemotherapy.  Patient differences 
in Eastern Cooperative Oncology Group (ECOG) performance status, nutritional status 
and mental status contributed two to three times more than chemotherapy differences 
to the risk of non-haematological toxicity47. Other studies have also shown the impact of 
geriatric factors on patient selection for (type of) chemotherapy and risk of toxicity. These 
factors included for example malnutrition and functional and cognitive impairment48,49. 
Additionally, declining food intake, the number of prescription drugs taken and dependence 
in shopping were predictive for a higher mortality risk34. Unfortunately, these geriatric 
factors were not available in the studies included in this thesis and only the presence of 
any grade III-V toxicity was found to be independently related to early discontinuation 
of both CAPOX and CapMono. It was previously shown that even low grade toxicities (i.e. 
grade I-II) can lead to treatment modification and early discontinuation in older patients50.
Especially for elderly, the impairment of functional capacities can have a significant 
impact on their (quality of) life. Chemotherapy-induced peripheral neuropathy (CIPN) is 
increasingly recognized as an important adverse effect of oxaliplatin. CIPN interferes 
with many aspects of daily life and is negatively associated with health-related quality of 
life, while its prevention and treatment remain difficult51-55. CIPN is only partly reversible, 
with chronic neuropathy still present in many patients more than one year after the 
termination of therapy56. Even as long as 11 years after diagnosis, neuropathic symptoms 
are still reported by colorectal cancer patients, especially sensory symptoms in the toes 
and feet among those treated with oxaliplatin57. A higher cumulative dose of oxaliplatin 
seems to be a predictive factor for the development of chronic peripheral neuropathy56,58,59. 
In this light, the results of The International Duration Evaluation of Adjuvant Chemotherapy 
(IDEA) study in which disease-free survival is compared between standard six months 
of adjuvant treatment with oxaliplatin versus three months of adjuvant treatment with 
oxaliplatin will be of great value60.
As CapMono is better tolerated and less toxic without limiting the recurrence-free and 
overall survival benefit, a shift towards fluoropyrimidine monotherapy as the standard 
of care with exceptions in which oxaliplatin-containing chemotherapy is preferable, is 
indicated. One such exception is the presence of microsatellite instability (MSI). MSI is 
present in approximately 15% of the patients with colon cancer61. Although MSI tumours 
have a favourable prognosis, they appear to be resistant for fluoropyrimidines25. For 
oxaliplatin-containing regimens, no difference in benefit was found between MSI tumours 
and microsatellite stable tumours26. Therefore, a combination regimen with oxaliplatin is 
the first choice of treatment in case of MSI tumours. This also implies that evaluation of 
the mismatch repair status should become standard of care.
With regard to the timing of adjuvant chemotherapy after surgery, this thesis showed 
that initiating adjuvant chemotherapy beyond 8 weeks was associated with a decrease in 
overall survival, even when relevant prognostic factors were taken into account. However, 
a negative effect on survival of initiating adjuvant chemotherapy between 5 and 8 weeks 
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post-surgery compared to initiation within 4 weeks was not present. A time window seems 
present in which patients can recover from surgery and prepare for the next step in the 
treatment process.
Methodological considerations
The studies in this thesis have several strengths and weaknesses related to the data sources 
and study designs that were used.
Data sources
NetherlaNds CaNCer registry
The main data source for most of the studies included in this thesis was the Netherlands 
Cancer Registry (NCR). More specifically, most studies focused on patients diagnosed and 
treated in the southeast of the Netherlands (the area formerly covered by the Eindhoven 
Cancer Registry), which comprises about 2.4 million inhabitants (~15% of the Dutch 
population) and encompasses 10 community hospitals. No academic or specialized cancer 
hospitals are included in the region. Information on patient and tumour characteristics and 
primary treatment are routinely collected within the NCR. Additionally, in the southeast 
of the Netherlands, comorbid conditions present at time of cancer diagnosis are also 
registered62,63. This is unique as compared to other cancer registries worldwide and provides 
essential information for studies among elderly cancer patients. However, no detailed 
information on the systemic treatment such as regimen, number of cycles and dosage 
were standardly available in the NCR. Data on the development of recurrences was also 
not yet collected. These data were additionally collected for several studies included in 
this thesis. A limitation is that information on the performance status of the patients was 
frequently missing from the medical files and could not be included.
PharMO
Data on drug dispensings as used for chapter 2 were retrieved from the out-patient 
pharmacy database from the PHARMO Database Network and linked to clinical data from 
the NCR, covering an overlapping demographic region in the southeast of the Netherlands 
of approximately 1.2 million inhabitants64. The PHARMO Database Network is a large 
patient-centric data network including multiple linked observational databases designed for 
drug safety and outcomes research. Strengths are that we were able to include a matched 
control group without cancer and that the sample size for this study was large (i.e. 2735 
elderly colon cancer patients and 2735 matched cancer-free controls). Limitations are that it 
remains unknown whether dispensed drugs are actually ingested by the patients, although 
possible misclassification will be non-differential; that details regarding prescription length 
and dosages were not taken into account; and that no data from in-hospital pharmacies 
was included, which may have resulted in an underestimation of drug dispensings. 
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QuestiONNaires 
For the study in chapter 3, in which we investigated subjective, doctor-related factors 
influencing the decision-making on adjuvant chemotherapy, we developed a short 
questionnaire for surgeons and medical oncologists. A limitation of this approach is that 
the questionnaire was not validated. However, we discussed the questionnaire with a 
medical oncologist for content and relevance. Another limitation was the small sample 
size, but strengths were the high response rate (i.e. 81%) and the inclusion of medical 
specialists from 10 different hospitals.
In chapter 6, we investigated differences in the course of patient-reported neuropathic 
symptoms between treatment modalities. In this study, we used the validated 
European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire-Chemotherapy Induced Peripheral Neuropathy 20 (EORTC QLQ-CPIN20) 
to measure peripheral neuropathy65. Other strengths of this study included the use of 
longitudinal data with a baseline measurement and the adjustment for comorbid conditions 
that are also associated with neuropathic symptoms. Furthermore, the initial response 
rate was relatively high (i.e. 76%) and comparable to other surveys66. The invitation for the 
study was sent by the attending surgeon, which may have resulted in this high response 
rate. A limitation is the relatively small sample size, especially during the second and third 
wave as many patients discontinued participation after the first measurement. This might 
have been a consequence of surveying patients shortly after major cancer surgery. The 
data from the questionnaires was collected within PROFILES (Patient Reported Outcomes 
Following Initial treatment and Long term Evaluation of Survivorship)67, which is linked 
to clinical data from the NCR. This linkage enabled us to compare sociodemographic and 
clinical characteristics between respondents and non-respondents.
Study design
The studies included in this thesis had an observational design and the following advantages 
and disadvantages of this approach should be considered. In general, randomized clinical 
trials (RCTs) are considered the gold standard in evaluating the efficacy  of treatments. 
In RCTs, participants are randomly assigned to a treatment or control group, thereby 
equalizing the treatment and control groups with respect to all features except the 
treatment assignment. RCTs have a superior internal validity compared to observational 
studies, but the generalizability of RCTs is limited as RCTs are often restricted to relatively 
healthy patients with minimal comorbidity and good performance status. Therefore, RCTs 
cannot establish treatment effectiveness and the knowledge gained from RCTs should be 
complemented with data from population-based observational studies. The observational 
nature of population-based studies limits in establishing causality but has the ability to 
provide a unique insight into the effects of treatments in everyday clinical practice68-70. 
The Netherlands Cancer Registry allows the evaluation of outcomes in the general patient 
population and provides information regarding the use, safety and outcomes in the real 
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world. Especially for patient groups who do not meet the eligibility criteria from RCTs, 
such as a large part of the elderly patient population who were the subject of the studies 
included in this thesis, observational studies are of paramount importance.
Several biases are inherent to population-based observational studies and should be 
considered when interpreting the results of the studies included in this thesis. Here, the 
most important biases and how these biases were dealt with are discussed. 
seleCtiON bias aNd attritiON bias
Selection bias can either refer to the selective recruitment of patients into the study who 
are not representative for the source population or to systematic differences between 
baseline characteristics of the groups that are compared in the study. 
The proportion of patients reporting neuropathic symptoms (chapter 6) may have been 
influenced by the first type of selection bias even though participants were selected from a 
population-based sample and initial response rate was relatively high (i.e. 76%). To explore 
the representativeness of the data, sociodemographic and clinical characteristics of the 
respondents and non-respondents were compared. We found that respondents were 
relatively younger at time of cancer diagnosis compared to non-respondents, but both 
groups did not differ with regard to gender, socioeconomic status, number of comorbid 
conditions and type of adjuvant chemotherapy. It is possible that non-respondents had 
more postoperative complications or a poorer performance status.
The findings of this study may also have been affected by attrition bias as a result of loss 
to follow-up. Of the 117 patients completing the first questionnaire, respectively 69 and 
59 patients completed the second and third questionnaire. Comparison of patients who 
completed 1 versus 2 or 3 questionnaires indicated that those patients who completed 2 or 
3 questionnaires represented a selection of the ‘fitter’ patients compared to those patients 
who completed 1 questionnaire.
The second type of selection bias is present in all studies included in this thesis in 
which patients were grouped according to (type of) adjuvant chemotherapy receipt 
(chapters 4-9). Patients treated with an oxaliplatin-based regimen, monotherapy or no 
adjuvant chemotherapy differed on several patient and tumour characteristics such as 
age and comorbidity. We used statistical techniques to adjust for imbalances between 
treatment groups. First, we used methods involving covariance adjustment in all studies. 
These methods produce estimates of treatment effects adjusted for patient and tumour 
characteristics (covariates) which are explicitly included in the statistical regression 
models. We were able to adjust for a large number of patient and tumour characteristics, 
including comorbidity.
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Second, in one study we also used propensity score matching (chapter 7). The propensity 
score was estimated using logistic regression and represented the probability that a 
patient would not receive adjuvant chemotherapy, conditional on the patient’s background 
characteristics (i.e. gender, age, socioeconomic status, comorbidity, T stage, N stage, 
differentiation grade, subsite and period of diagnosis). Patients who did not receive adjuvant 
chemotherapy were then matched to patients who did receive adjuvant chemotherapy on 
the basis of propensity scores, which could vary by no more than 1%, to create two groups 
comparable on baseline characteristics. 
Besides the choice for certain statistical techniques, we also contemplated on adequate 
outcomes. In addition to overall survival, we included the risk of recurrence and 
recurrence-free survival (chapters 7-8) whenever possible. These outcomes might be less 
prone to selection bias than overall survival.
iMMOrtal tiMe bias
In the studies included in this thesis, immortal time bias occurred in case the time between 
cancer diagnosis and treatment was taken into account in survival analyses (chapters 
8-9). In this period death could not occur, in other words, a period of ‘immortal time’ was 
present as the patient must have been alive to receive the treatment. This bias results in 
an overestimation of the effect of a treatment.
To minimize immortal time bias, we differed the starting points for the survival analyses. 
For recurrence-free and overall survival according to treatment modality (i.e. resection 
only, CAPOX or capecitabine), the date of resection of the primary tumour was used. For 
recurrence-free and overall survival according the chemotherapy regimen and completion 
of all planned cycles, the last date of chemotherapy was taken.
residual CONfOuNdiNg 
The lack of randomization in the studies included in this thesis may not only have resulted 
in differences between treatment groups on observed characteristics, but also on unobserved 
characteristics69. We were only able to adjust for known and observed characteristics in 
our statistical analyses, while other unobserved characteristics might also have influenced 
outcomes. For example, no information on ECOG performance status, nutritional status 
and mental status were available. 
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Implications for clinical practice 
Medical specialists will encounter an increasing number of elderly colon cancer patients. 
Based on the findings of this thesis, a number of recommendations on adjuvant chemotherapy 
among elderly patients with stage III colon cancer are formulated. 
• Consideration of adjuvant chemotherapy is warranted for all elderly stage III colon 
cancer patients. Elderly patients derive comparable benefit from adjuvant chemotherapy 
with regard to the risk of recurrence compared to their younger counterparts. 
• Every elderly patient, with or without comorbidity, should have a consultation with the 
medical oncologist after resection of the primary tumour for an assessment of their 
physiological and functional status after surgery and to receive sufficient information 
about the treatment with adjuvant chemotherapy. In certain circumstances, withholding 
adjuvant chemotherapy may be appropriate, i.e. in case of a short remaining life 
expectancy (<1-2 years). 
• In deciding on the administration of adjuvant chemotherapy, a careful weighing of the 
expected benefits and drawbacks of adjuvant chemotherapy should be performed. The 
potential reduction in recurrence risk must be weighed against the potential risk of 
toxicity and competing causes of death. The assessment of older patients is complex 
and should also include considerations of comorbidities, polypharmacy, activities of 
daily living, nutritional status and psychosocial and cognitive functioning. Additionally, 
remaining life expectancy and patient preference (i.e. with regard to preservation of 
independence or functional status) are of paramount importance. 
• For selected cases, for example in case of doubt on vitality or goal setting for individual 
patients, consultation with a geriatrician and possibly geriatric assessment is preferable. 
• In case adjuvant chemotherapy is administered, fluoropyrimidine monotherapy is the 
preferred regimen of choice. Capecitabine monotherapy seems preferable over CAPOX 
for the majority of the patients as capecitabine monotherapy is better tolerated and less 
toxic, without limiting the recurrence-free and overall survival benefit. When deciding 
on the dosage, upfront screening for  DPYD*2A is recommended to reduce the risk of 
fluoropyrimidine-associated toxicity. In certain circumstances, oxaliplatin-containing 
chemotherapy is indicated, for example in patients with a microsatellite instable (MSI) 
tumour. Therefore, analysis of the mismatch repair status should become standard 
of care.
• The risk of toxicity from adjuvant chemotherapy should explicitly be discussed with 
patients. Elderly patients often value quality of life including independent life expectancy 
above life expectancy itself. Therefore, especially the risk of oxaliplatin-induced 
neuropathy deserves attention because of the risk of long term disabling effects. 
• Adjuvant chemotherapy should be initiated within 8 weeks post-surgery, while providing 
a time window in which patients can recover from surgery.
146  |  Chapter 10
Implications for future research 
Elderly need to become the focus of future colon cancer research, as they represent a 
large part of the patient population. Although challenging, the realization of clinical trials 
designed for elderly cancer patients as well as prospective observational studies including an 
extensive description of elderly patient characteristics and with appropriate outcomes (i.e. 
preservation of independence, functional status and quality of life) is important to expand 
the evidence-base for the treatment of elderly colon cancer patients. For example, the almost 
exclusive use of capecitabine-based regimens in our study population disabled a direct 
comparison of the effectiveness of 5-fluorouracil-based therapy with capecitabine-based 
therapy among elderly stage III colon cancer patients. A trial in which the effect of the 
different chemotherapy regimens on 3-year disease-free survival are compared among 
elderly patients with colon cancer is now ongoing71. 
The Netherlands Cancer Registry underwent a large scale extension of its dataset for all 
colorectal cancer patients diagnosed from 2015 onwards and now encompasses more 
detailed information regarding systemic therapies, prognostic markers and long-term 
follow-up regarding tumour progression and recurrence. This offers unique opportunities 
for evaluating the use and effects of treatments in real life patients, especially in a patient 
group which is often excluded from trials. 
Of interest, the national screening program for colorectal cancer will have considerable 
impact on future (epidemiological) colorectal cancer research and clinical practice. The 
screening program started in 2014 and is further introduced in phases until in 2019 all 
persons aged 55-75 years will be invited to participate every 2 years. The primary aim 
of the screening program is to reduce mortality from colorectal cancer through earlier 
diagnosis, which will result in less invasive treatments and in less adjuvant treatments. 
Furthermore, after an initial sharp increase in the number of newly diagnosed colorectal 
cancer patients, the incidence will decrease72,73.
Concluding remarks
Elderly represent a substantial part of the colon cancer patients and this will increase 
even further in the near future due to demographic developments. This thesis provides 
a substantial contribution to the limited available evidence on the use and effectiveness 
of adjuvant chemotherapy among unselected elderly patients with stage III colon cancer 
treated in everyday clinical practice. It was shown that elderly derive comparable benefit 
from adjuvant chemotherapy as their younger counterparts, indicating that consideration 
of adjuvant chemotherapy is warranted for all patients. It was also shown that capecitabine 
monotherapy is better tolerated and less toxic, without limiting the recurrence-free and 
overall survival benefit, compared to a combination of capecitabine and oxaliplatin. Therefore, 
the addition of oxaliplatin should not be standard care for the majority of elderly stage III 
colon cancer patients treated in daily clinical practice.
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Inleiding
Vergrijzing en dikkedarmkanker
De naoorlogse geboortegolf en de stijgende levensverwachting hebben geresulteerd in 
een toename van het aantal ouderen in Nederland. Door deze vergrijzing, maar ook door 
ongezonde leefstijlveranderingen en introductie van het bevolkingsonderzoek, neemt het 
aantal nieuw gediagnosticeerde patiënten met dikkedarmkanker toe. Tussen 1990 en 2015 
steeg het aantal patiënten met dikkedarmkanker van 4.600 tot 10.900. Ook de komende 
jaren zal het aantal patiënten naar verwachting verder stijgen.
De gemiddelde leeftijd ten tijde van de diagnose dikkedarmkanker is 69 jaar; ongeveer 
een derde van de patiënten is 75 jaar of ouder. Door de hoge gemiddelde leeftijd op het 
moment van de diagnose, heeft een groot deel van de patiënten ook te maken met andere 
chronische ziekten (zogeheten comorbiditeiten). Meer dan de helft van de patiënten met 
dikkedarmkanker heeft één bijkomende ziekte en bijna een derde van deze patiënten 
heeft twee of meer bijkomende ziekten. De meest voorkomende comorbiditeiten zijn 
hoge bloeddruk, hart- en vaatziekten, andere vormen van kanker en diabetes. Als gevolg 
van comorbiditeit, gebruiken patiënten vaak meerdere medicijnen. Dit kan problematisch 
zijn wanneer interacties tussen medicijnen of verkeerde innames leiden tot toxiciteit en 
afname van de werkzaamheid van de medicijnen.
Adjuvante chemotherapie voor stadium III dikkedarmkanker
Ongeveer een kwart van alle patiënten met dikkedarmkanker heeft stadium III ten tijde 
van de diagnose. Dat houdt in dat de kanker niet beperkt is tot de dikke darm, maar dat 
de ziekte naar tenminste één regionale lymfeklier is verspreid, maar niet naar andere 
organen. De behandeling bestaat uit het chirurgisch verwijderen van de tumor en regionale 
lymfeklieren, gevolgd door chemotherapie (zogenaamde adjuvante chemotherapie). 
Adjuvante chemotherapie wordt gebruikt met de intentie om eventuele achtergebleven 
tumorcellen uit te roeien.
Het positieve effect van adjuvante chemotherapie op de overleving van patiënten met 
stadium III dikkedarmkanker is vastgesteld in klinische trials en is sinds de jaren negentig 
de standaardbehandeling. Tot 2005 was behandeling met de middelen 5-fluorouracil en 
leucovorin (5-FU/LV) de enige effectieve optie. Op dat moment kwam het middel capecitabine 
beschikbaar. In een trial werd aangetoond dat capecitabine gelijkwaardig is aan 5-FU/LV 
met betrekking tot de overleving. Een andere ontwikkeling was de introductie van het 
middel oxaliplatin. Verschillende trials lieten zien dat de toevoeging van oxaliplatin aan 
5-FU/LV (genaamd FOLFOX) voorzag in extra overlevingswinst, maar dit leidde wel tot 
meer bijwerkingen. In weer een andere trial werd aangetoond dat de combinatie van 
oxaliplatin met capecitabine (genaamd CAPOX) voor een vergelijkbare overlevingswinst 
zorgde waardoor een alternatieve behandelingsoptie beschikbaar kwam.
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Ondervertegenwoordiging en exclusie van ouderen in trials
Ondanks het feit dat dikkedarmkanker vooral voorkomt bij ouderen, waren patiënten in de 
leeftijd van 70 tot en met 75 jaar ondervertegenwoordigd in de hiervoor genoemde trials. 
Patiënten ouder dan 75 jaar werden zelfs volledig uitgesloten. Klinische trials gebruiken 
dus inclusiecriteria die geen rekening houden met patiëntkarakteristieken zoals deze in 
de dagelijkse klinische praktijk voorkomen. Het gevolg is dat oudere patiënten die wél 
deelnemen aan klinische trials vaak relatief vitaal zijn met weinig comorbiditeit. Deze 
patiëntengroepen zijn niet representatief voor de oudere patiënt in de dagelijkse klinische 
praktijk.
Om de effecten voor oudere patiënten toch te kunnen evalueren, werden subgroep analyses 
en analyses op gecombineerde data van trials uitgevoerd. Daaruit bleek dat geselecteerde 
ouderen hetzelfde voordeel hebben van 5-FU/LV en capecitabine als jongere patiënten. 
Patiënten in de leeftijd van 70 tot en met 75 jaar stopten wel vaker voortijdig met de 
behandeling in vergelijking met jongere patiënten. Ook waren er vaker dosisaanpassingen 
en dosisreducties nodig. Met betrekking tot een overlevingseffect werden inconsistente 
resultaten gevonden bij de toevoeging van oxaliplatin. Daarnaast braken ouderen behandeling 
met oxaliplatin vaker voortijdig af en trad er meer toxiciteit op.
Een beperking blijft dat de resultaten van deze studies mogelijk niet van toepassing 
zijn op ongeselecteerde, oudere patiënten in de dagelijkse klinische praktijk. Medisch 
specialisten worden steeds vaker geconfronteerd met oudere patiënten die zeer heterogeen 
zijn met betrekking tot hun onderliggende gezondheidsstatus. Clinici moeten de data 
extrapoleren om samen met de patiënt betekenisvolle beslissingen te kunnen nemen. 
Dat kan leiden tot onderbehandeling of overbehandeling al dan niet gepaard gaande 
met excessieve bijwerkingen. Daarom zijn er naast klinische trials andere bronnen van 
informatie nodig om de effecten van adjuvante chemotherapie bij oudere patiënten met 
stadium III dikkedarmkanker te evalueren.
Observationele studies
Observationele studies met data van patiënten uit de dagelijkse klinische praktijk 
kunnen inzicht geven in het gebruik en de effecten van de verschillende opties voor 
adjuvante chemotherapie bij ongeselecteerde, oudere patiënten. In 2012 stelde ZonMw 
een onderzoekssubsidie beschikbaar aan Integraal Kankercentrum Nederland (IKNL) 
om hier onderzoek naar te doen, wat resulteerde in dit proefschrift. Op dat moment 
hadden eerdere observationele studies reeds aangetoond dat oudere patiënten minder 
vaak met adjuvante chemotherapie worden behandeld en dat zij tevens minder vaak 
oxaliplatin-bevattende chemotherapie ontvangen. Daarnaast kwamen dosisreducties en 
het voortijdig afbreken van de behandeling vaker voor bij ouderen. Er werd echter zelden 
onderscheid gemaakt tussen de verschillende monotherapieën (5-FU/LV of capecitabine) en 
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combinatietherapieën (FOLFOX of CAPOX). Ook was er weinig bekend over de factoren die 
een rol spelen in de besluitvorming rondom het verstrekken van adjuvante chemotherapie 
bij oudere patiënten met stadium III dikkedarmkanker. Verder ontbrak inzicht in welke mate 
ongeselecteerde, oudere patiënten de verschillende adjuvante chemotherapieën verdragen, 
welke bijwerkingen zij ontwikkelen, en wat de verschillen in recidiefvrije en algemene 
overleving zijn tussen de diverse behandelingen in de dagelijkse, klinische praktijk.
Doel van dit proefschrift
Het doel van dit proefschrift is om meer bewijs te verzamelen waarop het gebruik 
van de bestaande adjuvante chemotherapieën voor oudere patiënten met stadium III 
dikkedarmkanker gebaseerd kan worden. De belangrijkste doelstellingen van dit proefschrift 
zijn:
• Inzicht geven in het gebruik van de verschillende opties voor adjuvante chemotherapie 
(deel I).
• Onderzoeken van de dosisintensiteit en gerelateerde toxiciteit van de verschillende 
adjuvante chemotherapieën (deel II).
• Evalueren van de samenhang tussen adjuvante chemotherapie en het risico op een 
recidief, en de samenhang tussen adjuvante chemotherapie en de recidiefvrije en 
algemene overleving (deel III). 
Belangrijkste bevindingen
Dit proefschrift begint met een overzicht van medicatie-uitgiftes van de openbare apotheek 
aan oudere patiënten met dikkedarmkanker in het jaar vóór de kankerdiagnose in 
vergelijking met een controlegroep zonder kanker die qua leeftijd en geslacht vergelijkbaar is 
(hoofdstuk 2). Gedurende dit hele jaar was het medicatiegebruik hoger bij deze ‘toekomstige’ 
patiënten in vergelijking met de kankervrije controlegroep. Dit aandeel nam verder toe 
gedurende de laatste drie maanden voorafgaand aan de kankerdiagnose. Het verhoogde 
aantal medicatie-uitgiftes bij patiënten in vergelijking met de controlegroep gedurende het 
totale jaar was voornamelijk gerelateerd aan comorbiditeit, terwijl de medicatie-uitgiftes 
in de laatste maanden voor de diagnose dikkedarmkanker waarschijnlijk voornamelijk 
aan (symptoombestrijding van) de dikkedarmkanker waren gerelateerd. Inzicht in 
medicatiegebruik in de periode voor de diagnose dikkedarmkanker kan huisartsen en 
medisch specialisten aanknopingspunten bieden om patiënten uit te nodigen voor 
verder onderzoek. Daarnaast is het van belang om rekening te houden met bestaand 
medicijngebruik bij het bepalen van een passende kankerbehandeling.
Gebruik van adjuvante chemotherapie
In hoofdstuk 3 zijn subjectieve, arts-gerelateerde factoren onderzocht die mee kunnen 
spelen in de besluitvorming rondom adjuvante chemotherapie voor oudere patiënten 
met stadium III dikkedarmkanker. Hiervoor zijn korte vragenlijsten opgesteld en naar 
chirurgen en medisch oncologen verstuurd. De door chirurgen het vaakst gerapporteerde 
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motieven voor niet doorverwijzen waren: comorbiditeit of slechte algemene conditie van 
de patiënt, chirurgische complicaties en weigering van adjuvante chemotherapie door de 
patiënt. Medisch oncologen rapporteerden deze motieven ook voor niet-behandelen, maar 
rapporteerden daarnaast dat de verwachte bijwerkingen naar hun idee te ernstig waren. 
Verder rapporteerden minder dan de helft van de chirurgen en iets meer dan de helft van 
de medisch oncologen een geriater te consulteren voor een minderheid van de patiënten. 
Wat betreft de beslissing van medisch oncologen voor behandeling met monotherapie of 
combinatietherapie, gaven zij aan dit te baseren op de aanwezigheid van comorbiditeit, 
de algemene conditie van de patiënt en het bijwerkingenprofiel van de middelen. Medisch 
oncologen waren het eens over acceptabele niveaus van bijwerkingen. 
Vervolgens zijn in hoofdstuk 4 patiënt- en tumorkarakteristieken geëvalueerd die de 
toediening van oxaliplatin-bevattende chemotherapie (FOLFOX en CAPOX) in vergelijking 
met non-oxaliplatin-bevattende chemotherapie (5FU/LV en capecitabine) beïnvloedden 
en is de variatie in de toediening van beide typen tussen ziekenhuizen geëvalueerd. 
In deze studie zijn 1.140 patiënten geïncludeerd afkomstig uit tien ziekenhuizen in 
Zuidoost-Nederland en gediagnosticeerd tussen 2008 en 2011. De mediane leeftijd van de 
patiënten die oxaliplatin ontvingen was 64 jaar, en de mediane leeftijden van patiënten die 
chemotherapie zónder oxaliplatin of géén chemotherapie ontvingen waren respectievelijk 
74 en 79 jaar. Er was grote ziekenhuisvariatie in de toediening van oxaliplatin-bevattende 
en non-oxaliplatin-bevattende chemotherapie, die niet volledig verklaard kon worden door 
verschillen in patiëntenpopulaties. De toediening van oxaliplatin-bevattende chemotherapie 
varieerde van 63% tot 87% voor patiënten jonger dan 70 jaar, van 15% tot 100% voor patiënten 
van 70 tot 75 jaar, en van 0% tot 19% voor patiënten van 75 jaar of ouder. Voor chemotherapie 
zonder oxaliplatin liepen deze proporties uiteen van 3% tot 20%, van 0% tot 29% en van 0% 
tot 28% in de respectievelijke leeftijdsgroepen. In een analyse waarbij alleen de patiënten 
die adjuvante chemotherapie ontvingen waren geïncludeerd, hing de toevoeging van 
oxaliplatin samen met leeftijd, de uitgebreidheid van de tumor, de periode van diagnose 
en het ziekenhuis van behandeling.
Intensiteit en toxiciteit van adjuvante chemotherapie
In hoofdstuk 5 is inzicht gegeven in het afmaken van alle geplande kuren en de totaal 
ontvangen cumulatieve dosering voor de in de dagelijkse klinische praktijk meest gebruikte 
chemotherapie schema’s en is het verband met toxiciteit onderzocht. Hiervoor zijn 
aanvullende data verzameld in de Nederlandse Kankerregistratie voor alle patiënten 
met stadium III dikkedarmkanker van 70 jaar of ouder, gediagnosticeerd in een van de 
tien ziekenhuizen in Zuidoost-Nederland tussen 2005 en 2012. Deze studie laat zien 
dat een grote meerderheid (88%) van de patiënten die een behandeling kregen met 
adjuvante chemotherapie CAPOX of capecitabine ontvingen. Het aandeel patiënten dat 
alle geplande kuren afmaakte, was lager voor patiënten behandeld met CAPOX (33%) dan 
voor patiënten behandeld met capecitabine (55%). De ontvangen cumulatieve dosering 
van capecitabine was ook lager voor patiënten behandeld met CAPOX (163.744 mg/m2) 
dan voor patiënten behandeld met capecitabine (189.195 mg/m2). Daarnaast was CAPOX 
geassocieerd met significant meer toxiciteit dan capecitabine (54% versus 38%), ook na 
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correctie voor patiënt- en tumorkarakteristieken. Voor patiënten behandeld met CAPOX 
waren de meest voorkomende bijwerkingen gastro-intestinaal (voornamelijk diarree en 
misselijkheid/overgeven, 29%), hematologisch (14%), neurologisch (voornamelijk neuropathie, 
11%) en overig (voornamelijk vermoeidheid, 13%). Voor patiënten behandeld met capecitabine 
waren dermatologische (hand-voetsyndroom, 17%), gastro-intestinale (voornamelijk diarree, 
13%) en overige (voornamelijk vermoeidheid, 11%) bijwerkingen het meest voorkomend. 
Neuropathie (zenuwbeschadiging) wordt steeds vaker erkend als een belangrijke bijwerking 
van oxaliplatin. De volgende studie evalueerde daarom verschillen in het beloop van 
neuropathie klachten tussen patiënten behandeld met CAPOX, capecitabine of geen 
adjuvante chemotherapie (hoofdstuk 6). Voor deze studie zijn patiënten uitgenodigd om 
een eerste vragenlijst na de operatie in te vullen en vervolgens zes en twaalf maanden 
later nog eens. Het aantal en het percentage patiënten dat milde tot ernstige neuropathie 
symptomen rapporteerde is gemeten. In totaal vulden 117 patiënten de eerste vragenlijst in 
(respons 76%), en respectievelijk 69 en 59 patiënten vulden de volgende twee metingen in. 
Het beloop van verschillende sensorische symptomen was minder gunstig voor de patiënten 
die behandeld zijn met adjuvante chemotherapie. Daarnaast was het beloop van doofheid 
in tenen of voeten ongunstiger voor patiënten behandeld met CAPOX en rapporteerden 
zij vaker tintelende tenen of voeten dan patiënten behandeld met capecitabine. Omdat 
neuropathie symptomen de functionele capaciteiten kunnen aantasten en negatief 
geassocieerd zijn met gezondheid-gerelateerde kwaliteit van leven gedurende en na de 
behandeling, is het van groot belang ouderen te informeren over deze risico’s om hen in 
staat te stellen een weloverwogen besluit te nemen over een gepaste behandeling. 
Adjuvante chemotherapie en recidiefvrije en algemene overleving
In hoofdstuk 7 is de samenhang tussen adjuvante chemotherapie en het risico op een 
afstandsrecidief (een uitzaaiing naar een ander orgaan) onderzocht. Ook is onderzocht of 
de samenhang hetzelfde was voor patiënten van 75 jaar of ouder als voor jongere patiënten. 
Patiënten gediagnosticeerd met stadium III dikkedarmkanker in Zuidoost-Nederland 
tussen 2003 en 2008 zijn geïncludeerd. Adjuvante chemotherapie was gecorreleerd met 
een verminderd risico op een afstandsrecidief (ruwe percentages over vijf jaar bij wel 
versus geen adjuvante chemotherapie: 36% versus 42%). In aparte analyses voor patiënten 
jonger dan 75 jaar en patiënten van 75 jaar of ouder, bleef de samenhang tussen adjuvante 
chemotherapie en het risico op een afstandsrecidief vergelijkbaar voor beide leeftijdsgroepen. 
Deze resultaten suggereren dat oudere patiënten hetzelfde voordeel genieten van adjuvante 
chemotherapie als jongere patiënten met betrekking tot het risico op een afstandsrecidief. 
Adjuvante chemotherapie moet daarom zeker overwogen worden.
In de volgende studie is de samenhang tussen de adjuvante chemotherapie schema’s 
CAPOX en capecitabine en de recidiefvrije en algemene overleving bij oudere patiënten 
met stadium III dikkedarmkanker onderzocht (hoofdstuk 8). De recidiefvrije en algemene 
vijfjaarsoverleving verschilden niet tussen patiënten behandeld met capecitabine en 
patiënten behandeld met CAPOX (recidiefvrije vijfjaarsoverleving: 63% versus 60%; algemene 
vijfjaarsoverleving: 66% versus 66%). Voor patiënten die geen adjuvante chemotherapie 
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ontvingen, waren de recidiefvrije en algemene vijfjaarsoverleving respectievelijk 38% en 37%. 
Met andere woorden, de behandeling met CAPOX of capecitabine is geassocieerd met een 
verbeterde recidiefvrije en algemene overleving. Omdat de overlevingswinst niet verschilt 
tussen de schema’s, is de toevoeging van oxaliplatin wellicht niet gerechtvaardigd bij oudere 
patiënten met stadium III dikkedarmkanker behandeld in de dagelijkse klinische praktijk.
In de laatste studie van dit proefschrift is onderzocht welke demografische en klinische 
variabelen geassocieerd waren met de timing van adjuvante chemotherapie en hoe 
deze timing geassocieerd was met algemene overleving (hoofdstuk 9). In deze studie 
zijn landelijke data van de Nederlandse Kankerregistratie gebruikt van alle patiënten 
met stadium III dikkedarmkanker die een operatie hadden ondergaan en adjuvante 
chemotherapie ontvingen tussen 2008 en 2013. De mediane tijd tussen operatie en adjuvante 
chemotherapie was 5 tot 6 weken. Veertien procent van de patiënten startte meer dan 
8 weken na de operatie met adjuvante chemotherapie. Factoren geassocieerd met het 
starten van de chemotherapie meer dan 8 weken na de operatie waren een hogere leeftijd 
van de patiënt, een spoedoperatie, naadlekkage, verwijzing naar een ander ziekenhuis 
voor de adjuvante chemotherapie en een verlengde postoperatieve ziekenhuisopname. 
De ruwe algemene vijfjaarsoverleving bij start van adjuvante chemotherapie binnen 4, 
5-6, 7-8, 9-10, 11-12 of 13-16 weken na operatie waren respectievelijk 75%, 76%, 72%, 64%, 61% 
en 54%. Na correctie voor verschillen in casemix, liet een start 5-8 weken postoperatief 
geen vermindering van de algemene overleving zien ten opzichte van een start binnen 
4 weken na operatie. Later dan 8 weken na operatie starten was echter wel geassocieerd 
met een verminderde algemene overleving ten opzichte van een start binnen 8 weken 
postoperatief. Deze resultaten ondersteunen het beeld dat bij patiënten met stadium III 
dikkedarmkanker adjuvante chemotherapie binnen 8 weken na de operatie gestart dient te 
worden, maar dat daarbij ruimte is om patiënten eerst te laten herstellen van de operatie.
Concluderende opmerkingen
Ouderen vertegenwoordigen een aanzienlijk deel van de patiënten met dikkedarmkanker 
en dit zal naar verwachting in de toekomst nog verder toenemen. Daarom is het van groot 
belang om de kennis over deze patiëntengroep te vergroten. Dit proefschrift draagt bij aan 
meer inzicht in het gebruik en de effecten van bestaande, adjuvante chemotherapieën bij 
oudere patiënten met stadium III dikkedarmkanker, behandeld in de dagelijkse klinische 
praktijk. Dit proefschrift laat zien dat adjuvante chemotherapie overwogen dient te worden 
voor oudere patiënten, omdat zij eenzelfde voordeel genieten van adjuvante chemotherapie 
met betrekking tot het verkleinen van het risico op een afstandsrecidief. Ook laat dit 
proefschrift zien dat capecitabine monotherapie over het algemeen de voorkeur geniet boven 
combinatietherapie met capecitabine en oxaliplatin, omdat monotherapie beter verdragen 
wordt, minder bijwerkingen geeft en de recidiefvrije en algemene overlevingswinst daarbij 
niet worden beperkt. De toevoeging van oxaliplatin zou om die reden in de klinische praktijk 
niet de standaard mogen zijn voor het merendeel van de oudere patiënten met stadium 
III dikkedarmkanker.
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